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 ABSTRACT 
 
Regulator of G Protein Signaling-12 (RGS12) in dopaminergic and kappa opioid receptor-
dependent signaling and behavior 
 
 
Joshua David Gross 
 
 Dopaminergic neurotransmission is critically involved in the etiology and treatment of 
many psychiatric and neurological disorders. One modulator of dopaminergic neurotransmission 
is the kappa opioid receptor (KOR) -- a G protein-coupled receptor (GPCR) that is densely 
expressed within dopaminergic neurons and circuits. GPCRs are tightly regulated by a variety of 
intracellular signaling molecules, including Regulator of G Protein Signaling (RGS) proteins. 
Canonically, RGS proteins act as GTPase accelerating proteins (GAPs) on GTP-bound Ga 
subunits following GPCR activation, thereby hastening the rate at which GPCR-mediated G 
protein signaling is terminated. However, some RGS proteins exhibit more complex mechanisms 
of action on cellular signaling. One such example is RGS12, which harbors the capacity to 
regulate both G protein-dependent and -independent signaling cascades. RGS12 is widely 
expressed across the developing and adult brain; we show that expression levels are notably high 
within dopamine- and KOR-enriched regions. We also observed that Rgs12 mRNA exhibits 
marked expression overlap with Oprk1 mRNA encoding KOR, which potently regulates 
dopaminergic neurotransmission following environmental stress and pharmacological challenge 
with psychostimulants. We revealed that genetic ablation of Rgs12 in mice upregulates dopamine 
transporter (DAT) function and attenuates behavioral responses to psychostimulants via KOR-
dependent mechanisms. Moreover, we showed that RGS12 differentially regulates G protein-
dependent versus G protein-independent signaling and behavior downstream of KOR activation. 
We also demonstrated that RGS12 displays region-specific effects in the striatum, and that 
RGS12 selectivity modulates KOR over other opioid receptors. Further studies are required to 
more completely elucidate the complex interaction between RGS12 and KOR, as well as to 
identify precisely the neuronal cell populations and brain regions mediating the effect of RGS12 
on dopaminergic and KOR-dependent signal transduction and behavior.  
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CHAPTER 1 
 
General Introduction 
1.1 - G Protein-Coupled Receptor Signal Transduction  
1.1.1 - Background 
 All organisms must convert extracellular stimuli into intracellular signals to enable 
physiological adaptation to the environment. A primary mechanism by which organisms transduce 
extracellular cues into cellular responses is via membrane-bound, cell surface-expressed 
receptor proteins (Gilman, 1987; Bockaert and Pin, 1999; Unwin, 1993; Ullrich and Schlessinger, 
1990). The largest class of receptor proteins is G protein-coupled receptors (GPCRs), which 
constitute more than 1% of the protein-coding human genome (Bockaert and Pin, 1999; 
Fredriksson et al., 2003). GPCRs are ubiquitously expressed throughout the body, and they 
respond to a diverse array of external stimuli, including neurotransmitters, hormones, ions, and 
sensory cues, such as light and odor (Rosenbaum et al., 2009; Lagerstrom and Schioth, 2008; 
Krishnan and Schioth, 2015). Accordingly, GPCRs represent the largest pharmacological drug 
target class (Hauser et al., 2017; Santos et al., 2017).  
 GPCRs (also referred to as 7TMRs) contain seven transmembrane a-helices, with an 
extracellular N-terminus, three extracellular loops, three intracellular loops, and an intracellular C-
terminus (Geppetti et al., 2015; Rosenbaum et al., 2009). Inactive GPCRs couple to intracellular 
heterotrimeric G protein complexes composed of a GDP-bound Ga subunit and an obligate Gbg 
dimer (Hepler and Gilman, 1992; Gilman, 1987). Binding of a GPCR agonist (activating ligand) 
induces conformational changes in the GPCR that promote the exchange of GDP for GTP (the 
latter nucleotide in higher cytosolic concentrations) on Ga subunits, thereby acting as a guanine 
nucleotide exchange factor (GEF). GTP-bound Ga subunits exhibit reduced affinity for the Gbg 
heterodimer and, thus, Ga·GTP dissociates from Gbg heterodimers (Lambright et al., 1994; Neer, 
1995; Oldham and Hamm, 2008). Heterotrimeric G protein complex dissociation reflects the ‘on’ 
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state of the receptor, as freed Ga·GTP subunits and Gbg heterodimers interact with various 
intracellular effectors, including adenylyl cyclase, isoforms of phospholipase C, ion channels, and 
many others. The engagement of specific effectors is predicated on the subtype of Ga subunit 
(Freissmuth et al., 1989; Simon et al., 1991; Hart et al., 1998; Siehler, 2009). For example, Gas 
activates adenylyl cyclase, resulting in the formation of cyclic adenosine monophosphate (cAMP) 
(i.e., stimulatory activity) (Hausdorff et al., 1989), whereas Gai/o blocks this process (i.e., exerts 
inhibitory activity) (Gilman, 1984). Effector signaling leads to a wide array of biological responses 
over short- and long-term timespans, including neuronal excitation/inhibition, 
neurotransmitter/hormone release, and gene transcription (Clapham and Neer, 1997; Carman et 
al., 1999; Simonds, 1999; Kammermeier et al., 2000; Lutz et al., 2007). Free Ga·GTP and Gbg 
subunits continue to impact intracellular effector molecules until GTP is hydrolyzed back to GDP 
via intrinsic GTPase catalytic activity of the Ga subunit (Cassel et al., 1979; Vuong and Chabre, 
1991). Ga·GDP has a higher affinity for Gbg heterodimers, thus GTP hydrolysis drives restoration 
of heterotrimeric complex formation and receptor coupling (i.e., the 'off’ state) until subsequent 
GPCR activation (Neubig and Siderovski, 2002; Kimple et al., 2011; Siderovski DP, 2008) 
 
1.2 - GPCR Regulation   
1.2.1 - Regulators of G Protein Signaling  
 The termination of GPCR signaling is tightly regulated by intracellular signaling molecules 
across a wide temporal scale (i.e., seconds to minutes to hours) (Berman and Gilman, 1998; 
Kimple et al., 2011; Smith and Rajagopal, 2016a). Although Ga subunits harbor intrinsic GTP 
hydrolysis activity, the spontaneous rate of this reaction is too slow to account for the physiological 
processes engendered by GPCR activation (Vuong and Chabre, 1991; Angleson and Wensel, 
1993; Breitwieser and Szabo, 1988). Regulators of G protein signaling (RGS) proteins serve as 
the primary mechanism by which GTP is rapidly hydrolyzed from active Ga subunits and thereby 
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act as the chief short-term negative regulators of G protein signaling in the cell. RGS proteins 
exhibit GTPase-accelerating protein (GAP) activity on GTP-bound Ga subunits via a conserved 
~120 amino acid RGS domain (Berman and Gilman, 1998; McCudden et al., 2005; Dohlman and 
Thorner, 1997; Soundararajan et al., 2008). The RGS domain exhibits strong affinity for the 
enzymatic transition state of Ga·GTP along its path of GTP hydrolysis. Once bound, RGS 
proteins stabilize the positioning of an essential glutamate residue within the intrinsic Ga 
catalytic region, thereby accelerating the rate of GTP hydrolysis to GDP + Pi (Kimple et al., 2011). 
An extensive literature has demonstrated that loss of RGS protein expression in mice (e.g., 
RGS2, RGS4, RGS9-2) engenders increased GPCR sensitivity to agonist stimulation (e.g., 
(Heximer et al., 2003; Ruiz de Azua et al., 2010; Han et al., 2010; Zachariou et al., 2003; 
Psifogeorgou et al., 2007), thus highlighting the importance of RGS proteins in vivo.  
 There are 20 classical RGS proteins, and these can be partitioned into smaller subfamilies 
(R4, R7, R12, RZ) on the basis of sequence and protein domain homology. Notably, many other 
protein classes contain an RGS domain, including G protein-coupled receptor kinases (GRKs), 
nexins, ankyrins, AKAPs, and Rho-GEFs, but these are considered non-canonical RGS proteins, 
as most of them do not exhibit Ga-directed GAP activity (Neubig and Siderovski, 2002; Sjogren, 
2017). The largest (in number) and simplest RGS protein subfamily is the R4 family (e.g., RGS2, 
RGS4, RGS21), which contains only a central RGS domain between the N- and C-termini. 
Members of the RZ family exhibit a similar domain architecture, except that they each contain an 
N-terminal post-cysteine segment that undergoes reversible palmitoylation. Members of other 
RGS subfamilies contain multi-domain architectures capable of mediating protein-protein 
interactions with adaptor proteins or regulating G protein-independent signaling. For example, 
stable expression of RGS proteins within the R7 subfamily (i.e., RGS6, RGS7, RGS9, RGS11) 
requires an obligatory physical interaction with Gb5 subunits via the N-terminal GGL (Gb-like) 
domain (Chen et al., 2003; Snow et al., 1998b). In contrast, RGS12 (a member of the R12 family) 
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contains an N-terminal PDZ domain that enables physical interactions with GPCRs expressing 
C-terminal PDZ recognition motifs (Snow et al., 2002; Snow et al., 1998a). Another 
distinguishable feature of R12 family members (e.g., RGS12, RGS14) is that these proteins are 
capable of modulating G protein-independent signal transduction. Specifically, RGS12 and 
RGS14 both contain tandem Ras-binding  domains (RBDs), which affect mitogen-activated 
protein kinase/extracellular-signaling regulated kinase (MAPK/ERK) cascades (Willard et al., 
2009; Willard et al., 2007); furthermore, RGS12 (but not RGS14) contains an N-terminal 
phosphotyrosine-binding domain that can modulate receptor-tyrosine kinase (RTK)-mediated 
signaling (Willard et al., 2007). For a deeper discussion on the molecular mechanisms and 
physiological outcomes of RGS12-dependent signaling, please see 1.2.1c - RGS12 and Its Role 
in the CNS below. Comprehensive reviews on the sequence and biochemical differences between 
RGS protein subfamily members can be found elsewhere (Siderovski and Willard, 2005; Neubig 
and Siderovski, 2002; Siderovski DP, 2013). 
 RGS proteins can exhibit specificity for GPCRs on multiple levels. First, the RGS domain 
displays Ga subunit specificity, although some can act upon multiple Ga subunit subtypes (Xu et 
al., 1999; Soundararajan et al., 2008). However, to date, there are no identified RGS proteins 
capable of acting as a functional GAP on Gas subunits (cf., (Zheng et al., 2001). Second, RGS 
proteins can exhibit specificity for particular GPCRs via compatible amino acid sequences 
between the RGS protein and its cognate GPCR. For example, RGS12 contains a PDZ binding 
domain on its N-terminus that enables selective GPCR interactions via direct physical association 
with GPCRs containing a C-terminal PDZ recognition motif (Snow et al., 1998a; Martemyanov et 
al., 2003; Snow et al., 2002; Sambi et al., 2006). Lastly, RGS proteins can exert specificity for 
GPCRs through differential and selective expression distributions across physiological systems 
and tissues. A stark example of this phenomenon is the RGS9 splice variants RGS9-1 and 
RGS9-2. The RGS9-1 isoform is exclusively expressed in rod and cone photoreceptors, where 
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it serves as the critical GAP for rhodopsin (He et al., 1998), whereas RGS9-2 is almost 
exclusively expressed in the striatum, where it acts on neurotransmitter GPCRs (Mancuso et 
al., 2010).  
 
1.2.1a - RGS Proteins in Neuronal Physiology  
 RGS proteins are widely expressed in the mammalian central nervous system (CNS) 
(Gold et al., 1997; Larminie et al., 2004) and have been extensively linked to a wide variety of 
neurological and psychiatric conditions (Rivero et al., 2012; Mirnics et al., 2001; Erdely et al., 
2006; Tekumalla et al., 2001). The functional role of RGS proteins in neuronal physiology has 
been predominantly elucidated through the use of transgenic mice. Classically, constitutive and 
conditional RGS knockout mice provided a method by which to investigate the role of specific 
RGS proteins in vivo (Grillet et al., 2005; Zachariou et al., 2003; Oliveira-Dos-Santos et al., 2000; 
Lee et al., 2010). These efforts have been augmented by the development and use of RGS-
insensitive Ga subunit knockin mice. In these mice, specific Ga subunits (Gao, Gai2) are incapable 
of functional coupling to RGS proteins (DiBello et al., 1998; Lan et al., 1998; Fu et al., 2004; Kaur 
et al., 2011; Lamberts et al., 2013). Studies utilizing these techniques have revealed the integral 
roles for RGS proteins in the modulation of GPCR signaling-driven neuroplasticity and behaviors 
via action within a variety of neuronal cell populations and circuits (Gerber et al., 2016; Roman 
and Traynor, 2011). A comprehensive summary of the mechanisms by which all CNS-expressed 
RGS proteins affect neuronal physiology is beyond the scope of this thesis. Therefore, I will focus 
specifically on the extant findings that strongly support a role for RGS proteins in the modulation 
of opioidergic signaling and behavior.  
 
1.2.1b - RGS Proteins and Opioidergic Signaling and Behavior 
 Several groups have demonstrated that RGS proteins are critical determinants of 
opioidergic signaling and behavior (Traynor, 2012; Zachariou et al., 2003; Wang et al., 2009; Xie 
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et al., 2007). There are three classical opioid receptors, the mu (MOR), delta (DOR), and kappa 
(KOR) opioid GPCRs (Waldhoer et al., 2004; Snyder and Pasternak, 2003). Historically, most 
work has focused on characterizing the functional relationship between several different RGS 
proteins and the MOR, which is the molecular target of opioid analgesics and drugs of abuse, 
such as morphine, hydrocodone, oxycodone, and heroin (Contet et al., 2004). Extensive prior 
work has demonstrated that RGS4 and RGS9-2 are required for the molecular and behavioral 
effects of MOR-directed drugs (for a comprehensive review, see (Traynor, 2012)).  
 RGS4 is one of the smallest RGS proteins, consisting only of a single RGS domain that 
promiscuously acts as a GAP on Gai/o and Gaq subunits (Zheng et al., 1999; Zhong and Neubig, 
2001). RGS4 is co-expressed with MOR in many brain regions, and Rgs4 mRNA is upregulated 
following spinal injury in rodents (Garnier et al., 2003; Mansour et al., 1995). In heterologous 
systems, RGS4 co-immunoprecipitates with MOR and acts as a GAP on MOR-mediated G protein 
signaling (Leontiadis et al., 2009; Georgoussi et al., 2006; Talbot et al., 2010). Although 
constitutive RGS4 knockout mice only display mild MOR-specific phenotypes, specific knockdown 
of Rgs4 in the nucleus accumbens (NAc -- a subregion of the ventral striatum) using lentiviral 
shRNA manifests more marked effects on MOR-induced reward (Han et al., 2010), suggesting 
that germline deletion of RGS4 may be compensated for by other related RGS proteins. 
Moreover, RGS4 has been shown to interact with DOR (Wang et al., 2009), supporting that 
permissive action of RGS4 on MOR-mediated signaling and behavior in vivo may relate to its 
redundant interactions with other opioid receptors.  
 In contrast to the relatively mild role that RGS4 plays in MOR-dependent outcomes, 
several groups have demonstrated that RGS9-2 exhibits considerably more robust and specific 
actions on MOR-mediated signaling and behavior (Xie and Palmer, 2005; Traynor, 2012). 
RGS9-2 is an alternative splice variant of the RGS9 gene that is nearly exclusively expressed in 
the striatum, but also exhibits low expression in the periaqueductal gray -- both brain regions 
being crucial for the effects of opioidergic drugs (Cowan et al., 1998; Granneman et al., 1998; 
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Rahman et al., 1999). Extensive in vitro and in vivo findings indicate that RGS9-2 potently affects 
MOR-mediated signal transduction and clinically relevant behavioral outcomes, including 
analgesia, reward, and drug tolerance (Rahman et al., 2003; Zachariou et al., 2003; Traynor et 
al., 2009; Traynor, 2012). Like RGS4, RGS9-2 acts as a potent GAP for MOR agonist-mediated 
G protein signaling in over-expression systems (Psifogeorgou et al., 2011). Consistent with 
RGS9-2 as a negative regulator of MOR-mediated signaling, prior studies with constitutive RGS9 
knockout mice demonstrated that RGS9 loss results in hypersensitivity to the rewarding and 
analgesic properties of morphine (Zachariou et al., 2003). These effects could be reversed upon 
virally mediated re-expression of RGS9 in the NAc (Zachariou et al., 2003), supporting a causal 
role for RGS9 in this striatal subregion in the regulation of morphine-induced reward. Further 
studies using antisense oligonucleotide-mediated knockdown of RGS9, or the obligate RGS9 
partner Gb5, recapitulated the enhanced analgesia and reward in response to morphine and 
DAMGO (a selective MOR agonist) observed with constitutive RGS9 knockout mice (Sanchez-
Blazquez et al., 2003). Notably, RGS9 exerts opposing effects on DOR, with knockdown of RGS9 
resulting in reduced DOR agonist-mediated analgesia (Sanchez-Blazquez et al., 2003). These 
findings, in contrast with prior findings using RGS4 loss, support that RGS proteins can exhibit 
selectivity for one opioid receptor over another. Furthermore, acute morphine administration to 
wildtype mice upregulates RGS9 protein in several analgesia- and reward-related brain regions, 
whereas chronic morphine downregulates RGS9 protein in these areas. Accordingly, RGS9 
knockout mice display enhanced analgesia as induced by acute morphine treatment, despite 
expressing attenuated tolerance to chronic administrations of morphine (Zachariou et al., 2003). 
Given that the acute and chronic effects of MOR-directed agonists are mediated by independent 
signaling mechanisms ((Bohn et al., 2003; Bohn et al., 2000) -- for further discussion see 1.2.2a 
b-arrestins in Neuronal Physiology below), these findings and others (Psifogeorgou et al., 2007) 
support that RGS proteins can exert distinct effects on signal transduction cascades downstream 
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of their cognate GPCRs and, consequently, perturbation of RGS protein expression can result in 
separable behavioral outcomes in response to opioidergic drug administration. 
 
1.2.1c - RGS12 and Its Role in the CNS 
 RGS12 is a Gai/o-selective RGS protein originally cloned in 1997 by the Siderovski group 
from cultures of the rat C6 glioblastoma cell line treated with morphine (Snow et al., 1997). 
RGS12 is relatively widely expressed throughout mammalian tissues, although it does exhibit 
some cellular and regional specificity within certain physiological systems, especially the brain 
(Snow et al., 1998a; Lopez-Aranda et al., 2006). RGS12 is unique among RGS proteins in that 
it exhibits a complex domain architecture capable of independently modulating and coordinating 
across several signaling pathways beyond canonical RGS domain-mediated GAP activity; 
accordingly, RGS12 is considered a “signaling scaffold” (Willard et al., 2007; Sambi et al., 2006; 
Wang et al., 2017; Huang et al., 2014). RGS12 possesses an N-terminal PDZ domain, a 
phosphotyrosine binding domain (PTB), a central Gai/o-specific RGS domain, tandem Ras 
binding domains (RBDs), and a C-terminal GoLoco motif (Siderovski and Willard, 2005). The 
GoLoco motif of RGS12 acts as a guanine nucleotide dissociation inhibitor (GDI) by 
sequestering inactive Ga subunits, thereby prolonging Gbg signaling (Kimple et al., 2001). Thus, 
RGS12 uniquely contains two Gai-interaction domains, the RGS domain and the GoLoco motif, 
which differentially affect Gai-dependent signaling. Moreover, RGS12 harbors Gai-independent 
domains that are common among signaling adaptors and scaffolds (e.g., PDZ, PTB, RBDs) 
(Romero et al., 2011; Yaffe, 2002; Willard et al., 2007). Together, the diverse domain 
architecture and biochemical properties of RGS12 support the notion that it coordinates 
complex and integrative regulation of signal transduction initiated by both G protein-dependent 
and -independent pathways.  
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 Two primary isoforms of RGS12 exist: a full-length variant containing N-terminal PDZ 
and PTB domains, and a truncated variant lacking these N-terminal domains. The truncated 
variant of RGS12 exhibits a domain architecture identical to another R12 family member, 
RGS14 (Snow et al., 1997; Snow et al., 1998a). However, the expression distributions of RGS12 
and RGS14 in the developing and adult brain differ considerably (Martin-McCaffrey et al., 2005; 
Lopez-Aranda et al., 2006), suggesting there is likely little, if any, genetic compensation of 
RGS14 upon transgenic deletion of RGS12.  
 RGS12 is required for nerve growth factor-mediated axonogenesis by dorsal root 
ganglion neurons via PTB domain-dependent mitogen-activated protein kinase (MAPK) 
scaffolding (Willard et al., 2007). These findings highlight at least one way in which RGS 
proteins can perform integral physiological functions independent of their canonical GAP-
mediated termination of G protein signaling. Consistent with its effects on neurodevelopmental 
processes, such as axonogenesis, RGS12 is highly expressed in CNS progenitor cell 
populations during early stages of brain development (Martin-McCaffrey et al., 2005), although 
the functional implications of this temporal and spatial expression pattern in the developing CNS 
remain to be determined. Consistent with the notion that RGS12 is important for 
neurodevelopmental processes, studies in both mice and humans have identified changes in 
RGS12 protein expression and mutations in the RGS12 gene, respectively, in 
neurodevelopmental disease models/states. In a whisker-trimming animal model of 
somatosensory cortical development, RGS12 was significantly down-regulated under 
conditions of early-life sensory deprivation (Butko et al., 2013). In a rat model of schizophrenia 
in which a non-mutant variant of the human disrupted-in-schizophrenia (DISC1) gene is over-
expressed, RGS12 was found to be down-regulated in the striatum (Sialana et al., 2018). These 
findings are strengthened by exome sequencing analyses of humans diagnosed with 
schizoaffective disorder and schizophrenia (considered neurodevelopmental disorders of the 
CNS; (Owen et al., 2011; Birnbaum and Weinberger, 2017)), in which two independent groups 
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identified de novo missense mutations in RGS12 (Xu et al., 2011; Guipponi et al., 2014). 
Collectively, these studies suggest that RGS12 likely plays a crucial role in neurodevelopmental 
processes and that perturbation of its function could manifest neurobiological disruptions 
consistent with psychiatric diseases, such as schizophrenia.  
 
1.2.2 - b-arrestin   
 In addition to the homeostatic feedback exerted by RGS proteins, GPCRs are also 
negatively regulated by another class of proteins called b-arrestins (barrs) (Pierce et al., 2002; 
Lohse et al., 1990). barrs are ubiquitously expressed and exist in two relatively homologous (78% 
sequence homology) but distinct isoforms within the CNS, barr1 and barr2 (Lohse et al., 1990; 
Attramadal et al., 1992). Initial work identified barrs as an essential mediator of GPCR 
desensitization following intense, repeated and/or prolonged receptor stimulation (Wilden et al., 
1986; Lohse et al., 1990). However, a considerable number of studies since these initial 
observations have demonstrated that barrs also are essential modulators of other processes, 
such as GPCR internalization (i.e., receptor endocytosis), GPCR degradation/downregulation, 
signaling crosstalk/receptor transactivation (e.g., with RTKs), and that these proteins can even 
act as scaffolds of signal transduction cascades (e.g., MAPK/ERK signaling) independent of 
canonical G protein signaling. For comprehensive reviews on the myriad functional outcomes of 
GPCR-mediated barr signaling, see (Kang et al., 2014; Lefkowitz and Whalen, 2004; Shenoy and 
Lefkowitz, 2011; Smith and Rajagopal, 2016b).  
 barr-dependent signaling is engaged following GPCR activation by an agonist/activating 
ligand, or under conditions in which the GPCR is constitutively active (Scheerer and Sommer, 
2017). Following receptor activation, cytosolic G protein receptor kinases (GRKs) are recruited to 
the GPCR, resulting in phosphorylation of serine/threonine residues on the receptor C-terminus 
or intracellular loop regions (Benovic et al., 1986a; Benovic et al., 1986b; Gurevich and Gurevich, 
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2019). To date, there have been seven independent GRK isoforms identified (GRK1-7), and these 
are separated into subclasses based on sequence homology and function. GRK1 and GRK7 
(GRK1-like subfamily) are found only in the visual system. The GRK4-like subfamily includes 
GRK4, which is expressed predominantly in the testes, as well as GRK5 and GRK6, which exhibit 
more ubiquitous expression. The GRK2-like subfamily includes GRK2 and GRK3, which are also 
ubiquitously expressed (Pitcher et al., 1998; Gainetdinov et al., 2004). The mechanisms by which 
GRKs are recruited to GPCRs varies across GRK subtypes/subfamilies (Gurevich and Gurevich, 
2019). Given that the GRK2/3 subfamily has been the most extensively characterized in the brain 
(Gainetdinov et al., 2004; Evron et al., 2012), I will focus on outlining only GRK2/3-initated 
signaling cascades. Classical models indicate that GRK activation is directly stimulated by free 
Gbg subunits, which interact with the pleckstrin homology (PH) domain of the GRK molecule 
(Koch et al., 1993; Touhara et al., 1994). However, more recent evidence suggests that GRK 
signaling can be initiated independent of Gbg (i.e., G protein)-mediated mechanisms (Pack et al., 
2018). GRK-mediated GPCR phosphorylation mobilizes cytoplasmic barr to the 2nd or 3rd 
intracellular loop regions of the GPCR, leading to functional uncoupling of the GPCR and 
heterotrimeric G protein complex by steric hindrance, thereby preventing further signaling (i.e., 
desensitization) (DeGraff et al., 2002; Marion et al., 2006). Additionally, barrs act as cellular 
scaffolds of AP-2, resulting in GPCR internalization via dynamin-dependent endocytosis in 
clathrin-coated pits (Ferguson et al., 1996; Kang et al., 2013; Claing et al., 2001). Internalized 
GPCRs either recycle back to the plasma membrane (via recycling endosomes) or undergo 
degradation/downregulation (via sorting into late endosomes targeted to lysosomes) (Kang et al., 
2014; Oakley et al., 2000). Lastly, the scaffolding properties of barrs enable the nucleation of 
cellular signal transduction cascades, most notably of the MAPK/ERK family, that are distinct from 
signaling engendered by G proteins (Luttrell et al., 1999; Luo et al., 2008; Sun et al., 2002; 
Bruchas et al., 2006; Breitman et al., 2012). For example, some GPCRs will induce MAPK/ERK 
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signaling in early (e.g., ~5 minutes) and late (e.g., ~30 minutes) phases via distinct G protein- and 
barr-dependent mechanisms (Gesty-Palmer et al., 2006; McLennan et al., 2008). Moreover, 
GPCR-mediated p38 MAPK activation has been shown to be barr-, but not G protein-, dependent 
(Bruchas et al., 2006), further highlighting that barr-mediated signaling cascades can be 
engendered independently of those evoked by G proteins following receptor activation.   
 
1.2.2a - b-arrestins in Neuronal Physiology  
 The physiological importance of barrs has been elucidated predominantly through the use 
of transgenic knockout mice. Double knockout of barr1 and barr2 is embryonically lethal (DeWire 
et al., 2007), thus barrs play a prominent developmental role. However, knockout of either barr1 
or barr2 produces viable offspring that display grossly normal phenotypic profiles, suggesting that 
loss of a single barr isoform can result in, at least some, physiological compensation by the 
alternate barr. Despite relatively normal baseline phenotypes in barr1 and barr2 knockout mice, 
these strains often display perturbed physiological responses to environmental stressors or 
pharmacological challenge (Conner et al., 1997; Bohn et al., 1999).  
 
1.2.2b - b-arrestins and Opioidergic Signaling and Behavior  
 One of the most widely recognized examples of the physiological importance of barr 
function is work performed by the Caron group, which demonstrated that constitutive barr2 
knockout mice exhibit enhanced and prolonged morphine-induced analgesia (Bohn et al., 1999), 
despite marked reductions in morphine-induced tolerance and physical dependence (Bohn et al., 
2000; Bohn et al., 2002). These findings were among the first to confirm that barrs play an 
important role in agonist-induced desensitization and/or internalization/downregulation of CNS-
expressed GPCRs in vivo and suggested that specific behavioral outcomes (e.g., analgesia) 
could be mediated by distinct signal transduction cascades. Further work demonstrated that 
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MOR-induced analgesia is lost following pertussis toxin (PTX) treatment (Parolaro et al., 1990; 
Bodnar et al., 1990), which abolishes Gai/o signaling via irreversible ADP-ribosylation (Moss and 
Vaughan, 1988). These findings, when considered along with the aforementioned studies utilizing 
barr2 knockout mice, support that MOR-induced analgesia is mediated specifically by G i/o protein 
signaling. Continued work by Bohn, Caron, and others highlighted that barr2 loss also blunts some 
of the negative side effects produced by morphine and other MOR-directed opioids, including 
respiratory depression and constipation (Raehal et al., 2005; Raehal et al., 2011). Taken together, 
these seminal studies revealed that G protein and barr signaling downstream of opioidergic 
GPCRs can differentially determine behavioral outcomes.  
 
1.2.3 - GPCR Functional Selectivity (also known as Biased Agonism)  
 More recent work has focused on applying the mechanistic insight obtained from barr 
knockout mice toward designing and characterizing novel pharmacological compounds that 
exhibit the capacity to differentially or preferentially engage G protein- or barr-dependent signaling 
downstream of GPCRs (Urban et al., 2007; Violin and Lefkowitz, 2007). In classical models of 
ligand-receptor interactions, ligands possess two properties: affinity and efficacy. Affinity reflects 
how tightly a ligand binds to a receptor, whereas efficacy refers to the capacity of the ligand to 
produce a biological response following receptor binding (Stephenson, 1956; Kenakin, 2004). 
Thus, classical models suggested that GPCRs exist in either an active or inactive conformation, 
contingent on whether an agonist was bound (active conformation) or unbound (inactive 
conformation) (De Lean et al., 1980; Violin and Lefkowitz, 2007). These models permitted the 
classification of ligands as full agonists, partial agonists, neutral antagonists, or inverse agonists 
across a continuum of affinities. Specifically, full agonists produce maximal biological responses 
(i.e., maximal efficacy) via stabilization of an active state conformation of the GPCR. Partial 
agonists also stabilize an active state conformation of the GPCR, but exhibit submaximal efficacy 
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relative to full agonists. Inverse agonists stabilize an inactive state of the GPCR and exert an 
inhibitory effect on signal transduction that results from constitutive activity of the receptor (i.e., 
receptor activity that is independent of agonist binding). Lastly, ligands can be neutral antagonists, 
which prevent binding of other ligands and do not exhibit any efficacy at the receptor (Ariens, 
1954; Kenakin, 1995). While these categories accurately described many ligands, classical 
models of ligand-receptor pharmacology did not account for the aberrant property of some GPCR-
directed ligands to exhibit differential efficacy for distinct signal transduction cascades (e.g., G 
protein and barr signaling) within the same cellular system (Wei et al., 2003; Gesty-Palmer et al., 
2006), a process previously described as "imbalanced efficacy." For example, a ligand can act as 
an antagonist of one signaling pathway (e.g., barr signaling), while simultaneously acting as an 
agonist at a distinct signaling pathway (e.g., G protein signaling), despite identical expression of 
signal transduction machinery (e.g., RGSs, GRKs, barrs) within that particular cellular milieu 
(Allen et al., 2011). This concept is now more commonly known as functional selectivity or biased 
agonism (Urban et al., 2007; Reiter et al., 2012; Kenakin, 2011). Under this principle, an agonist 
(full, partial, or inverse) may stabilize a conformation of its cognate GPCR that preferentially or, 
in some cases, exclusively drive G protein (a 'G protein-biased' agonist) or barr (a 'barr-biased' 
agonist) signaling cascades.  
 The use of biased agonists in animal models has provided an additional strategy (i.e., 
along with transgenic manipulation) by which to further elucidate of how G protein or barr signaling 
mediates specific physiological or behavioral outcomes. Perhaps more importantly, biased 
agonists permit the opportunity to design a drug that can, in theory, produce enhanced therapeutic 
efficacy and/or mitigate disadvantageous side effects if these physiological/behavioral outcomes 
are independently induced by G protein versus barr signaling (Whalen et al., 2011). For example, 
the aforementioned work on the effects of morphine in barr2 knockout mice led to speculation that 
a MOR-selective G protein-biased agonist would be expected to preserve and/or enhance 
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analgesia, while reducing or eliminating clinically undesired side effects, such as tolerance, 
dependence, respiratory depression, and constipation (Schmid et al., 2017; Madariaga-Mazon et 
al., 2017). Indeed, MOR-selective G protein biased agonists have been synthesized and are 
considered to display a more clinically advantageous behavioral profile relative to unbiased, 
conventional MOR agonists, such as morphine (Manglik et al., 2016; DeWire et al., 2013; Koblish 
et al., 2017; Urits et al., 2019). These studies have led to a clinical trial of a MOR-selective G 
protein biased agonist called TRV-130 (oliceridine, brand name Olinvo) for severe pain (Singla et 
al., 2017), but the candidate compound failed due to weak efficacy and safety concerns related 
to QT interval prolongation, addiction, and tolerance liability (Research, 2018). Nonetheless, the 
design and characterization of biased agonists (directed against a wide variety of GPCRs) 
remains an encouraging and highly active pursuit that seeks to both deepen our mechanistic 
understanding of how GPCR signaling mediates a diverse array of physiological outcomes, as 
well as provide novel therapeutic candidates for clinical application across many different 
diseases and pathologies.  
 
 
1.3 - Kappa Opioid Receptor (KOR) Signaling and Behavior 
1.3.1 - Background: Opioid Receptor Signal Transduction  
 Each opioid receptor (MOR, DOR, and KOR) is a Gi/o-coupled GPCR and thus activation 
leads to adenylyl cyclase inhibition and reduced cAMP production (Al-Hasani and Bruchas, 2011). 
Via freed Gbg subunits, opioid receptor activation also leads to the activation of G protein inwardly 
rectifying potassium channels (GIRKs) (Luscher and Slesinger, 2010; Nockemann et al., 2013) 
and inhibition of P/Q-, N-, and L-type Ca2+ channels (Wang et al., 2010; Tedford and Zamponi, 
2006), thereby reducing neuronal excitation (via hyperpolarization) and decreasing 
neurotransmitter/neuropeptide release, respectively. Opioid receptors also recruit barr via 
activation-dependent receptor phosphorylation by GRK2/3, primarily at the C-terminal tail of the 
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receptor; thus, opioid receptors undergo barr-dependent desensitization and internalization in an 
agonist-dependent manner (Al-Hasani and Bruchas, 2011). The recruitment of barr also promotes 
G protein-independent signaling cascades, including the activation of kinases, such as ERK1/2, 
MAPK p38, and c-Jun N-terminal kinase (JNK) (Appleyard et al., 1999; Bruchas et al., 2006; 
McDonald et al., 2000; Wagley et al., 2013). MOR, DOR, and KOR show approximately 50-70% 
sequence similarity (Katritch et al., 2013), but display distinct neuroanatomical distributions and 
behavioral outcomes upon activation (Pan, 1998; Al-Hasani and Bruchas, 2011). In this section, 
I will focus on the mechanisms by which KOR signal transduction manifests specific behavioral 
outcomes following endogenous or exogenous activation. 
 
1.3.2 - KOR Expression in the Mouse Brain 
 The endogenous ligands of KOR are dynorphins, a class of neuropeptides derived from 
the precursor preprodynorphin (Sohn et al., 2014; Draisci and Iadarola, 1989). Dynorphin is 
released under conditions of stress and mediates a variety of acutely adaptive behavioral 
responses that chiefly serve to enable escape, and later avoidance, of environmental threats 
and/or aversive stimuli. Specifically, dynorphin-stimulated KOR activation can produce behavioral 
states of dysphoria (displeasure and unease), anhedonia (reduced responses to rewarding 
stimuli), anxiety, cognitive disruption, psychosis, analgesia, neuroendocrine dysfunction, and 
withdrawal following drug abuse (Chavkin and Koob, 2016). Continued or severe acute exposure 
to stressors upregulates dynorphin and often produces hypersensitization of the dynorphin/KOR 
system, which can promote the manifestation of disease-related physiological and behavioral 
states (Van't Veer and Carlezon, 2013; Vien et al., 2009; Karkhanis et al., 2016; Yorgason et al., 
2016). As one would expect based on this notion, KOR expression is densely distributed 
throughout the stress-sensitive limbic system of the brain, including the mesolimbic dopamine 
(DA) system (the reward system; the VTA and NAc), the dorsal raphe nucleus (DRN; the site of 
most serotonergic neurons innervating the forebrain), the prefrontal cortex (PFC), the amygdala 
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(AMY), the hippocampus (HPC), and the hypothalamus (Yasuda et al., 1993; Crowley and Kash, 
2015; Lalanne et al., 2014). A comprehensive review of the known actions of KOR activation 
within each of these brain regions can be found elsewhere (Crowley and Kash, 2015; Knoll and 
Carlezon, 2010; Van't Veer and Carlezon, 2013) and is beyond the scope of this thesis. Given the 
critical importance of KOR in regulating the mesolimbic DA system and the robust expression of 
RGS12 within mesolimbic substructures, I will focus on the specific mechanisms by which KOR 
affects mesolimbic DAergic neurotransmission and behavior.  
 
1.3.3 - KOR and Dopaminergic Neurotransmission  
1.3.3a - Background: KOR in the Mesolimbic DA System  
 KOR is enriched on presynaptic terminals of the NAc (a subregion of the ventral striatum 
[vSTR]), which originate from VTA DAergic projection neurons (Crowley and Kash, 2015; 
Bruijnzeel, 2009; Britt and McGehee, 2008). KORs are also expressed on VTA cell bodies, but 
these receptors preferentially regulate subpopulations of DAergic neurons that project to the 
prefrontal cortex (the mesocortical DA tract) (Margolis et al., 2006). Under conditions of elevated 
synaptic DA tone in the NAc, extracellular DA stimulates post-synaptic DA receptors (e.g., 
dopamine D1 receptor [D1R] and dopamine D2 receptor [D2R]) expressed on the cell bodies of 
GABAergic medium spiny neurons (MSNs), which comprise ~95% of the cells making up the 
striatum (Gerfen et al., 1990). Activation of D1R-expressing MSNs stimulates the release of 
dynorphin in a retrograde fashion to act upon presynaptic KORs expressed on DAergic terminals, 
leading to reductions in extracellular DA. Thus, KOR serves an important role in the negative 
feedback of mesolimbic DAergic neurotransmission (Trifilieff and Martinez, 2013). KOR-mediated 
decreases in DA occur by two primary, PTX-sensitive (i.e., Gi/o heterotrimer signaling-dependent), 
mechanisms; (1) inhibition of exocytotic DA release (Di Chiara and Imperato, 1988; Donzanti et 
al., 1992) and (2) increased dopamine transporter (DAT)-mediated DA uptake (Thompson et al., 
2000; Kivell et al., 2014). KOR-mediated reductions in DAergic neurotransmission are proposed 
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to underlie the dysphorigenic effects of KOR agonists in mice and humans (Pfeiffer et al., 1986; 
Shippenberg et al., 1993) and, accordingly, conditioned place aversion produced in mice by KOR 
agonists is lost upon ablation of KORs in DAergic neurons (Chefer et al., 2013). Furthermore, 
many drugs of abuse exert their rewarding effects by increasing mesolimbic DA (Nestler, 2001); 
thus, either acute administration of KOR agonists or endogenous activation of KOR by dynorphin 
effectively reduces behavioral responses to addictive substances (e.g., such psychostimulants as 
amphetamine and cocaine), and this reduction is dependent on KOR action in vSTR (Thompson 
et al., 2000; Gray et al., 1999).  
 
1.3.3b - Dopamine Release  
 Extensive prior evidence supports the notion that activation of KOR on presynaptic 
mesolimbic DA neurons reduces exocytotic DA release. Systemic administration of KOR agonists 
(e.g., U50,488, U69,593), or their direct infusion into the NAc, reduces extracellular DA in vivo 
(Spanagel et al., 1992; Chefer et al., 2005). Moreover, direct application of KOR agonists to NAc-
containing brain slices attenuates electrically-evoked, depolarization-dependent release of 
exogenously applied [3H]DA and endogenous DA stores (Heijna et al., 1990; Grilli et al., 2009; 
Rose et al., 2016). More recent studies using optogenetics demonstrate that the inhibitory effect 
of KOR on DA is preserved following the selective activation of DA terminals (i.e., absent the 
recruitment of local striatal microcircuitry, such as GABAergic MSNs or cholinergic interneurons) 
(Melchior and Jones, 2017), supporting the idea that KOR reduces DA release via a direct, cell-
autonomous mechanism. KOR-mediated inhibition of DA release is PTX- and Ca2+-sensitive (Grilli 
et al., 2009; Dalman and O'Malley, 1999), supporting the notion that reduced DA exocytosis by 
KOR activation is Gi/o heterotrimer signaling-dependent and likely mediated by Gbg-dependent 
inhibition of Ca2+ channels. KOR is also expressed, albeit at relatively low levels, in local striatal 
cholinergic interneurons. Cholinergic interneurons constitute only ~1% of the cell populations 
making up the striatum; however, they densely innervation DAergic terminals and serve an 
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integral role in the modulation of DA release via stimulatory release of acetylcholine (ACh) (Bolam 
et al., 1984; Contant et al., 1996). Accordingly, prior work supports that KOR-dependent 
regulation of DA release is, in part, related to the activation of KORs on striatal cholinergic 
interneurons (Threlfell and Cragg, 2011; Karkhanis et al., 2017). Perhaps the most compelling 
support for the notion that KOR regulates DA release via action within cholinergic interneurons 
comes from work by the Jones lab, which has demonstrated that KOR activation more potently 
inhibits DA release in the NAc following electrical stimulation (which directly recruits cholinergic 
interneurons) than after selective DAergic terminal activation (using optogenetics) (Rose et al., 
2016; Melchior and Jones, 2017). The most parsimonious explanation for these findings is that 
the activation of DA terminal-expressed KORs is necessary, but not sufficient, to account for the 
inhibitory effect that KOR exerts on striatal DA release and that cholinergic interneuron-expressed 
KORs contribute, in part, to this effect.  
  
1.3.3c - The Dopamine Transporter (DAT)  
 A central determinant of striatal DA tone (extracellular DA concentration) is the dopamine 
transporter (DAT). DAT is a 12-transmembrane protein with cytosolic N- and C-termini and is 
expressed exclusively within presynaptic and somatodendritic compartments of DAergic neurons 
(Chen and Reith, 2000; Ciliax et al., 1995). Under normal physiological conditions, DAT 
recaptures released DA back into DA neurons via a Na+/Cl--dependent mechanism, thereby 
terminating DAergic neurotransmission (Kuhar et al., 1990; Amara and Sonders, 1998). DAT can 
also display reverse transport, and thereby elevate extracellular DA via the non-exocytotic efflux 
of free cytosolic DA, in response to several psychostimulants (e.g., amphetamine [AMPH], 
methamphetamine [METH]), which are aptly characterized as releasing agents (Rothman et al., 
2001). Releasing agents are substrates for DAT; thus, in addition to their action as releasers, they 
also increase extracellular DA levels via competitive reuptake inhibition with endogenous DA 
(Rothman et al., 2001). In contrast, psychostimulants such as cocaine and methylphenidate 
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(RitalinTM) are not DAT substrates: they bind directly to the extracellular face of DAT and preclude 
the reuptake of DA, thereby augmenting extracellular DA levels predominantly via non-
competitive DAT inhibition (Beuming et al., 2008). Mice genetically engineered to lack DAT 
expression (i.e., DAT KO mice) exhibit markedly elevated extracellular DA tone at baseline and 
display remarkable levels of spontaneous hyperactivity; moreover, these mice do not exhibit 
locomotor activation or DA release to such psychostimulant drugs as AMPH and cocaine (Giros 
et al., 1996), highlighting the integral role that DAT plays in mediating the effects of 
psychostimulant drugs (Gainetdinov et al., 2002). Under both basal and psychostimulant-
stimulated conditions, DAT expression, subcellular trafficking, and uptake/efflux functions are all 
tightly regulated by a host of direct and indirect interactants, including receptors (e.g., GPCRs), 
kinases, and scaffolds (Torres et al., 2003; Vaughan and Foster, 2013).  
 KORs are robustly expressed on the plasma membrane of NAc DA neurons in direct 
apposition to DAT (Svingos et al., 2001), and KOR forms an oligomeric complex with DAT in 
transfected cells (Kivell et al., 2014). Activation of KOR leads to increased DAT-mediated DA 
uptake (Thompson et al., 2000; Kivell et al., 2014), likely by increasing the translocation of DAT 
to the plasma membrane (Kivell et al., 2014). However, at least one report found that KOR 
agonism (using the KOR agonist mesyl Sal B) induced an augmentation of DAT-mediated DA 
uptake with no change in cell surface DAT levels (Simonson et al., 2015). Thus, the effects of 
KOR activation on DAT, particularly with respect to DAT trafficking, are likely ligand-dependent. 
KOR activation-mediated increases in DA uptake are PTX-sensitive, supporting that these 
processes are mediated by a Gi/o heterotrimer signaling-dependent mechanism (Kivell et al., 
2014). DAT expression and function are both altered following either acute or chronic KOR 
activation (Chefer et al., 2005), thereby providing, at least in part, a mechanistic explanation for 
the observation that both acute and prolonged stress (e.g., via environmental stress-induced 
dynorphin upregulation or pharmacological activation of KOR) results in mesolimbic hypoDAergia 
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and disrupted responses to DAT-dependent psychostimulants (Walker and Koob, 2008; 
Karkhanis et al., 2016).  
 
1.3.3d - Psychostimulants  
 Ample prior evidence supports that KOR activation strongly regulates the behavioral and 
biochemical responses to psychostimulants such as AMPH and cocaine. Acute administration of 
the KOR-selective agonist U69,593 attenuates AMPH-induced behavioral activation and AMPH-
induced elevations in ventral striatal DA, while local application of the KOR-selective antagonist 
nor-BNI into the vSTR reverses these effects (Gray et al., 1999). These data strongly support that 
KOR signaling within the vSTR is able to regulate the DA-dependent behavioral effects of AMPH. 
However, repeated administration of U69,593 has no effect on locomotor sensitization to AMPH 
following repeated administration (Escobar Adel et al., 2012), suggesting that KOR signaling may 
play a more important role in modulating the acute effects of AMPH. Indeed, acute administration 
of AMPH potently stimulates the release of endogenous dynorphin, which can result in the 
desensitization of striatal KORs (Xia et al., 2008). These findings provide at least one explanation 
for why KORs may not be as important under conditions of chronically administered AMPH. 
 Considerably more work has been performed to elucidate the role that KOR plays in the 
behavioral and biochemical effects of cocaine. Administration of KOR agonists blocks acute 
cocaine-induced locomotor activation (Heidbreder et al., 1993; Vanderschuren et al., 2000). In 
contrast to AMPH, some work has shown that KOR agonists also blunt locomotor sensitization 
and conditioned place preference to cocaine (Heidbreder et al., 1993; Shippenberg et al., 1996; 
Zhang et al., 2004), measures of repeated/chronic cocaine administration. Moreover, chronic 
cocaine adminstration upregulates KOR protein levels (Collins et al., 2002). Together, prior 
evidence supports that cocaine and KOR exhibit a reciprocally functional interaction, particularly 
within the mesolimbic DA system (Trifilieff and Martinez, 2013).  
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 However, some work has shown that KOR agonists do not affect cocaine-induced 
locomotor sensitization (Vanderschuren et al., 2000), and the effect of KOR on cocaine self-
administration is similarly mixed (Karkhanis et al., 2017). More recent work convincingly 
reconciles these mixed findings by demonstrating the nuanced temporal dependence of KOR 
activity on the chronic effects of cocaine. For example, the Chavkin group has shown that 
systemic administration of the KOR-selective agonist U50,488 15 minutes prior to cocaine 
administration in a conditioned place preference paradigm decreases cocaine preference, and 
these effects correlate with traditionally observed KOR-mediated reductions in the elevation of 
extracellular DA (in the NAc) evoked by cocaine (Zhang et al., 2004). However, when U50,488 is 
administered 60 minutes prior to cocaine administration, cocaine preference is markedly 
increased with concomitantly augmented DA levels in the NAc relative to baseline conditions. The 
authors conclude that 60-minute pretreatment with a KOR agonist initially results in reduced 
synaptic DA levels, thereby resetting baseline DAergic tone to a lower starting point, and thus 
permitting a greater effect of cocaine (i.e., an enhanced effect size of cocaine-stimulated DAergic 
tone relative to baseline) (Ehrich et al., 2014). Notably, potentiation of cocaine-induced CPP is 
also observed following chronic stress (using a chronic forced swim paradigm), a process that 
increases dynorphin release and KOR activation (McLaughlin et al., 2006; Schindler et al., 2010; 
Ehrich et al., 2014). This biphasic, time-dependent effect of KOR activation on cocaine-induced 
DA tone has been observed by other groups, even when employing different KOR agonists and 
behavioral paradigms (Chartoff et al., 2016). Together, these findings support that KOR 
dynamically responds to, and can determine, the overall effects of cocaine and perturbations in 
mesolimbic DA neurotransmission.  
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1.4 - 'Functionally Selective' Behavioral Outcomes of KOR Activation  
1.4a - Background 
 Consistent with the aforementioned studies demonstrating that functional selectivity at 
MOR can produce profoundly distinct molecular and behavioral outcomes (Bohn et al., 1999; 
Bohn et al., 2000; Bohn et al., 2002), recent work has shown that similar processes occur with 
KOR (Bohn and Aube, 2017; Schmid et al., 2013; White et al., 2015; Brust et al., 2016; Dunn et 
al., 2018). KOR activation results in a wide array of clinically relevant effects, including analgesia 
(Kivell and Prisinzano, 2010), anti-addiction/reward (Bruijnzeel, 2009), anxiety/depressive-like 
behaviors (Van't Veer and Carlezon, 2013), anti-pruritus (anti-itch) (Brust et al., 2016), diuresis 
(DeHaven-Hudkins and Dolle, 2004), sedation (Vonvoigtlander et al., 1983), dysphoria/aversion 
(Ehrich et al., 2015), and psychotomimesis (Pfeiffer et al., 1986). Clearly, a subset of these 
outcomes are clinically advantageous (e.g., analgesia, anti-itch, anti-reward), while others are 
disadvantageous (anxiety/depression, dysphoria, psychotomimesis). To date, the only approved 
KOR-directed ligand, nalfurafine (Remitch), is used in Japan for the treatment of intractable itch 
in patients with uremic pruritus related to chronic kidney disease (Kumagai et al., 2010). However, 
most work with animal models has focused on leveraging the notion that KOR agonists produce 
analgesia, but lack addictive potential; thus, many have proposed that KOR agonists could 
represent a viable replacement (or adjuvant) for highly addictive MOR-directed pain relievers 
(e.g., oxycodone, hydrocodone, etc.) (Bohn and Aube, 2017; Vanderah, 2010).  
 The clinical viability of KOR agonists has been largely hampered by an inability to identify 
KOR-selective drugs that preserve clinically beneficial outcomes, while mitigating (or abolishing) 
detrimental outcomes. This issue may be addressable by exploiting functional selectivity at KOR, 
as the prevailing notion in the literature supports that the analgesic properties of KOR agonists 
are mediated by G protein signaling-dependent mechanisms, whereas the dysphoric/aversive 
effects of KOR agonists are mediated by barr-dependent processes (Bruchas et al., 2007; Brust 
et al., 2016). Considerably less work has sought to identify the functional selectivity underlying 
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other clinically relevant KOR-mediated behaviors (e.g., anxiety/depression). Therefore, in this 
section, I will focus on the extant findings related to the G protein- and barr-dependent 
mechanisms underlying KOR-induced analgesia and dysphoria/aversion.  
 
1.4b - KOR-induced Analgesia 
 KOR is expressed within many ascending sensory and descending inhibitory pain-
associated cell types/regions within the spinal cord and brain (Mansour et al., 1994; Ji et al., 
1995). Accordingly, KOR activation in both the CNS and periphery reduces inflammatory, visceral, 
neuropathic, and acute pain (Kivell and Prisinzano, 2010; Vanderah, 2010; Simonin et al., 1998; 
Cunha et al., 2012). The upregulation of dynorphin and/or KOR is an important mechanism 
underlying the negative affective response experienced under conditions of chronic pain (Cahill 
et al., 2014; Liu et al., 2019; Massaly et al., 2019), further highlighting the diverse and integrative 
role that KOR signaling plays in pain processing. The signaling mechanisms underlying KOR-
mediated analgesia have largely been elucidated using assays of supraspinal (hot plate assay) 
and spinal (tail immersion/withdrawal assay) analgesia in rodents. Using these assays, it has 
been shown that KOR agonist-induced analgesia is abolished with PTX pretreatment (Hernandez 
et al., 1995) and is unaffected in mice lacking GRK3 or barr expression (McLaughlin et al., 2004; 
White et al., 2015). Moreover, several G protein-biased KOR agonists retain analgesic efficacy 
comparable to conventional unbiased agonists (White et al., 2015; Brust et al., 2016; Schattauer 
et al., 2017). Collectively, these findings strongly support that KOR agonist-induced supraspinal 
analgesia is mediated by G protein signaling downstream of receptor activation. Similar 
mechanistic underpinnings have been ascribed to the anti-pruritic effects of KOR agonists 
(Morgenweck et al., 2015; Brust et al., 2016), although these effects are mediated by KORs within 
the dorsal root ganglion (DRG) (Kardon et al., 2014). Under conditions of chronic pain (e.g., 
neuropathic injury), dynorphin and KOR are upregulated, enabling an analgesic compensation in 
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response to injury (Xu et al., 2004; Wagner et al., 1993; Wang et al., 2001). However, prolonged 
dynorphin release desensitizes KOR via a GRK/barr-dependent mechanism (Xu et al., 2004), 
thereby reducing the analgesic effects of KOR activation. Thus, the acute analgesic effects of 
KOR activation are mediated via G protein-dependent signaling, whereas the efficacy of KOR-
mediated analgesia in chronic pain states may rely predominantly on barr-dependent signaling.  
 
1.4c - KOR-induced Dysphoria/Aversion 
 Early investigation into the effects of KOR agonists in humans revealed KOR activation 
can result in profound dysphoria and psychotomimesis (Pfeiffer et al., 1986). The dysphoric and 
hallucinogenic effects in humans have been derived predominantly from observations with the 
KOR-selective agonist salvinorin A, the psychoactive constituent of the plant Salvia divinorum. 
The Mazatec peoples of Oaxaca, Mexico have traditionally used Salvia divinorum for religious 
practices, while the general recreational use of salvinorin A extracts has become more 
widespread over the last few decades (Roth et al., 2002; Mahendran et al., 2016). Salvinorin A 
administration produces profound effects of mind-body dissociation and cognitive disruption 
(MacLean et al., 2013; Maqueda et al., 2015), although participants do not always rate these 
experiences as dysphoric or anxiety-inducing (Johnson et al., 2011; Ranganathan et al., 2012; 
MacLean et al., 2013). However, some speculate that the absence of dysphoria or negative affect 
in some participants may be confounded by prior use of other hallucinogens/psychedelics and/or 
expectation(s) of experience (Gonzalez et al., 2006).  
 In contrast to the mixed affective responses observed in humans, KOR agonists 
administered to rodents very reliably induce aversion, a behavioral response considered to be a 
measure of dysphoria (Al-Hasani and Bruchas, 2011; Valentino and Volkow, 2018). The standard 
assay employed for measuring aversion in rodents is the conditioned place aversion (CPA) 
paradigm, which employs Pavlovian conditioning to determine the aversive properties of drugs 
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and/or the actions of neural circuits or neurotransmitter systems. Early work (Shippenberg and 
Herz, 1986) identified KOR agonists as potently aversive agents using the CPA paradigm. The 
dysphoric effects of KOR agonists were later reinforced by independent results from behavioral 
tasks less reliant on learning, such as intracranial self-stimulation (ICSS) (Todtenkopf et al., 
2004). Aversion produced by systemic KOR agonist administration is abolished following 6-
hydroxydopamine (6-OHDA)-induced lesioning of DAergic neurons or pharmacological DA 
receptor inhibition in the mesolimbic (i.e., NAc), but not mesocortical (i.e., PFC), system 
(Shippenberg et al., 1993). Moreover, microinjection of the KOR agonist U50,488 into the NAc is 
sufficient to produce CPA, and this behavioral outcome correlates with KOR agonist-induced 
reductions in DAergic tone (Bals-Kubik et al., 1993). Additionally, more recent work demonstrated 
that KOR agonist-induced CPA is lost upon DA neuron-specific knockout of KOR (Chefer et al., 
2013). Together, these findings support the idea that KOR agonist-induced aversion is mediated 
by reductions in DA within the NAc, a biological process consistent with a state of negative affect. 
However, not all studies support this model. For example, DA-deficient mice still exhibit KOR 
agonist-induced CPA (Land et al., 2009). Although this finding is compelling, it is confounded by 
the fact that CPA assays with DA-deficient mice required caffeine administration (Land et al., 
2009) in order to reverse the marked inactivity exhibited by these mice at baseline. Perhaps more 
convincing are experiments demonstrating that selective inactivation of KOR expressed within 
serotonergic dorsal raphe nucleus (DRN) neurons (specifically those projecting to the NAc) 
prevents KOR agonist-induced CPA; moreover, selective re-expression of KOR within 
serotonergic DRN neurons of KOR knockout mice was sufficient to produce KOR agonist-induced 
aversion (Land et al., 2009). Thus, in contrast to prior studies supporting KOR's effects on 
mesolimbic DA as being required for agonist-induced aversion, this study supports an integral 
role of serotonin in these processes.  
 The intracellular signaling determinants underlying KOR-induced aversion have also been 
controversial, although the traditional theory within the field supports that the dysphoric/aversive 
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properties of KOR agonists are mediated by barr-dependent processes. This notion is 
predominantly predicated on extensive work by the Chavkin group utilizing pharmacologic and 
genetic manipulations of upstream (GRK3) and downstream (p38 MAPK) signaling molecules of 
barr following KOR activation (Bruchas et al., 2006; Ehrich et al., 2015; Al-Hasani and Bruchas, 
2011). The dependence of barr in mediating KOR-induced aversion is further bolstered by the 
lack of dysphoria/aversion produced by some G protein-biased KOR agonists (Brust et al., 2016; 
Kivell et al., 2018). However, a study by the Roth group (White et al., 2015) provided conflicting 
evidence to this theory when the authors evaluated KOR agonist-induced CPA in barr-2 knockout 
mice. These experiments showed that the CPA induced by the conventional KOR agonist 
U69,593 was unaffected in mice constitutively lacking barr-2. Notably, the authors recognize the 
possibility that compensation of barr-1 could underlie these results, especially given their 
overlapping expression (White et al., 2015). Moreover, barr-2 plays an integral role in 
neurodevelopmental processes (Philipp et al., 2013); thus, it is highly plausible that constitutive 
loss of barr-2 from conception could engender disruptions to neuronal cell and circuit function, 
thereby confounding a determination of whether KOR agonist-induced aversion is mediated by a 
direct barr-2-dependent mechanism. Future studies employing selective ablation of barr within 
KOR neurons (e.g., progeny from KOR::Cre mice crossed with Barr2 floxed mice) may provide 
the best model to determine whether barr is absolutely required for KOR agonist-induced 
aversion, as this would obviate issues of genetic compensation and off-target effects (i.e., loss of 
barr in non-KOR-expressing cell populations).  
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2.1 - Abstract 
Regulators of G protein Signaling (RGS) are proteins that accelerate the termination of 
effector stimulation after G protein-coupled receptor (GPCR) activation. Many RGS 
proteins are highly expressed in the brain and therefore considered potential drug 
discovery targets for CNS pathologies; for example, here we show that RGS12 is highly 
expressed in microdissected mouse ventral striatum. Given a role for the ventral striatum 
in psychostimulant-induced locomotor activity, we tested whether Rgs12 genetic ablation 
affected behavioral responses to amphetamine and cocaine. RGS12 loss significantly 
decreased hyperlocomotion to lower doses of both amphetamine and cocaine; however, 
other outcomes of administration (sensitization and conditioned place preference) were 
unaffected, suggesting that RGS12 does not function in support of the rewarding 
properties of these psychostimulants. To test whether observed response changes upon 
RGS12 loss were caused by changes to dopamine transporter (DAT) expression and/or 
function, we prepared crude membranes from the brains of wild type and RGS12-null 
mice and measured DAT-selective [3H]WIN 35428 binding, revealing an increase in DAT 
levels in the ventral—but not dorsal—striatum of RGS12-null mice. To address DAT 
function, we prepared striatal synaptosomes and measured [3H]dopamine uptake. 
Consistent with increased [3H]WIN 35428 binding, DAT-specific [3H]dopamine uptake in 
RGS12-null ventral striatal synaptosomes was found to be increased. Decreased 
amphetamine-induced locomotor activity and increased [3H]WIN 35428 binding were 
recapitulated with an independent RGS12-null mouse strain. Thus, we propose that 
RGS12 regulates DAT expression and function in the ventral striatum, affecting 
amphetamine- and cocaine-induced increases in dopamine levels that specifically elicit 
acute hyperlocomotor responses. 
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2.2 - Introduction 
Psychostimulant drugs of abuse such as (+)-amphetamine (AMPH) and cocaine are 
among the most widely abused substances in the United States (Quality., 2015). These 
psychostimulants impose severe liabilities of high abuse potential, capacity to induce 
psychoses, considerable neurotoxicity, and mortality (Heal et al., 2013; Ciccarone, 2011). 
The locomotor-activating and rewarding properties of these psychostimulants are 
dependent on the mesolimbic dopamine (DA) system of the brain (Adinoff, 2004; Kauer 
and Malenka, 2007; Thomas et al., 2008; Nutt et al., 2015), defined as the projections 
from DAergic cell bodies in the ventral tegmental area (VTA) to presynaptic terminals in 
the nucleus accumbens (NAc) of the ventral striatum (vSTR). Dopaminergic signaling 
within the vSTR is central to psychostimulant-induced locomotor activity (Ikemoto, 2002):  
lesioning of DAergic terminals within the NAc—but not in the dorsal striatum (dSTR)—by 
local injection of 6-hydroxydopamine markedly reduces the hyperlocomotor responses to 
the dopaminergic indirect agonists AMPH and cocaine (Kelly and Iversen, 1976). 
Similarly, microinjections of AMPH or cocaine into the NAc—but not dSTR—increase 
locomotion and rearing behavior in rodents (Staton and Solomon, 1984; Carr and White, 
1987; Kelley et al., 1989; Delfs et al., 1990).  
AMPH and cocaine exert their effects by increasing extracellular DA levels in the vSTR 
via their action at the dopamine transporter (DAT; refs. (Giros et al., 1996; Federici et al., 
2014)), which acts to translocate released DA back into the presynaptic DA terminal, thus 
terminating neurotransmission at post-synaptic DA receptors. However, the mechanisms 
by which AMPH and cocaine modulate DAT are mechanistically distinct. AMPH acts as 
an indirect dopaminergic agonist in two ways: first, the drug acts as a substrate for (and 
hence, a competitive inhibitor of) DAT (Sitte and Freissmuth, 2010), whose role is to re-
uptake dopamine after its release (Ramsey et al., 2008). Upon entry into dopaminergic 
terminals, AMPH also acts as a substrate for the vesicular monoamine transporter, whose 
role is to transport synaptoplasmic dopamine into vesicles for release (Sulzer, 2011). 
Once inside dopaminergic vesicles, AMPH causes release, through reverse transport of 
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the vesicular monoamine transporter, of free dopamine into the synaptoplasm (Sitte and 
Freissmuth, 2010). In addition, amphetamine causes release of that free dopamine 
through DAT, thereby increasing synaptic levels of dopamine (Sitte and Freissmuth, 
2010). Cocaine acts more simply: it is not a DAT substrate rather, it is a competitive 
inhibitor of the protein (Rothman, 1990). Cocaine blocks the ability of DAT to re-uptake 
released dopamine, thereby increasing levels of dopamine in the synapse (Nestler, 2005). 
Thus, each drug (AMPH and cocaine) ultimately yields increased levels of synaptic 
dopamine in dopaminergic (dopamine transporter-expressing) synapses. These 
increased levels of dopamine in response to AMPH or cocaine act on post-synaptic, 
dopamine-responsive, G protein-coupled receptors (GPCRs) to elicit responses post-
synaptically (Schultz, 2002). 
DAT expression, subcellular trafficking, and DA uptake function are all tightly 
regulated by a host of protein interactants (Torres, 2006), such as receptors, kinases, and 
scaffolds. In particular, several groups have identified presynaptic GPCRs and scaffolding 
proteins that directly and/or functionally interact with DAT (Torres, 2006), suggesting that 
GPCR-dependent, multiprotein networks are critical to DAT function. RGS12, a member 
of the ‘Regulator of G protein Signaling’ (RGS) protein superfamily (Snow et al., 1998; Snow 
et al., 1997), has not previously been associated with DAT regulation. RGS proteins are known 
to accelerate the inactivation of GPCR-activated Ga subunits (i.e., GTP-bound Ga 
subunits) by stimulating their intrinsic GTPase activity (Berman et al., 1996). This 
inactivation is followed by the reassociation of GDP-bound (i.e., inactive) Ga subunits 
with Gbg subunits, thereby terminating signaling originally evoked by free GTP-bound Ga 
subunits (e.g., inhibition of adenylyl cyclase; (Clark and Traynor, 2004)) and/or free Gbg 
subunits (e.g., stimulation of G protein-coupled inwardly rectifying potassium (GIRK) 
channels; (Zhou et al., 2012)).  
As many RGS proteins are expressed in the CNS (e.g., ref. (Gold et al., 1997)), they are 
suspected to play key roles in neuronal function and behavior (Neubig and Siderovski, 2002). 
For example, RGS14, the closest related paralog to RGS12, is integral to hippocampal 
 48 
synaptic plasticity underlying learning and memory (Lee et al., 2010). Several RGS 
proteins, including RGS12 and RGS14, are endowed with functional domains other than 
the RGS domain (Kimple et al., 2011). In addition to being a Ga-directed GTPase-
accelerating protein (GAP) (Snow et al., 1998), RGS12 contains four additional functional 
motifs: a PDZ binding domain (common among scaffolding proteins), a phosphotyrosine 
binding domain, tandem Ras binding domains, and a GoLoco motif (which sequesters 
GDP-bound Ga subunits) (Kimple et al., 2002; Snow et al., 1998; Willard et al., 2007). 
Thus, the function of RGS12 in vivo need not be restricted to Ga-directed GAP activity in 
opposition to GPCR activation; for example, we have shown that RGS12 acts as a 
scaffold for Ras, Raf, and MEK in prolonging NGF-stimulated ERK signaling and 
stimulating axonogenesis by dorsal root ganglion neurons, as detailed in (Willard et al., 
2007).  
To explore more deeply the potential roles for RGS12 function in the CNS, we created 
both conventional and conditional mouse knockout strains and conducted subsequent 
behavioral (locomotion, sensitization, conditioned place preference) and biochemical 
(tissue radioligand binding, synaptosome uptake and release) studies. Based on our 
findings, we propose that RGS12 modulates the expression and function of DAT in the 
ventral striatum, thus explaining decreased hyperlocomotor responses in RGS12-null 
mice to AMPH or cocaine compared with wild type littermates. Our findings are 
compatible with a robust literature indicating that DAT function is modulated by a number 
of accessory proteins/enzymes (Torres, 2006). Thus, we have identified RGS12 as a 
novel regulator of DAT and suggest that the locomotor-activating effects of 
psychostimulants are dependent, in part, on RGS12 function.  
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2.3 Methods 
2.3.1 - Animals 
Generation of two independent strains of RGS12-null mice (constitutive Rgs12Δ5-8/Δ5-8 and 
Cre-dependent Rgs12Δ5-6/Δ5-6) is described in Figure 1 and Supplementary Figure S1. 
Both mouse strains are in the C57BL/6J background. Mice were housed under standard 
temperature, humidity, and lighting conditions (12 hours light / 12 hours dark). All 
behavioral experiments performed during the light cycle using mice between 8-10 weeks 
of age. All mice were provided food and water ad libitum. All experiments were conducted 
in accordance with West Virginia University Animal Care and Use Committee and 
followed the National Institute of Health guidelines for use of animals in research. The 
procedures of the behavioral assays are described below and were conducted according 
to previously published methods (as cited); mice were used for only one behavioral assay 
involving either acute or chronic drug dosing (i.e., all drug-based studies were performed 
with drug-naïve mice; there is no sequence of multiple, drug-based experimental trials to 
define for individual mice used in this study).  
 
2.3.2 - In situ hybridization 
In situ hybridization with an antisense riboprobe directed against Rgs12 was performed 
in order to assess the distribution of Rgs12 mRNA in brain. cDNA from the mouse Rgs12 
open reading frame (full-length) was subcloned into a pBluescript II SK vector by 
restriction enzyme digestion. In vitro transcription with T7 RNA polymerase was 
conducted to produce a digoxigenin-labeled antisense riboprobe. In situ hybridization was 
then performed by the University of North Carolina Neuroscience Center In Situ 
Hybridization Core using standardized protocols (UNC-Chapel Hill).   
 
2.3.3 - Immunoblots 
Immunoblot analyses of microdissected dopaminergic brain regions (frontal cortex, dorsal 
and ventral striatum, and midbrain) were performed in order to identify which regions 
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contained RGS12 protein, to compare the relative abundances of RGS12 protein across 
selected regions, and to verify complete knockout of RGS12 protein in Rgs12Δ5-8/Δ5-8 mice. 
Mice were injected with a lethal dose of pentobarbital (200 mg/kg, ip), decapitated, rapidly 
dissected, and frozen on dry ice. Dorsal striatum, ventral striatum, and midbrain were 
sonicated in 10 volumes of RIPA buffer containing 25 mM Tris-HCl (pH 7.6), 150 mM 
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS (Pierce) supplemented with 
protease inhibitors (HaltTM protease inhibitor cocktail, Thermo Fisher). Lysates were 
cleaned by centrifugation at 20,800 g for 20 min and pellets were discarded. Proteins 
were then separated by SDS-PAGE on a gradient 4-15% gel (BioRad), electrotransferred 
to nitrocellulose membranes, and incubated overnight (4°C) with a monoclonal primary 
antibody directed against the N-terminus of RGS12 (generated in-house) or beta-actin 
(Thermo Fisher). Blots were then probed with HRP-conjugated goat anti-mouse 
secondary antibodies and visualized by chemiluminescence (Pierce). Data were derived 
from a sample size of n = 6-9 per genotype per experiment. 
 
2.3.4 - Locomotor assays 
AMPH- or cocaine-induced locomotor activity assessments were carried out in order to 
evaluate behavioral phenotypes in RGS12-null mice. Open field locomotor activity was 
evaluated in a 16 x 16 photobeam activity system (PAS) under standard environmental 
conditions (San Diego Instruments, San Diego, CA). Horizontal locomotor activity was 
measured as the sum of the total X and Y coordinate beam breaks collected every 5 
minutes. Acute psychostimulant-induced locomotor activity experiments were carried out 
over 3 days. On day 1, mice were habituated to locomotor chambers over 150 minutes to 
reduce the influence of novelty. On day 2, all mice we allowed to habituate to locomotor 
chambers for 30 min before intraperitoneal (ip) administration of saline (0.9% NaCl) at a 
volume 10 mL/kg and locomotor activity was measured over 110 minutes.  
On day 3, mice were habituated to locomotor chambers for 30 min and then injected with 
d-amphetamine (1, 3, or 5 mg/kg, ip) (Salahpour et al., 2008; Tzschentke, 2007) or 
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cocaine (10, 20, or 40 mg/kg, ip) (Ramsey et al., 2008; Jung et al., 2013) dissolved in 
saline (ip, at a final volume of 10 mL/kg). Psychostimulant-induced hyperlocomotion was 
then measured over 110 minutes. All drugs were obtained from Sigma-Aldrich (St. Louis, 
MO). Data were derived from a sample size of n = 7-23 per genotype per experiment. 
 
2.3.5 - Psychostimulant-induced locomotor sensitization 
Sensitization experiments were performed in order to assess whether RGS12-null mice 
exhibited reduced responsiveness to repeated administration of AMPH or cocaine as was 
observed with acute hyperlocomotion induced by these psychostimulants. Experiments 
were performed as previously described (Steinkellner et al., 2014) with minor 
modifications. Briefly, mice were habituated to locomotor chambers on day 1 and 2 as 
described in acute psychostimulant-induced locomotor activity experiments. Mice were 
then administered d-amphetamine (2 mg/kg, ip) or cocaine (20 mg/kg, ip) (Ramsey et al., 
2008) for 6 consecutive days (d1-d6) to induce sensitization under the conditions 
described for day 3 of acute psychostimulant-induced locomotor activity experiments. 
After the sixth day of psychostimulant administration, drug was withdrawn for 14 days. 
Following washout (d20), mice were challenged with d-amphetamine (2 mg/kg, ip) or 
cocaine (20 mg/kg, ip) and horizontal locomotor activity was evaluated. Data were 
analyzed by two-way, repeated measures ANOVA. Data were derived from a sample size 
of n = 6-9 per genotype per experiment. 
 
2.3.6 - Conditioned place preference (CPP) 
CPP was conducted with RGS12-null mice in order to evaluate whether RGS12 
influences the rewarding properties of AMPH or cocaine. CPP studies were performed in 
a two-chambered apparatus (Med Associates, ENV-3013-2, Georgia, VA) with the 
paradigm described by Ramsey and colleagues (Ramsey et al., 2008) with minor 
modifications. The two chambers of the CPP apparatus contained distinguishable floor 
grating (grid floor vs rod floor) and colored walls (white vs black). Each experiment 
consisted of habituation, preconditioning, conditioning, and post-conditioning phases. 
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Habituation (day 1) was carried out to reduce the influence of apparatus novelty.  Mice 
were allowed free access to either chamber for 30 min and measurements of time spent 
in each chamber was measured. For the preconditioning phase (day 2), mice were again 
allowed free access to either chamber for 30 min and time spent in each chamber was 
measured to determine the least-preferred chamber of each mouse. Preference on days 
1 and 2 were comparable (data not shown). The next day (day 3) began the conditioning 
phase. Mice were injected with either d-amphetamine (2 mg/kg, ip) or cocaine (20 mg/kg, 
ip) and were restricted to the least preferred chamber for 30 min. On day 4, mice were 
injected with saline (0.9% NaCl, ip) and restricted to the other chamber for 30 min. The 
remainder of the conditioning phase consisted of two more repetitions of alternating drug 
(days 5 and 7) and saline (days 6 and 8). For the postconditioning test phase, conditioned 
place preference was determined by allowing mice free access to either chamber and 
measuring the time spent for 30 min. No differences in chamber preference were 
identified between habituation (day 1) and preconditioning day (day 2). Preconditioning 
and postconditioning were calculated by subtracting the time spent (seconds) in the 
preferred chamber (as determined on day 2) from the least preferred chamber (as 
determined on day 2). Data were analyzed by two-way, repeated measures ANOVA. Data 
were derived from a sample size of n = 7-8 per genotype per experiment. 
 
2.3.7 - Preparation of brain sections and immunohistochemistry for c-Fos 
Psychostimulant-induced c-Fos immunohistochemistry was performed in order to 
determine whether RGS12-null mice showed a reduction in neural activity specifically 
within the NAc of the vSTR. Mice received ip injection of saline or d-amphetamine (3 
mg/kg). Following 90 min, mice were anesthetized with pentobarbital (200 mg/kg) and 
transcardially perfused with 4% paraformaldehyde. Perfused brains were post-fixed 
overnight and then placed in 30% sucrose solution until brains sank. Cryoprotected brains 
were then frozen overnight at -80°C and 40-μm free-floating sections were prepared. 
Sections were incubated with a polyclonal anti-c-Fos primary antibody (1:100; Santa 
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Cruz, Dallas, TX) overnight at 4°C, followed by incubation of a flurophore-conjugated goat 
anti-rabbit secondary antibody (Thermo Fisher Sci.) for 2 hr at RT. Psychostimulant-
induced c-Fos expression was visualized on an Evos epifluorescent microscope and c-
Fos-positive nuclei were counted in a 0.16-mm2 field of dorsal and ventral striatum. 
Anatomical landmarks, such as the anterior commissure, corpus callosum, and septum, 
were utilized to demarcate the dorsal and ventral striatum. Three independent sections 
separated by 200 μm were counted per mouse, and presented data were determined by 
computing the average number of c-Fos-positive nuclei per field in 3-4 mice per genotype.  
 
2.3.8 - Preparation of synaptosomes and measurement of [3H]dopamine uptake and 
release These biochemical experiments were performed to assess whether the observed 
reductions in acute psychostimulant-induced hyperlocomotion were correlated with 
changes in DA uptake and/or AMPH-induced DA release. For [3H]dopamine uptake 
experiments, dorsal and ventral striatal synaptosomes were prepared by homogenizing 
brain tissue from 3-4 mice per genotype in 10 volumes ice-cold sucrose buffer (10% 
sucrose, 5 mM HEPES, pH 7.4) with a Potter-Elvehjem homogenizer (10 strokes). 
Homogenates were then centrifuged at 1,000 g for 10 min and supernatants containing 
crude synaptosomes were maintained on ice. Synaptosomes were then added to tubes 
containing Krebs-Ringer uptake buffer (120 mM NaCl, 20 mM Tris-HCl, 5 mM KCl, 1.2 
mM MgSO4, 2.5 mM CaCl2, 10 mM glucose, 1 mM ascorbic acid, and 0.1 mM pargyline) 
plus [3H]dopamine (33.5 μCi, Perkin-Elmer, Bridgeville, PA) and incubated for 10 min at 
RT for uptake to occur. Non-specific [3H]dopamine uptake was determined in the 
presence of 10 μM cocaine and subtracted from total uptake. Uptake was terminated by 
rapid filtration (Brandel harvester) through 0.1% PEI-soaked Whatman GF/B filters with 
ice-cold Krebs-Ringer buffer and washed three times before radioactivity measurement 
via liquid scintillation counting. Data were analyzed with nonlinear fitting software 
(GraphPad Prism 7) to determine Vmax and Km. AMPH-induced [3H]dopamine release 
assays were performed as previously described (Rothman et al., 2001) with minor 
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modifications. Briefly, dorsal and ventral striatal synaptosomes were prepared as 
described above but with ice-cold sucrose buffer supplemented with 1 μM reserpine. 
Synaptosomes were then incubated to steady-state with 5 nM [3H]dopamine (30 min) in 
Krebs-Ringer buffer supplemented with 1 μM reserpine. Following incubation, 900 μL of 
preloaded synaptosomes were added to 12 x 75 mm polystyrene tubes containing d-
amphetamine (1 x 10-8.5 to 1 x 10-5 M) in Krebs-Ringer buffer. The release reaction 
proceeded for 5 min, then terminated by rapid filtration over Whatman GF/B filters with 
ice-cold Krebs-Ringer buffer, washed three times, and radioactivity was measured via 
liquid scintillation counting. Data were analyzed with nonlinear fitting software (GraphPad 
Prism 7) to determine EC50. Data were derived from a sample size of n = 6-12 per 
genotype per experiment. 
 
2.3.9 - Preparation of brain tissue and measurement of [3H]WIN 35428 binding 
DAT saturation binding experiments were conducted in order to determine whether the 
increased DA uptake in RGS12-null mice was associated with elevated DAT protein 
levels. Dorsal and ventral striatal brain regions were rapidly dissected and frozen on dry 
ice. Tissue was then homogenized with a Polytron homogenizer with 10 volumes of 
transporter binding buffer (50 mM Tris-HCl, 120 mM NaCl, and 5 mM MgCl2, pH 7.4). 
Homogenates were then centrifuged at 20,800 g for 20 min. The resulting pellet was then 
resuspended in transporter binding buffer and added to tubes containing [3H]WIN 35428 
(1.75 to 52.5 nM) and incubated for 1 hr at RT. Nonspecific binding was determined in 
the presence of 10 GBR12909. Binding was terminated by rapid filtration over Whatman 
GF/B filters with ice-cold transporter binding buffer, washed three times, and radioactivity 
was measured via liquid scintillation counting. Data were analyzed with nonlinear fitting 
software (GraphPad Prism 7) to determine Bmax and Kd. Data were derived from a sample 
size of n = 6-9 per genotype per experiment. 
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2.3.10 - High-performance liquid chromatography (HPLC) with dual-cell electrochemical 
detection 
HPLC on microdissected dopaminergic brain regions was carried out to assess whether 
tissular DA levels differed between RGS12-null and wild type mice. Dorsal and ventral 
striatal brain regions were rapidly dissected and frozen on dry ice. Tissue was then 
sonicated in 10 volumes of 0.3 N perchloric acid and homogenates were centrifuged at 
12,000 x g for 15 min. Supernatants were collected, passed through a 0.22 µm filter, and 
dopamine levels in the homogenates were determined by HPLC with dual-cell 
electrochemical detection. Cleared lysates underwent automated direct injection of 10 µL 
into a Dionex Ultimate 3000 HPLC system equipped with a pump (ISO-3100BM, Thermo 
Scientific, Waltham, WA) linked to an autosampler (WPS-3000TBRS, Thermo Scientific), 
ESA HPLC column (MD-150 x 3.2) and dual coulometric/amperometric electrochemical 
detectors (ECD-3000RS, Thermo Scientific) set at -170 mV and +400 mV, respectively. 
Mobile phase (MD-TM; Thermo Scientific) was pumped at a flow rate of 0.6 mL/min. 
Chromatograms were analyzed using Chromeleon software and dopamine peak height 
(concentration) was determined from a standard curve. The identity of the dopamine peak 
in the sample was confirmed by standard addition.  
 
2.3.11 - Statistics 
All data are presented as the mean ± SEM. Statistical significance was set at p < 0.05 
for all experiments, and data were analyzed by student’s t-test or two-way ANOVA 
followed by Sidak’s post hoc test where appropriate. 
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2.4 Results 
 
2.4.1 - RGS12 protein is abundantly expressed in the ventral striatum of the mouse CNS 
Our study was initiated by the generation of two independent strains of RGS12-null 
mice on the C57BL/6J background (Figure 1A-C). Rgs12 mRNA was detected within the 
brain by in situ hybridization in wild type, but not in RGS12-null, mice (Figure 1D-E). Rgs12 is 
expressed in the ventral tegmental area (VTA) and the substantia nigra pars compacta 
(SNc) (Figure 1D); there was also clear labeling of Rgs12 in the dentate gyrus and the 
CA regions of the hippocampus (HPC). As shown in Figure 1E, there was also diffuse 
labeling of Rgs12 in the striatum (STR) and cortex (CTX), as well as marked labeling of 
Rgs12 in the claustrum (CLA). RGS12 protein immunoreactivity was detected in the 
midbrain (the seat of the VTA and SNc) (Figure 1F); however, midbrain RGS12 protein 
content was low in comparison to the high abundance of Rgs12 mRNA. There was also 
detectable RGS12 immunoreactivity in the frontal cortex and dorsal striatum (dSTR) 
(Figure 1F). RGS12 immunoreactivity was greater in the ventral striatum (vSTR) than in 
frontal cortex, dSTR, or midbrain (Figure 1G). Quantification of immunoblots is presented 
as the mean ± SEM (n = 6 per group), and statistical significance was assessed by one-
way ANOVA with Tukey’s multiple comparisons post-hoc analysis: e.g., frontal cortex vs 
dSTR (*, P < 0.05); dSTR vs vSTR (**, P < 0.01); midbrain vs dSTR (ns, P = 0.72). Despite 
dense RGS12 immunoreactivity, Rgs12 mRNA labeling in the ventral striatum is quite 
sparse (Figure 1E).  
 
2.4.2 - RGS12 loss blunts hyperlocomotion to low doses of amphetamine and cocaine 
Given marked RGS12 expression in the vSTR, and an established role for the vSTR 
in psychostimulant actions, as a next step we evaluated RGS12-null mice in 
psychostimulant-induced behavioral assays. Both RGS12-null mouse strains exhibited a 
markedly reduced response to a standard hyperlocomotive-inducing dose (3 mg/kg) of 
AMPH compared with wild type littermates (Figure 2A-C). Data indicating lack of a saline 
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effect (Fig. 2A) are displayed as the mean ± SEM (n = 7-8 per group) and analyzed by 
two-way ANOVA: genotype effect, F (1,13) = 0.04, P = 0.84; time, F (21,273) = 5.4, P  < 
0.0001; genotype x time, F (21,273) = 1.1, P = 0.40. Data indicating reduced 
hyperlocomotion of conditional RGS12-null mice to 3 mg/kg AMPH (Fig. 2B) are displayed 
as the mean ± SEM (n = 7-8 per group) and analyzed by two-way ANOVA: genotype 
effect, F (1,12) = 8.9, P = 0.011; time, F (21,252) = 11.3, P < 0.0001; genotype x time, F 
(21,252) = 3.2, P < 0.0001. Data indicating reduced hyperlocomotion of constitutive 
RGS12-null mice (Fig. 2C) are the mean ± SEM (n = 9-23 per group) and analyzed by 
two-way ANOVA: genotype effect, F (1,41) = 18.6, P < 0.0001; time,  
F (21,861) = 42.3, P < 0.0001; genotype x time, F (21,861) = 9.6, P < 0.0001.  
An initial dose of 3 mg/kg AMPH was selected because it has been extensively 
characterized as eliciting robust locomotor responses in wild type C57BL/6 mice 
(Salahpour et al., 2008; Ramsey et al., 2008; Medvedev et al., 2013). We next assessed 
whether RGS12-null mice exhibit reduced locomotor responses to lower doses of AMPH. 
We found that AMPH at 1 mg/kg was sufficient to observe hyperlocomotion in wild type 
mice relative to saline injection (Figure 2D); however, there was only a trend towards 
reduced AMPH-stimulated hyperlocomotion in RGS12-null mice at this lower dose (Figure 
2D). At a high dose of AMPH (5 mg/kg), the hyperlocomotive responses of wild type and 
Rgs12-null mice were identical (Figure 2D). Data from these additional AMPH doses are 
displayed as the mean ± SEM (n = 8-23 per group) and analyzed by multiple t-test 
analysis: saline, P = 0.52; 1 mg/kg, P = 0.057; 3 mg/kg, P < 0.0001 (****); 5 mg/kg: P = 
0.086. 
Having obtained the described results with AMPH, we proceeded to determine 
whether the response to another dopaminergic psychostimulant, cocaine, was similarly 
affected upon RGS12 loss. As shown in Figure 2E, 10 mg/kg cocaine elicited a 
hyperlocomotive response in wild type mice that was markedly reduced in Rgs12-null 
mice. Data indicating reduced hyperlocomotion to cocaine in RGS12-null mice are 
displayed as the mean ± SEM (n = 9-10 per group) and analyzed by two-way ANOVA: 
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genotype effect, F (1,17) = 17.2, P = 0.016; time, F (21,357) = 8.8, P < 0.0001; genotype 
x time, F (21,357) = 2.4, P = 0.0006. In follow-up studies with 20 mg/kg and 40 mg/kg of 
cocaine, doses established by others’ studies (Salahpour et al., 2008; Ramsey et al., 
2008; Elliot, 2002; Reith et al., 1991), we observed no genotype-dependent differences 
in drug-induced hyperlocomotion (Figure 2F). Data from these additional cocaine doses 
are displayed as the mean ± SEM (n = 7-20 per group) and analyzed by multiple t-test 
analysis:  saline, P = 0.99; 10 mg/kg, P = 0.02, **, P < 0.01); 20 mg/kg, P = 0.84; 40 
mg/kg, P = 0.72. 
Both AMPH and cocaine are well known to exert their actions via the neurotransmitter 
dopamine (Ciccarone, 2011). One possible explanation for these observations of reduced 
hyperlocomotion is that, in RGS12-null mice, post-synaptic dopamine receptor sensitivity 
is decreased. SKF 81927 is a selective D1-like (D1/D5) dopamine receptor full agonist 
(Weed et al., 1993; Desai et al., 2005), which has been extensively characterized as 
eliciting robust horizontal locomotor activity in mice (Desai et al., 2005; Scott et al., 2005; 
Medvedev et al., 2013). However, we found no differences in hyperlocomotion between 
the two genotypes at each of the three different doses of SKF 81927 tested (Figure 2G), 
suggesting a pre-synaptic, rather than a post-synaptic, effect of RGS12 loss on 
dopaminergic psychostimulant action. Data on SKF 81927-mediated hyperlocomotion are 
displayed as the mean ± SEM (n = 8 per group) and analyzed by multiple t-test analysis:  
saline, P = 0.73; 1 mg/kg, P = 0.64; 3 mg/kg, P = 0.59; 5 mg/kg, P = 0.71.  
 
2.4.3 - RGS12 loss does not affect sensitization nor conditioned place preference 
Having established a phenotype based on acute administration of AMPH or cocaine,  
we next tested the effects of repeated dosings of these psychostimulants on RGS12-null 
mice with doses known to elicit robust sensitization in wild type C57BL/6 mice (Ramsey 
et al., 2008; Eisener-Dorman et al., 2011). Despite recapitulating the reduced acute 
locomotor responses to AMPH by RGS12-null mice (Figure 3A), sensitization to repeated 
administration of AMPH—a measure of neuronal plasticity of the mesolimbic dopamine 
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system (Steketee and Kalivas, 2011; Berg and Olsson, 2004)—was intact in RGS12-null 
mice compared to wild type littermates (Figure 3B-C). Locomotion observations from the 
first day of acute 2 mg/kg AMPH administration (Fig. 3A) were analyzed by two-way 
ANOVA: genotype effect, F (1,308) = 10.3, P = 0.002 (**); time, F (21,308) = 1.7, P = 
0.03; genotype x time, F (21,308) = 7.6, P = 0.75. Locomotion observations from the sixth 
day of acute 2 mg/kg AMPH administration (Fig. 3B) were analyzed by two-way ANOVA:  
genotype effect, F (1, 14) = 0.45, P = 0.52; time, F (21, 294) = 36.2, P < 0.0001; genotype 
x time, F (21, 294) = 1.1, P = 0.36. AMPH sensitization time-course data (Fig. 3C) were 
analyzed by two-way, repeated-measures ANOVA: genotype effect, F (1,14) = 2.7, P = 
0.6; time, F (6, 84) = 25.4, P < 0.0001; genotype x time, F (6, 84) = 25.4, P = 0.95.  
Similarly, sensitization to cocaine was not affected in RGS12-null mice (Figure 3D-F). 
Locomotion observations from the first day of acute 20 mg/kg cocaine administration (Fig. 
3D) were analyzed by two-way ANOVA: genotype effect, F (1, 10) = 0.31, P = 0.59; time, 
F (21, 210) = 14.2, P < 0.0001; genotype x time, F (21, 210) = 3.6, P < 0.0001. Locomotion 
observations from the sixth day of acute 20 mg/kg cocaine administration (Fig. 3E) were 
analyzed by two-way ANOVA:  genotype effect, F (1, 10) = 0.08, P = 0.78; time, F (21, 
210) = 17.7, P < 0.0001; genotype x time, F (21, 210) = 0.61, P = 0.91. Cocaine 
sensitization time-course data (Fig. 3F) were analyzed by two-way, repeated-measures 
ANOVA: genotype effect, F (1, 10) = 1.0, P = 0.33; time, F (21, 210) = 17.4, P < 0.0001; 
genotype x time, F (21, 210) = 0.73, P = 0.80.  
In another behavioral paradigm elicited by repeated psychostimulant administration—
conditioned place preference (CPP), which measures the ‘rewarding’ properties of drugs 
(Tzschentke, 2007)—we observed no differences in the effects of either AMPH or cocaine 
in RGS12-null vs wild type mice (Figure 3G-H). CPP as induced by 2 mg/kg doses of 
AMPH was analyzed by two-way, repeated-measures ANOVA: genotype effect, F (1,12) 
= 0.23, P = 0.64; time, F (1,12) = 54.1, P < 0.0001; genotype x time, F (1,12) = 0.04, P = 
0.84. CPP as induced by 10 mg/kg doses of cocaine was analyzed by two-way, repeated-
measures ANOVA: genotype effect, F (1,14) = 3.43, P = 0.09; time, F (1, 14) = 41.4, P < 
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0.0001; genotype x time, F (1, 14) = 0.04, P = 0.84. All CPP data are presented as the 
mean ± SEM (n = 6-9 per group). 
 
2.4.4 - AMPH-elicited neuronal excitation is reduced in the NAc upon RGS12 loss 
In light of the locomotor data and RGS12 expression data, we suspected that RGS12 loss 
might affect psychostimulant-dependent neuronal activation in at least one locus within 
the ventral striatum: namely, the nucleus accumbens (NAc). Therefore, we addressed 
this hypothesis by measuring c-Fos induction in AMPH-treated RGS12-null and wild type 
mice. c-Fos immunoreactivity (measured as c-Fos-positive nuclei per field; Figure 4A) 
was pronounced in the NAc (i.e., ventro-lateral to the anterior commissure [ac]) after an 
acute dose of 3 mg/kg AMPH. Consistent with the reduced hyperlocomotion of RGS12-
null mice to acute, low-dose AMPH, c-Fos immunoreactivity was significantly reduced in 
the NAc of AMPH-treated RGS12-null mice compared with wild type littermates (Figure 
4B). Conversely, in the dorsal striatum, the number of c-Fos-positive nuclei was not 
different between AMPH-treated RGS12-null mice and wild type littermates (Figure 4B). 
c-Fos immunoreactivity data are presented as the mean ± SEM (n = 3-4 mice per group) 
and were analyzed by two-way ANOVA with Sidak’s multiple comparisons: vSTR, P < 
0.0001 (****); dSTR, P = 0.85.  
 
2.4.5 - Dopamine uptake is enhanced in ventral striatal synaptosomes from RGS12-null 
mice 
The reduced effects of psychostimulants on RGS12-null mice could be explained by 
increased dopamine transporter (DAT)-mediated uptake in the ventral striatum of 
dopamine, the major neurotransmitter affected by AMPH and cocaine (Ciccarone, 2011). 
Thus, to test this hypothesis, we next prepared ventral and dorsal striatal synaptosomes 
from RGS12-null mice to measure [3H]dopamine uptake. A significant increase in the Vmax 
(maximal rate of [3H]dopamine uptake) of RGS12-null ventral striatal synaptosomes was 
observed as compared with wild type ventral striatal synaptosomes (Figure 5A and 5B 
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inset); however, no genotype-specific differences in Vmax were observed for dorsal striatal 
synaptosomes (Figure 5B). Km values were equivalent between genotypes in both ventral 
and dorsal striatal synaptosomes (Figure 5A-B). [3H]Dopamine uptake Vmax data are 
presented in Fig. 5B as the mean ± SEM (n = 9-12 per group) and were analyzed by 
genotype using two-way ANOVA with Sidak’s multiple comparisons: vSTR, P = 0.0054 
(**); dSTR, P = 0.91 (ns, no significant difference). [3H]Dopamine uptake Km values were 
as follows:  vSTR, wild type mice = 0.36 ± 0.16 µM, RGS12-null mice = 0.33 ± 0.16 µM; 
dSTR, wild type mice = 0.86 ± 0.32 µM, RGS12-null mice = 0.80 ± 0.32 µM; two-way 
ANOVA with Sidak’s multiple comparisons: vSTR, P = 0.99; dSTR: P = 0.49.   
To evaluate whether the observed increase in [3H]dopamine uptake in the ventral 
striata of RGS12-null mice was mediated specifically by DAT, we also performed 
[3H]dopamine uptake studies using RGS12-null ventral striatal synaptosomes in the 
presence of the DAT-selective re-uptake inhibitor GBR12935 in order to quantify (and 
subtract out) non-specific uptake. A significant increase in the Vmax of DAT-specific 
[3H]dopamine uptake was observed in RGS12-null vSTR synaptosomes as compared 
with those derived from wild type littermates (Figure 5C). DAT-specific [3H]dopamine 
uptake data are presented as the mean ± SEM (n = 6 per group) and were analyzed by 
unpaired t-test: P = 0.001 (**). 
 
2.4.6 - DAT binding sites are significantly elevated in the ventral striatum 
Data indicating increased dopamine uptake by ventral striatal synaptosomes 
prompted us next to probe the expression levels of DAT in striatal tissue from RGS12-
null mice. Radioligand saturation binding assays were performed with [3H]WIN 35428 (a 
DAT-selective radioligand) to determine the maximal number of DAT binding sites in wild 
type and Rgs12-null crude membrane fractions of ventral and dorsal striatal tissue. A 
marked increase was seen in [3H]WIN 35428 binding to ventral striatal membrane 
fractions from Rgs12-null mice compared with wild type mice (Figure 5D and 5E inset). 
Although unable to accurately determine Bmax given the absence of saturation binding, 
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we were able to establish relative expression levels of DAT by comparing the binding of 
wild type and RGS12-null ventral and dorsal striatal crude membrane fractions at the 
maximal concentration of [3H]WIN 35428 tested (52.5 nM). As shown in the bar graph 
inset within Figure 5E, [3H]WIN 35428 binding to RGS12-null ventral striatal crude 
membrane fractions was markedly greater than radioligand binding to wild type ventral 
striatal crude membrane fractions; however, there was no statistically significant, 
genotype-specific effect on [3H]WIN 35428 binding to dorsal striatal crude membrane 
fractions. Data for [3H]WIN 35428 binding in Fig. 5E (inset) are presented as the mean ± 
SEM (n = 6-9 per group) and analyzed by genotype using two-way ANOVA with Sidak’s 
multiple comparisons: vSTR, P = 0.0051 (**); dSTR, P = 0.11 (ns). 
To assess whether the observed increase in vSTR DAT binding sites in Rgs12Δ5-8/Δ5-8 
mice was recapitulated in an independent mouse strain lacking RGS12 expression, we 
next performed [3H]WIN 35428 binding assays on crude membrane fractions from Cre-
recombinase dependent RGS12-null (Rgs12Δ5-6/Δ5-6) mice (Figure 1C and Figure S1E; 
i.e., Rgs12fl/fl mice expressing an ubiquitously-expressed, CMV-driven Cre transgene). 
We found that maximal DAT binding sites are also elevated in this Rgs12 Δ5-6/Δ5-6 mouse 
strain relative to wild type (Rgs12+/+; CMV::Cre) littermate controls (Figure 5F). Data for 
[3H]WIN 35428 binding in Fig. 5F are presented as the mean ± SEM (n = 6 per group) 
and were analyzed by genotype using unpaired t-test: P < 0.0001 (****). 
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2.5 - Discussion 
 
Our major finding from these analyses is that the loss of RGS12 engenders reduced 
acute responses (hyperlocomotion and c-Fos induction) in response to the psychoactive 
drugs AMPH or cocaine. This reduction is likely caused by increased dopamine uptake in 
the ventral striatum—in particular, the nucleus accumbens—due to elevated levels of 
surface-exposed (and, hence, functional) DAT. The presence of RGS12, in one (or more) 
brain region(s), must in some way negatively regulate DAT expression levels and/or 
activity, given that RGS12 loss has been observed in this study to increase DAT 
expression and activity, at least in the ventral striatum.  
The expression pattern of Rgs12 mRNA compared with the distribution of RGS12 
protein renders it tempting to speculate that RGS12 is being synthesized in the 
dopaminergic projections from the midbrain (i.e., the VTA and SNc; e.g., Figure 1D) and 
trafficked to striatal terminals (e.g., Figure 1F) Put another way, RGS12 appears to be a 
pre-synaptic protein in the striatum. Furthermore, the lack of genotype-dependent 
differences in locomotor responses to a post-synaptically active dopaminergic agonist 
(i.e., SKF 81927; Figure 2G) suggests RGS12 acts pre-synaptically. Biochemical data 
are also in line with this notion: the expression and function of DAT, a pre-synaptic protein 
(Torres and Amara, 2007), are both increased upon RGS12 loss (Figure 5). However, 
baseline dopamine levels in the ventral and dorsal striatum of wild type and RGS12-null 
mice are identical, as measured by HPLC with dual-cell electrochemical detection 
(Supplementary Figure S2). In addition, no changes were observed in the levels of 
tyrosine hydroxylase, the rate-limiting enzyme for dopamine synthesis (Daubner et al., 
2011) (Supplementary Figure S2). Thus, the observed changes in DAT expression levels 
and function are likely a direct result of RGS12 loss, and not necessarily caused indirectly 
by a compensatory upregulation (Kimmel et al., 2001; Jakowec et al., 2004; Salvatore et 
al., 2016) in response to altered dopamine synthesis or basal levels upon RGS12 loss 
per se. 
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Despite reduced locomotor responses to acute administration of AMPH and cocaine, 
RGS12-null mice developed locomotor sensitization and CPP to each drug in a manner 
similar to wild type mice. Although these latter behaviors are mediated by mesolimbic 
dopamine (Steketee and Kalivas, 2011; Henry et al., 1989; Baik, 2013), their expression 
is found to be dependent on neuroplastic changes (i.e., increased VTA excitability and 
firing rate) to postsynaptic NMDA glutamate and dopamine receptor signaling/expression 
levels, as well as to somatodendritic dopamine autoreceptors located on VTA neurons 
(Henry et al., 1989; White and Wang, 1984; Neisewander et al., 1998; Tanabe et al., 
2004; Ramsey et al., 2008). These findings also support the notion that RGS12 is acting 
pre-synaptically and thus why only acute behavioral responses to AMPH and cocaine are 
affected. 
Biochemical assays revealed no significant differences in DAT levels or activity in the 
dorsal striatum. Thus, the phenomenon of RGS12 regulation of DAT appears to be region 
specific; i.e., RGS12 affects DAT in the mesolimbic system (i.e., VTA to the nucleus 
accumbens -- a major effector of locomotor behavior). Notably, the levels of RGS12 are 
greater in the ventral striatum than in the dorsal striatum (Figure 1).  
One possible explanation for this enrichment could be a functional and/or physical 
interaction with pre-synaptic GPCR(s) in the ventral striatum that is not expressed or 
relevant in the dorsal striatum. For example, striatal DAT expression and function are 
potently regulated by two Gai-coupled GPCRs expressed on striatal presynaptic 
membranes: D2 dopamine receptors and  -opioid receptors (KORs). Activation of these 
receptors serves as a negative feedback mechanism upon elevated striatal dopamine 
tone, thus augmenting dopamine uptake and increasing surface DAT expression (Bolan 
et al., 2007; Kivell et al., 2014) in a region-specific manner. Acute administration of KOR 
agonists increases dopamine uptake in ventral, but not dorsal, striatum (Thompson et al., 
2000). Additionally, D2 receptor agonists decrease DAT expression in the dorsal striatum, 
but increase DAT expression in the ventral striatum (Kimmel et al., 2001).  Thus, removal 
of RGS12 as a negative regulator of G protein-mediated signaling downstream of either 
GPCR may feasibly lead to augmented pre-synaptic D2 receptor and/or KOR-mediated 
signaling, resulting in elevated DAT surface expression and dopamine uptake.  
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There are several possible mechanisms by which RGS12 could impact DAT trafficking 
and/or function, given the multiple protein-protein interaction domains present within 
RGS12 (Kimple et al., 2002; Snow et al., 1998; Willard et al., 2007). One simple 
explanation for involvement of RGS12 in curtailing DAT function evokes the C-terminal 
GoLoco motif of RGS12 -- a guanine nucleotide dissociation inhibitor (GDI) activity that 
results in the sequestration of inactive Ga subunits (Kimple et al., 2002), which normally 
re-associate with Gbg subunits. This re-association blocks any signaling that is mediated 
by Gbg. Thus, by sequestering inactive Ga subunits, the GoLoco motif of RGS12 may 
extend the lifetime of free Gbg subunits, which are known to, among other things, inhibit 
DAT activity (Garcia-Olivares et al., 2013). 
Another plausible explanation for RGS12 affecting DAT function in the ventral striatum 
lies in the ability of RGS12 to interact with components of the MAPK/MEK/ERK cascade, 
the activity of which supports DAT trafficking to the cell surface (Moron et al., 2003; Willard 
et al., 2007). We speculate that RGS12, as a MAPK/MEK/ERK scaffold, diverts this 
signaling cascade from facilitating the trafficking of DAT to the synaptic plasma 
membrane in the ventral striatum. Another possibility that cannot be excluded is that 
RGS12, through its established interactions with Ras, Raf, MEK, and/or other as-yet 
unidentified proteins, regulates transcription factors that negatively modulate the 
transcription of DAT. To explore this possibility, we performed immunoblot analyses on 
whole lysates of ventral striatum using a validated DAT antibody (Garcia-Olivares et al., 
2013; Chen et al., 2006; Foster et al., 2012; Steinkellner et al., 2012); total DAT levels 
were seen to be comparable in wild type and RGS12-null ventral striatum (Supplemental 
Figure S2), arguing against any transcriptional effect (e.g., in VTA-to-NAc projection 
neurons). Thus, we are currently assessing whether RGS12 regulates the trafficking of 
DAT to the synaptic membrane in the ventral striatum. 
There is a clear dose dependence to the differences seen in acute responses to AMPH 
and cocaine between RGS12-null and wild type mice (Figure 2). We suspect that this is 
due to a saturation of DAT by the uptake inhibitors AMPH and cocaine at higher 
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concentrations. We propose that, at lower doses of DAT inhibitor (1 and 3 mg/kg AMPH; 
10 mg/kg cocaine), the excess DAT that is expressed in RGS12-null ventral striatum is 
available to clear more synaptic dopamine, reducing the acute locomotor responses of 
RGS12-null mice vs those of wild type mice. However, at higher doses of DAT inhibitor 
(5 mg/kg AMPH; 20 mg/kg and 40 mg/kg cocaine), even the extra DAT expressed in 
RGS12-null mice becomes saturated by drug, so all DAT molecules in the ventral striatum 
of both genotypes are blocked, thereby eliminating any difference in acute locomotor 
responses between RGS12-null and wild type mice.  
This hypothesis of extra, unsaturated DAT in RGS12-null mice would suggest that 
DAT levels would become saturated at lower doses in wild type mice. Yet, in both 
genotypes, locomotor response is seen to increase with 20 mg/kg cocaine over that of 10 
mg/kg, and again with 40 mg/kg cocaine over that of 20 mg/kg (Figure 2F). Therefore, an 
additional possibility is that RGS12 loss affects the regulation of autoreceptors on DAT-
positive terminals, thereby lowering the threshold for pre-synaptic feedback by synaptic 
dopamine and resulting in curtailed DA release at low drug concentrations. On the other 
hand, it has been reported that 20 mg/kg cocaine increases locomotor response even in 
mice lacking vesicular monoamine transporter 2 (VMAT2), critical for dopamine transport 
into synaptic vesicular stores (Wang et al., 1997). Thus, another possibility to consider is 
a role for RGS12 in VMAT2 function affecting DA release - a role absent in RGS12-null 
mice but dependent on DAT inhibitor dose for full elaboration and observation in 
behavioral outcomes. 
It is also notable that AMPH acts not only as an antagonist of DAT, but also as a 
releaser of dopamine. This dual effect explains the increased locomotor activity elicited 
by AMPH compared with cocaine, which is solely a DAT antagonist (Figure 2D vs 2F, 
note the difference in y-axis scales). We propose that, at higher doses of AMPH (5 mg/kg), 
due to saturation of DAT, the maximum quantity possible of dopamine is released (i.e., at 
5 mg/kg, dopamine is completely depleted from the pre-synaptic terminals of both wild 
type and RGS12-null mice), potentially explaining why there is no difference between the 
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genotypes. Moreover, in ventral striatal synaptosomal preparations, the ability of AMPH 
to enhance the release of [3H]dopamine is not markedly different between wild type and 
RGS12-null mice (Supplemental Figure S3). This latter observation suggest that RGS12 
somehow modulates the uptake functionality – but not the release functionality – of DAT. 
Molecular studies to address this issue are currently underway.  
In summary, our studies have uncovered a novel regulator of ventral striatal DAT 
expression and activity: namely, RGS12. The neuroanatomical site(s) of RGS12 action 
and the mechanism(s) by which it regulates ventral striatal DAT expression and function 
remain to be identified. However, the observed functional interaction between RGS12 and 
DAT clearly impacts acute mesolimbic-dependent responses to dopaminergic 
psychostimulants. Future work is required to establish the molecular determinants within 
both proteins that underlie this regulation, be it direct (e.g., via possible RGS12/DAT 
interactions) or indirect via the presynaptic regulation of G protein subunits or other 
intermediates. 
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2.6 - Figures 
2.6.1 - Targeting sites for Rgs12 gene locus deletion and expression patterns of 
Rgs12 mRNA and protein in the adult mouse brain.  
 
Figure 1. Independent targeting of two separate ablations to the mouse Rgs12 locus.  
(A) Multiple, protein-protein interaction domain architecture of the encoded RGS12 
protein, including a PSD-95/Dlg/ZO-1 (PDZ; orange) domain capable of binding the 
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C-termini of the MAPK middle-tier kinase MEK2 and the interleukin-8 receptor CXCR2 
(Willard et al., 2007; Snow et al., 1998), a phosphotyrosine-binding (PTB; pink) domain 
thought to bind the NGF receptor TrkA (Willard et al., 2007), an RGS domain (yellow) which 
binds and inactivates heterotrimeric G protein Ga subunits of the Gi/o subfamily (Snow 
et al., 1998), a tandem repeat of Ras-binding domains (RBDs; cyan) that bind indicated 
members of the Ras GTPase and MAPK first-tier (Raf) kinases (ref. (Willard et al., 2007)), 
a GoLoco motif which binds inactive Ga subunits of the Gi subfamily (ref. (Kimple et al., 
2002)), and regions of predicted low complexity (rose). Vertical lines indicate exon-exon 
junctions within the open-reading frame encoded by the Rgs12 mRNA. (B) Mice lacking 
functional RGS12 (Rgs12D5-8/D5-8) were obtained from the Texas A&M Institute of Genomic 
Medicine (TIGM) in a 129/Sv x C57BL/6 mixed background. Because congenic C57BL/6 
mice are standard for neuropsychopharmacological behavioral assays, we back-crossed 
the TIGM Rgs12D5-8/D5-8 mice with C57BL/6J mice for more than ten generations. 
Henceforth, Rgs12D5-8/D5-8 mice will refer to congenic Rgs12D5-8/D5-8 mice on the C57BL/6J 
background. Exons 5-8, encoding the entire polypeptide sequence of the RGS domain of 
RGS12 (yellow; panel A), were targeted for replacement with a neomycin resistance, 
drug-selectable marker. (D) Coronal in situ hybridization (Allen Brain Atlas) reveals 
marked Rgs12 mRNA labeling in the ventral tegmental area (VTA) and substantia nigra 
pars compacta (SNc), beds of the mesolimbic and nigrostriatal dopaminergic soma. 
Analyses also reveal hippocampal (HPC) Rgs12 mRNA, particularly in the dentate gyrus. 
(E) Coronal in situ hybridization from our group shows sparse Rgs12 mRNA in dorsal 
(dSTR) and ventral (vSTR) striatum and cortex (CTX). Marked labeling was observed in 
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the claustrum (CLA).  (F) Immunoblotting for RGS12 protein levels in microdissected 
frontal cortex, dorsal striatum (dSTR), ventral striatum (vSTR), and midbrain in WT and 
RGS12-null mice. b-actin immunoreactivity served as a loading control. (G) Densitometric 
analysis demonstrates that RGS12 in vSTR is higher than frontal cortex, dSTR, and 
midbrain and, specifically is 157% more abundant than in dSTR. Data are the mean ± 
SEM (n = 6 mice per group) relative to dSTR set to 100%. One-way ANOVA with Tukey’s 
multiple comparisons: dSTR vs frontal cortex P = 0.018 (*, P < 0.05), dSTR vs vSTR P = 
0.0014 (**, P < 0.01), dSTR vs midbrain P = 0.724 (not significant [ns], P > 0.05).  
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2.6.2 - RGS12-null mice exhibit reduced hyperlocomotor responses to the 
presynaptically-acting psychostimulants d-amphetamine (AMPH) and cocaine. 
 
Figure 2. Acute psychostimulant-induced locomotion in Rgs12-null mice. (A) Locomotor 
activity in Rgs12 D5-6/D5-6 mice (i.e., conditional Rgs12fl/fl mice cross-bred with an ubiquitous 
CMV::Cre transgene) following 30 min acclimation to activity chambers and then saline 
(at a final volume of 10 mL/kg) administration. Data are the mean ± SEM (n = 7-8 per 
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group). (B) AMPH (3 mg/kg)-induced hyperlocomotion in Rgs12 D5-6/D5-6 mice for 80 min 
following 30 min acclimation to activity chambers. Data are the mean ± SEM (n = 7-8 per 
group). (C) AMPH (3 mg/kg)-induced hyperlocomotion in constitutive Rgs12 D5-8/D5-8 mice 
for 80 min following 30 min acclimation to activity chambers. Data are the mean ± SEM 
(n = 9-23 per group). (D) Cocaine (10 mg/kg)-induced hyperlocomotion in constitutive 
Rgs12 D5-8/D5-8 mice for 60 min following 30 min acclimation to activity chambers. Data are 
the mean ± SEM (n = 9-10 per group). (E) Total locomotion by constitutive Rgs12 D5-8/D5-
8 mice over 80 min following ip injection of saline or various doses of AMPH after 30 min 
acclimation to activity chambers. Data are the mean ± SEM (n = 8-23 per group). (F) Total 
locomotion by constitutive Rgs12 D5-8/D5-8 mice over 60 min following ip injection of saline 
or various doses of cocaine after 30 min acclimation to activity chambers. Data are the 
mean ± SEM (n = 7-20 per group). (G) Total locomotion by constitutive Rgs12 D5-8/D5-8 
mice over 60 min following ip injection of saline or indicated doses of SKF 81927 after 30 
min acclimation to activity chambers. Data are the mean ± SEM (n = 8 per group).  
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2.6.3 - RGS12-null mice display normal locomotor sensitization and conditioned 
place preference to AMPH and cocaine.  
 
Figure 3. Psychostimulant-induced locomotor sensitization and conditioned place 
preference in RGS12-null mice. Total locomotion over 80 min following AMPH (2 mg/kg; 
A-B) or 60 min following cocaine (20 mg/kg; D-E). Total locomotion normalized to day 1 
total locomotion plotted as fold change across drug treatment days (C, F). Data are the 
mean ± SEM (n = 6-9 per group). Psychostimulant-induced conditioned place preference 
in Rgs12-null mice. Data shown are the difference in the time spent between AMPH (2 
mg/kg) (panel G)- or cocaine (10 mg/kg) (panel H)-paired and saline-paired chamber for 
pre-conditioning (day 2) and post-conditioning (day 9). Data are the mean ± SEM (n = 7-
8 per group).  
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2.6.4 - AMPH-induced c-Fos immunoreactivity is reduced in the nucleus 
accumbens (NAc), but not dorsal striatum (dSTR), of RGS12-null mice.  
 
Figure 4. AMPH-stimulated c-Fos induction in RGS12-null mice. (A) 
Immunohistochemical analysis of c-Fos in the NAc of RGS12-null and WT mice injected 
with AMPH (3 mg/kg). (B) Quantification of the number of c-Fos-positive neurons per field 
in RGS12-null vs wild type dSTR and vSTR (3-4 matched sections per genotype). Data 
are the mean ± SEM. (n = 3-4 mice per group).  
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2.6.5 - The number of DAT binding sites and [3H]dopamine (DA) uptake are 
increased in the ventral (vSTR), but not dorsal (dSTR), striatum of RGS12-null mice.  
 
Figure 5. Analysis of DAT function and expression in RGS12-null mice. [3H]Dopamine 
uptake in ventral (A) and dorsal (B) striatal synaptosomes prepared from RGS12-null and 
wild type mice. (B, inset) Uptake rates (Vmax) of [3H]dopamine in ventral and dorsal striatal 
synaptosomes derived from data in panels A and B; non-specific uptake determined in 
the presence of 10 µM cocaine. Data are the mean ± SEM (n = 9-12 per group). (C) 
Uptake rates (Vmax) by DAT of [3H]dopamine in ventral striatal synaptosomes derived from 
data in Supplementary Figure S4; non-specific uptake determined in the presence of 10 
µM GBR12935 (a selective dopamine reuptake inhibitor). Data are the mean ± SEM (n = 
6 per group). (D, E) Levels of DAT determined from [3H]WIN 35428 saturation binding 
analysis of ventral (D) and dorsal (E) striatal crude membrane fractions. Non-specific 
binding was determined in the presence of 10 µM GBR12935. (E, inset) Maximal DAT 
binding sites at 52.5 nM [3H]WIN 35428 in ventral and dorsal striatal membranes derived 
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from data in D and E. Data are the mean ± SEM (n = 6-9 per group). (F) Maximal DAT 
binding sites at 52.5 nM [3H]WIN 35428 in ventral striatal membranes derived from data 
in Supplementary Figure S4. Data are the mean ± SEM (n = 6 per group). 
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2.8 - Supplementary Information 
2.8.1 - Supplementary Figures 
2.8.1a - Validation of two independent RGS12-null mouse strains.  
 
Supplementary Figure S1. Validation of the independent targeting of two separate 
ablations to the mouse Rgs12 locus. (A, A') Southern blot analyses using 5’ and 3’ 
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external probes that flank the Rgs12 gene region targeted for homologous recombination 
(see Figure 1B), indicating that embryonic stem cell clone 1A7 harbors the predicted 
homologous recombination event. (B) Immunoblotting for RGS12 and  
b-actin expression within lysates of brain cortex (CTX), hippocampus (HPC), and striatum 
(STR) from wild type (+/+) and RGS12-null (Rgs12D5-8/D5-8) mice, indicating the loss of 
RGS12 expression in the latter mouse strain. (C) Mice engineered to harbor a loxP- and 
FRT-site flanked Rgs12 gene were obtained from genOway (France) in the C57Bl/6 
background. Exons 5-6, encoding the initial third of the RGS domain of RGS12 (see 
Figure 1A), were targeted for replacement with a FRT-flanked neomycin resistance, drug-
selectable marker and flanking loxP recombination sites. (C, C') Southern blot analyses 
using 5’ external (panel C) and 3’ internal (panel C') probes that flank the Rgs12 gene 
region targeted for homologous recombination (see Figure 1C), indicating that embryonic 
stem cell clone #99-1G harbors the predicted homologous recombination event. (D) 
Southern blot analysis using 5’ external probe to verify that mice #1365, #1366, #1370, 
#1371, and #1372, derived from breeding germ-line transmitted mice from clone #99-1G 
with an ubiquitous Flp recombinase-expressing driver strain, have the correct Rgs12 gene 
locus (Rgs12fl) lacking the FRT-site flanked neo cassette but retaining the loxP sites 
flanking exons 5 and 6. (E) Immunoblotting for RGS12 and b-actin expression within 
whole brain lysates of wild type mice (+/+), RGS12-null (Rgs12D5-8/D5-8) mice, and both 
wild type mice and Rgs12fl/fl mice bred to a ubiquitously-expressed Cre recombinase 
driver strain, leading the latter mouse to be deleted in exons 5 and 6 of Rgs12 (i.e., 
Rgs12D5-6/D5-6). (F) Sagittal sections of wild type (Rgs12+/+) and RGS12-null (Rgs12D5-8/D5-
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8) mouse brain sections probed by in situ hybridization. Note the dense expression 
of Rgs12 mRNA in the claustrum in the wild type section. Also notable is the labeling in 
the hippocampus (Hpc), which is denser in the dentate gyrus than in the CA regions in 
the wild type section. In addition, sparse labeling was observed in the caudate putamen 
(CPu) and the cortex (Ctx) in the wild type section. Also notable is the absence of labeling 
in the Rgs12D5-8/D5-8 section in all of these regions. (G) i. (Left half) Frontal coronal section 
demonstrating dense Rgs12 mRNA labeling in the claustrum and sparse labeling in the 
ventral and dorsal striatum (vSTR, dSTR) and cortex (Ctx). (Right half) Note the absence 
of labeling in these regions in the Rgs12D5-8/D5-8 section. (G) ii. (Left half) Marked labeling 
of the deep, lateral layers of the cortex (Ctx) and sparse labeling in the dorsal striatum 
(dSTR) and hippocampus (Hpc) are shown. (Right half) Note the absence of labeling in 
these regions in the Rgs12D5-8/D5-8 section.  
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2.8.2 - Baseline levels of dopaminergic markers are normal in RGS12-null mice.   
 
Supplementary Figure S2. Baseline dopamine levels and dopaminergic marker 
expression in RGS12-null mice. (A) Immunoblot analysis of DAT and tyrosine hydroxylase 
(TH) immunoreactivity in dorsal striatum (dSTR) and ventral striatum (vSTR) of RGS12-
null and wild type mice. Densitometric analysis of (B) DAT and (C) TH immunoreactivity 
normalized to average DAT or TH levels detected in wild type mice. Data are the mean ± 
S.E.M (n = 6 per group). Data were analyzed by two-way ANOVA with Sidak’s multiple 
comparisons. (D) Total tissue levels of dopamine detected by HPLC with dual-cell 
electrochemical detection in dorsal striatal and ventral striatal homogenates from RGS12-
-null and wild type mice. Data were analyzed by two-way ANOVA with Sidak’s multiple 
comparisons. 
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2.8.3 - AMPH-induced [3H]dopamine (DA) efflux is only mildly affected in ventral 
(vSTR), but not dorsal (dSTR), striatal synaptosomes.  
 
Supplementary Figure S3. AMPH-stimulated [3H]dopamine release in preloaded 
synaptosomes. Release assays were performed as previously described (Rothman et al., 
2001) with minor modifications. Briefly, dorsal and ventral striatal synaptosomes were 
prepared as described in the main text but with ice-cold sucrose buffer supplemented with 
1 μM reserpine. Synaptosomes were then incubated to steady-state with 5 nM 
[3H]dopamine (30 min) in Krebs-Ringer buffer supplemented with 1 μM reserpine. 
Following incubation, 900 μL of preloaded synaptosomes were added to 12 x 75 mm 
polystyrene tubes containing (+)-amphetamine (1 x 10-8.5 to 1 x 10-5 M) in Krebs-Ringer 
buffer. The release reaction proceeded for 5 min, and was then terminated by rapid 
filtration over 0.5% PEI-soaked Whatman GF/B filters with ice-cold Krebs-Ringer buffer, 
washed three times, and remaining radioactivity in the filtered synaptosomes was 
measured via liquid scintillation counting.  
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2.8.4 - Increased DAT binding sites and [3H]dopamine (DA) uptake are recapitulated 
in an independent, Cre-dependent RGS12-null mouse strain.   
 
Supplementary Figure S4. DAT-specific [3H]dopamine uptake in vSTR-derived 
synaptosomes of Rgs12D5-8/D5-8 mice and DAT binding in striatal tissue samples from Cre 
recombinase-dependent Rgs12D5-6/D5-6 mice. (A) [3H]Dopamine uptake in ventral striatal 
synaptosomes prepared from Rgs12D5-8/D5-8 and wild type mice. Non-specific uptake was 
determined in the presence of 10 µM GBR12935 (a selective dopamine reuptake 
inhibitor). (B, C) Levels of DAT determined from [3H]WIN 35428 saturation binding 
analysis of ventral (E) and dorsal (F) striatal crude membrane fractions from Rgs12D5-6/D5-
6 and wild type mice (i.e., Rgs12fl/fl and Rgs12+/+ mice additionally expressing the CMV-
driven Cre recombinase transgene). Non-specific binding was determined in the presence 
of 10 µM GBR12935. 
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2.8.2 - Supplemental Reference: 
Rothman RB, Baumann MH, Dersch CM, et al. (2001) Amphetamine-type central nervous 
system stimulants release norepinephrine more potently than they release 
dopamine and serotonin. Synapse 39(1): 32-41. 
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3.1 - Abstract 
Kappa opioid receptor (KOR) agonists show promise in ameliorating disorders, such 
as addiction and chronic pain, but are limited by dysphoric and aversive side effects. 
Clinically beneficial effects of KOR agonists (e.g., analgesia) are predominantly mediated 
by heterotrimeric G protein signaling, whereas b-arrestin signaling is considered central 
to their detrimental side effects (e.g., dysphoria/aversion). Here we show that Regulator 
of G protein Signaling-12 (RGS12), via independent signaling mechanisms, 
simultaneously attenuates G protein signaling and augments b-arrestin signaling 
downstream of KOR, exhibiting considerable selectivity in its actions for KOR over other 
opioid receptors. We previously reported that RGS12-null mice exhibit increased 
dopamine transporter-mediated dopamine (DA) uptake in the ventral (vSTR), but not 
dorsal striatum (dSTR), as well as reduced psychostimulant-induced hyperlocomotion; in 
the current study, we found that these phenotypes are reversed following KOR 
antagonism. Fast-scan cyclic voltammetry studies of dopamine (DA) release and 
reuptake suggest that striatal disruptions to KOR-dependent DAergic neurotransmission 
in RGS12-null mice are restricted to the nucleus accumbens. In both ventral striatal tissue 
and transfected cells, RGS12 and KOR are seen to interact within a protein complex. 
Ventral striatal-specific increases in KOR levels and KOR-induced G protein activation 
are seen in RGS12-null mice, as well as enhanced sensitivity to KOR agonist-induced 
hypolocomotion and analgesia -- G protein signaling-dependent behaviors; a ventral 
striatal-specific increase in KOR levels was also observed in b-arrestin-2-deficient mice, 
highlighting the importance of b-arrestin signaling to establishing steady-state KOR levels 
in this particular brain region. Conversely, RGS12-null mice exhibited attenuated KOR-
induced conditioned place aversion (considered a b-arrestin signaling-dependent 
behavior), consistent with the augmented KOR-mediated b-arrestin signaling seen upon 
RGS12 over-expression. Collectively, our findings highlight a role for RGS12 as a novel, 
differential regulator of both G protein-dependent and -independent signaling 
downstream of KOR activation.   
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3.2 - Introduction 
KOR is highly expressed in mood- and pain-related CNS regions and is involved in 
such pathologies as addiction, depression, anxiety, and chronic pain (Crowley and 
Kash, 2015; Chavkin and Koob, 2016). During stress, KOR activation by endogenous 
dynorphins results in analgesia, depressive / anxiety-like behaviors, and altered drug 
reward (Chavkin and Koob, 2016; Schindler et al., 2012; Van't Veer and Carlezon, 
2013; Schenk et al., 1999; Chartoff et al., 2016). KOR antagonists have shown promise 
in preclinical models of stress-related psychiatric diseases including addiction 
(Chavkin, 2011; Carlezon and Krystal, 2016). In contrast, acute administration of KOR 
agonists has been shown to exert utility specifically in reducing pain and drug reward -
- behavioral outcomes particularly relevant to the current United States opioid epidemic 
(Kolodny et al., 2015; Koh, 2015; Volkow and Collins, 2017; Kaski et al., 2019). 
However, the advantageous effects of KOR agonists are limited by dysphoric side-
effects (Van't Veer and Carlezon, 2013; Chavkin and Koob, 2016; Bohn and Aube, 
2017). Behaviors produced by KOR agonists depend upon which signaling cascade(s) 
is/are activated (Ehrich et al., 2015; White et al., 2015; Brust et al., 2016; Liu et al., 
2018) – an example of biased agonism (a.k.a. functional selectivity) (Urban et al., 2007; 
Rankovic et al., 2016). Agonists induce KOR conformational change (Che et al., 2018), 
driving G protein dissociation (Siderovski and Willard, 2005). Freed G protein subunits 
then induce biological responses, including cAMP reduction, potassium channel 
activation, and inhibition of calcium influx (Karkhanis et al., 2017; Schoffelmeer et al., 
1988; Tallent et al., 1994; Henry et al., 1995). KOR activation also recruits GPCR 
kinases (GRKs) and b-arrestin to trigger desensitization, internalization, and activation 
of other pathways (McLaughlin et al., 2003; Bruchas et al., 2006). Pharmacological or 
genetic inhibition of the KOR-stimulated b-arrestin signaling pathway abolishes KOR 
agonist-induced conditioned place aversion (CPA) - a metric of dysphoria (Ehrich et 
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al., 2015; Chavkin et al., 2014). Thus, KOR-induced CPA is considered b-arrestin-
dependent. Conversely, KOR-mediated analgesia is considered G protein-dependent 
and b-arrestin-independent (Brust et al., 2016; Hernandez et al., 1995; Chavkin, 2011; 
Schattauer et al., 2017).  
GPCR signaling is tightly controlled by Regulators of G protein Signaling, which 
contain an RGS domain (Soundararajan et al., 2008), serving as a GTPase-accelerating 
protein (GAP) for Ga (Snow et al., 1998a) and thereby inhibiting G protein signaling 
(Lambert et al., 2010). Loss of RGS expression increases GPCR sensitivity to agonist 
stimulation (e.g., (Han et al., 2010; Traynor, 2012)). Some RGS proteins contain 
additional domains that modulate signaling independent of GAP activity (Anderson et al., 
2009; Shu et al., 2010). For example, RGS12 contains a PDZ domain, a phosphotyrosine 
binding (PTB) domain, Ras binding domains (RBDs) (Willard et al., 2007), and a GoLoco 
motif, which sequesters inactive Ga·GDP and thereby serves as a GDP dissociation 
inhibitor (GDI) (Webb et al., 2005). 
We recently found (Gross et al., 2018) that RGS12 is enriched in the ventral striatum 
(vSTR) of the mesolimbic dopamine (DA) system which contributes to reward and affect 
(Chao and Nestler, 2004; Russo and Nestler, 2013). RGS12 loss reduces 
psychostimulant-induced hyperlocomotion and elevates dopamine transporter (DAT) 
expression and DA uptake in the vSTR, but not dorsal striatum (dSTR) (Gross et al., 
2018). We hypothesized that RGS12 loss could elevate vSTR KOR activity/sensitivity, as 
KOR is highly expressed in the mesolimbic DA system and enriched on presynaptic 
terminals of the nucleus accumbens (NAc) (terminals that originate from ventral tegmental 
area (VTA) DAergic projections (Crowley and Kash, 2015; Bruijnzeel, 2009)). Mesolimbic 
KOR activation reduces extracellular DA – an action proposed to underlie dysphoric 
effects (Knoll and Carlezon, 2010; Chefer et al., 2013). KOR-mediated DA decrease 
occurs by inhibition of exocytotic DA release (Di Chiara and Imperato, 1988; Donzanti et 
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al., 1992) and increased DAT-mediated DA reuptake via Gai/o- and MAPK-dependent 
signaling (Thompson et al., 2000; Kivell et al., 2014). Here, we examined whether 
augmented vSTR DA uptake and reduced psychostimulant-induced hyperlocomotion in 
RGS12-null mouse strains (Gross et al., 2018) results from enhanced KOR action, given 
that RGS12 is an established inhibitor of Gai/o signaling (Snow et al., 1998a). Our 
investigation revealed that RGS12 more robustly affects KOR-mediated signaling than it 
does other opioid receptors, RGS12 differentially modulates G protein-dependent 
versus -independent KOR signaling, and RGS12 loss differentially affects KOR-mediated 
behaviors, likely contingent upon which KOR-initiated signaling cascade is required to 
elicit the particular behavioral outcome.  
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3.3 - Materials and Methods 
3.3.1 - Drugs and radioligands 
The opioid receptor agonists U50,488 hydrochloride (Cat. no. 0495), DAMGO (Cat. no. 
1171), and DADLE (Cat. no. 3790) were purchased from Tocris Bioscience (Minneapolis, 
MN). For all in vitro experiments with opioid receptor agonists, 10 mM stocks were 
prepared with dimethyl sulfoxide (DMSO), then diluted to the appropriate final working 
concentrations in assay buffer. The KOR antagonist nor-Binaltorphimine dihydrochloride 
(nor-BNI; Cat. no. 0347) was also purchased from Tocris Bioscience, and was dissolved 
in sterile 0.9% sodium chloride (saline) for all experiments. D-Amphetamine hemisulfate 
salt and morphine sulfate salt pentahydrate were both purchased from Sigma Aldrich (St. 
Louis, MO) and dissolved in sterile saline for all experiments. For all animal experiments, 
drugs were administered intraperitoneally (ip). [3H]Dihydroxyphenylethylamine 
([3H]dopamine; Cat. no. NET673250UC), [3H]WIN35593 (Cat. no. NET1033250UC), and 
[3H]U-69,593 (Cat. no. NET952250UC) were purchased from Perkin-Elmer (Waltham, 
WA).  
 
3.3.2 - Subjects 
Rgs12Δ5-8/Δ5-8 mice (a.k.a. Rgs12-/- or RGS12-null) (Gross et al., 2018) and wildtype 
(Rgs12+/+) littermates, both C57BL/6J and of both sexes, were housed under 
conventional lighting (12 hours light / 12 hours dark), humidity, and temperature, with food 
and water ad libitum. Behaviors were tested within the light cycle. All mice used were 8-
12 weeks of age. Experiments were in accordance with WVU Animal Care and Use 
Committee and NIH guidelines. 
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3.3.3 - Synaptosomal [3H]DA uptake 
Synaptosomal [3H]DA uptake was performed as described (Gross et al., 2018), with 
modifications described in Supplementary Methods.  
 
3.3.4 - Locomotor activity 
AMPH-induced locomotor activity was measured as described (Gross et al., 2018) with 
modifications denoted in Supplementary Methods.  
 
3.3.5 - Fast-scan cyclic voltammetry (FSCV)  
RGS12-null and wildtype littermates were injected with 10 mg/kg nor-BNI or saline (i.p.). 
24 hours later, brain slices were prepared and FSCV performed as described (Schmidt 
et al., 2018), with modifications detailed in Supplementary Methods.  
 
3.3.6 - Radioligand binding assays  
3.3.6a - [3H]WIN35428 binding to DAT 
DAT binding sites were quantified as described (Gross et al., 2018), with modifications 
detailed in Supplementary Methods.  
 
 
3.3.6b - [3H]U69,593 binding to KOR and [35S]GTPgS incorporation upon KOR activation 
 
KOR saturation binding and GTPgS incorporation assays were performed as described 
(Zhou et al., 2015), with modifications detailed in Supplementary Methods.  
 
3.3.7 - Co-immunoprecipitations 
Co-immunoprecipitations (co-IPs) from brain tissue were performed with the Pierce co-IP 
Kit (Waltham, MA) according to manufacturer’s instructions, with modifications described 
in Supplementary Methods. Co-IP analyses in HEK293T cells were performed with the 
 95 
Pierce HA-Tag IP/Co-IP Kit according to manufacturer’s instructions, with modifications 
detailed in Supplementary Methods.  
 
3.3.8 - cAMP inhibition  
HEK293T cells were transfected via CaPO4 (Jordan et al., 1996) with GloSensor-22F 
cAMP biosensor (Promega) and HA-tagged opioid receptor (3XHA-hKOR, 3XHA-hMOR, 
or 3XHA-hDOR; www.cdna.org), with or without wildtype human RGS12, RGS domain 
loss-of-function RGS12 (Rgs12E740K), or GoLoco motif loss-of-function RGS12 
(Rgs12R1206F). Additional procedures are detailed in Supplementary Methods.  
 
3.3.9 - b-arrestin recruitment  
Agonist-induced b-arrestin recruitment was determined using ‘Tango’ assay (Barnea et 
al., 2008; Allen et al., 2011). HTLA cells expressing b-arrestin-TEV protease fusion and 
tetracycline transactivator-driven luciferase reporter (Barnea et al., 2008) were 
transfected via CaPO4 (Jordan et al., 1996) with opioid receptor-Tango vectors (FLAG-
KOR-Tango, FLAG-MOR-Tango, or FLAG-DOR-Tango; contributed to Addgene by Dr. 
Bryan Roth) with or without WT hRGS12, Rgs12E740K, or Rgs12R1206F vectors. Additional 
procedures are detailed in Supplementary Methods.  
 
3.3.10 - Hot plate analgesia and conditioned place aversion (CPA) tests 
To detect sensitivity to painful stimuli, the hot plate test of nociception was performed as 
previously described (Bohn et al., 1999) with modifications detailed in Supplementary 
Information. CPA was performed as described (Schindler et al., 2012) with modifications 
denoted in Supplemental Methods. 
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3.4 - Results 
3.4.1 - vSTR DAT dysfunction in RGS12-null mice is KOR-dependent 
Rgs12 mRNA is detected in multiple Oprk1-expressing neuronal populations in the 
mouse brain (Fig. S1), including the VTA and substantia nigra pars compacta (SNc), the 
anatomical loci of DAergic projection neurons; within the striatum, RGS12 protein is seen 
(Gross et al., 2018) to be particularly enriched within the ventral striatum. To evaluate 
whether increased KOR activity is responsible for elevated DAT-mediated DA uptake 
observed (Gross et al., 2018) in the vSTR of RGS12-null mice, [3H]DA uptake by vSTR 
synaptosomes was measured following systemic pretreatment with the KOR-selective 
antagonist nor-BNI (Fig. 1A). Omnibus analyses revealed an effect of genotype, 
antagonist treatment, and a genotype x treatment interaction (genotype, F(1,9) = 13.5, p 
= 0.005; treatment, F(1,9) = 13.4, p = 0.005; interaction, F(1,9) = 7.0, p = 0.026). 
Synaptosomes from saline-pretreated RGS12-null mice exhibited increased DAT-
mediated [3H]DA uptake compared with wildtype mice (p = 0.001) (Fig. 1A). nor-BNI 
pretreatment (10 mg/kg, ip) reversed this effect (p = 0.002); nor-BNI pretreatment did not 
affect [3H]DA uptake in wildtype controls (p = 0.768). All data from [3H]DA uptake analyses 
are the mean ± SEM and analyzed by two-way ANOVA followed by Sidak's post hoc test 
(n = 4-8 mice/group).   
 To test whether increased DAT binding sites in the vSTR of RGS12-null mice 
(Gross et al., 2018) was due to increased KOR expression/sensitivity, we systemically 
pretreated RGS12-null and wildtype mice with nor-BNI (10 mg/kg, ip) or saline over 14 
days and assessed [3H]WIN35428 binding to DAT (Fig. 1B). Omnibus analyses revealed 
an effect of genotype and a genotype x antagonist treatment interaction (genotype, 
F(1,16) = 19.5, p < 0.001; treatment x genotype interaction, F(1,16) = 8.0, p = 0.011). 
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Multiple comparisons analysis showed that saline-treated RGS12-null mice display 
increased [3H]WIN35428 binding to DAT relative to saline-treated wildtype mice (p < 
0.001). Prolonged nor-BNI pretreatment reversed this effect (p = 0.048) to levels 
comparable to saline-treated wildtype mice (p = 0.149). nor-BNI treatment did not 
significantly affect DAT binding in wildtype mice (p = 0.673). All data from DAT binding 
analyses are the mean ± SEM and analyzed by two-way ANOVA followed by Sidak's post 
hoc test (n = 6 mice/group). 
Augmented DA uptake and DAT binding sites in RGS12-null mice were previously 
correlated with decreased hyperlocomotor response to the DA-dependent 
psychostimulant d-amphetamine (AMPH) (Gross et al., 2018). To assess whether this 
blunted hyperlocomotion is due to increased KOR activity, RGS12-null mice were 
pretreated with nor-BNI (10 mg/kg, ip) 24 hours prior to AMPH treatment. Omnibus 
analyses revealed an effect of genotype and antagonist treatment (genotype, F(1,44) = 
7.5, p = 0.009; treatment, F(1,44) = 7.0, p = 0.011). Attenuated AMPH-induced 
hyperlocomotion in RGS12-null mice (p = 0.039) was reversed following nor-BNI 
pretreatment (p = 0.045) (Fig. 1C); in contrast, nor-BNI pretreatment did not affect AMPH-
induced hyperlocomotion of wildtype mice (p = 0.305). Hyperlocomotion data are the 
mean ± SEM and analyzed by two-way ANOVA followed by a Sidak's post hoc test (n = 
10-13 mice/group).  
 FSCV analyses of DA release and reuptake revealed significant effects of 
genotype and nor-BNI treatment within the NAc core, but not the NAc shell nor dSTR, in 
mice lacking RGS12 expression (Fig. 1D-G and Fig. S2). Examining peak DA release in 
the NAc core, we found significant main effects of stimulation amplitude (F(62,2) = 34.439, 
p < 0.001) and genotype (F(1,31) = 4.875, p = 0.035), and a non-significant genotype x 
antagonist treatment interaction (F(1,31) = 3.206, p = 0.083) (Fig. 1D). Furthermore, a 
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significant main effect of antagonist treatment (F(1,31) = 6.089, p = 0.019) was seen on 
DA reuptake dynamics (Fig. 1F) as measured by t1/2 (Yorgason et al., 2011). Within the 
NAc shell (Fig. 1E), a significant main effect of stimulation amplitude was observed 
(F(1.4,43.3) = 38.2, p < 0.0001), as well as a non-significant stimulation x genotype x 
antagonist treatment interaction (F(2,62) = 2.5, p = 0.089); however, there was no 
significant effect of genotype, antagonist treatment, or genotype x treatment interaction 
(p > 0.05) regarding peak DA concentration. In the dSTR, we observed only an effect of 
stimulation amplitude (F(1.2,38.3) = 2, p < 0.0001) and no effect of genotype, antagonist 
treatment, nor any interaction (p > 0.05) (Fig. S2A). There were no significant effects, in 
the NAc shell or the dSTR, on t1/2 measures of DA reuptake (p > 0.05) (Shell: Fig. 1G; 
dSTR: Fig. S2B). All data are mean ± SEM and were analyzed by general linear mixed 
model with stimulation amplitude as a repeated factor and genotype and antagonist 
treatment as between-subject factors (n = 6 - 11 mice/group). It is important to note that 
electrical stimulation of striatal brain slices during FSCV also recruits local microcircuitry, 
including cholinergic interneurons, which can strongly influence DA release magnitude 
via acetylcholine release and subsequent activation of nicotinic cholinergic receptors 
expressed on DA terminals (Threlfell et al., 2012; Melchior et al., 2015). Given high Rgs12 
expression in ChAT+ (cholinergic) interneurons, yet relatively low expression of KOR in 
these neurons (e.g., Fig. S1C), it is possible that the KOR-independent reductions in 
accumbal DA release seen in RGS12-null mice may be due, in part, to RGS12 loss within 
ChAT+ striatal interneurons. Future studies will be required to parse out the relative 
contributions of this specific interneuron population. 
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3.4.2 - RGS12 forms a protein complex with KOR in brain tissue and transfected 
cells  
 Endogenous KOR co-immunoprecipitates with endogenous RGS12 in vSTR tissue 
from wildtype mice (Fig. 2). KOR immunoreactivity was absent in immunoprecipitated 
samples from RGS12-null vSTR (Fig. 2A), suggesting that KOR immunoreactivity from 
the wildtype mouse vSTR sample was not due to non-specific KOR binding. Consistent 
with this finding from vSTR (Fig. 2A), we found robust RGS12 immunoreactivity in 
immunoprecipitates of HA-tagged KOR expressed in transfected HEK293T cells (Fig. 
2B). Notably, co-expression of RGS12 with the mu opioid receptor (3XHA-MOR) resulted 
in only a weak, non-specific signal (relative to RGS12 alone-transfected cells; Fig. 2B), 
supporting the notion of a selective interaction of RGS12 with KOR and not MOR.  
 
3.4.3 - KOR sensitivity and binding sites are increased in vSTR of RGS12-null mice 
Given the effect of KOR antagonism in reversing the DAT-mediated DA dysfunction 
of RGS12-null mice, we probed for changes in KOR signaling and/or levels upon RGS12 
loss. Systemic administration of KOR agonists, including U50,488, reduces mouse 
locomotion (Castellano et al., 1988) -- an index of KOR sensitivity in vivo. Following 2.5 
mg/kg U50,488, RGS12-null, but not wildtype, mice displayed hypolocomotion relative to 
vehicle-treated controls (Fig. 2C; RGS12-null: p = 0.012; wildtype: p = 0.892), indicating 
increased KOR sensitivity in RGS12-null mice. A higher dose (5 mg/kg) significantly 
reduced locomotion in both genotypes (Fig. 2C; RGS12-null: p = 0.000; wildtype: p = 
0.0007). All data are the mean ± SEM and analyzed by two-way ANOVA (n = 7-13 
mice/group). Omnibus analyses of summed data (Fig. 2C) revealed an effect of genotype, 
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U50,488 treatment, and a trend for a genotype x treatment interaction (genotype, F(1,55) 
= 4.4, p = 0.040; treatment, F(2,55) = 20.1, p < 0.0001; interaction, F (2,55) = 2.8, p = 
0.072). Multiple comparisons were analyzed by a Sidak's post hoc test and performed 
with each dose of U50,488 statistically compared to saline-treated controls.  
We also measured [35S]GTPgS incorporation upon U50,488-elicited G protein 
activation in vSTR and dSTR membranes. At 1 µM U50,488, RGS12-null, but not 
wildtype, mice displayed significant GTPgS incorporation in vSTR membranes (Fig. 2D) 
relative to vehicle control (RGS12-null [1 µM]: p = 0.015; wildtype [1 µM]: p = 0.996), 
supporting the notion of enhanced KOR-stimulated G protein activation in the vSTR upon 
RGS12 loss. A two-way ANOVA of the data across multiple U50,488 dosings (Fig. 2D) 
revealed omnibus effects of genotype, U50,488 treatment, and a genotype x treatment 
interaction (genotype: p = 0.005; treatment: 0.004, interaction: p = 0.015). 
vSTR and dSTR preparations from wildtype mice, as well as dSTR preparations from 
RGS12-null mice, only displayed significant [35S]GTPgS incorporation at the highest 
concentration tested (Fig. 2D: e.g., vSTR of wildtype mice at 100 µM U50,488: p = 0.028). 
Low signal window (e.g., ~0.2-fold max) in assays of [35S]GTPgS binding to endogenous 
receptors in native brain tissue has been previously noted (Bohn et al., 2015). U50,488-
induced [35S]GTPgS binding was not differentially elevated in dSTR preparations from 
RGS12-null vs wildtype mice (Fig. 2D inset: Student’s t-test t(7) = 0.06; p = 0.946). All 
data from [35S]GTPgS incorporation are the mean ± SEM (n = 13-19 mice/group). 
 We next assessed whether increased KOR levels/binding sites, in addition to 
augmented KOR signaling, could account for KOR antagonism-mediated reversal of 
increased DA uptake in RGS12-null mice. We performed saturation binding with the KOR-
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selective agonist [3H]U69,593 on vSTR and dSTR membranes from RGS12-null mice vs 
wildtype controls. With loss of RGS12, KOR binding sites (Bmax) were increased in vSTR 
(Fig. 2E) (F(1,87) = 12.9, p = 0.0005), but not dSTR (F(1,62) = 0.3, p = 0.618;); in contrast, 
Kd values were equivalent between RGS12-null and wildtype mice in both vSTR (F(1,87) 
= 0.008, p = 0.931) and dSTR (F(1,62) = 0.3, p = 0.610) preparations. All data from 
[3H]U69,593 saturation binding are the mean ± SEM, and the inset of Fig. 2E was 
analyzed by two-way ANOVA (n = 9-12 mice/group), revealing an effect of genotype, 
brain region, and a genotype x brain region interaction (genotype, F(1,24) = 10.0, p = 
0.004; region, F(1,24) = 4.6, p = 0.043 ; interaction, F (1,24) = 6.1, p = 0.021); multiple 
comparisons were analyzed by Sidak's post hoc test (multiple comparisons: vSTR, 
RGS12-null vs wildtype, p < 0.0001; dSTR, RGS12-null vs wildtype, p = 0.879). To 
ascertain whether increased KOR protein levels/binding sites in RGS12-null mice was 
due to KOR (Oprk1) transcriptional upregulation, we performed qRT-PCR on vSTR and 
midbrain tissue. RGS12-null and wildtype mice exhibited similar Oprk1 mRNA levels in 
both regions (Fig. S3A), suggesting that enhanced KOR activation observed in RGS12-
null mice is not likely due to elevated KOR expression.  
 
3.4.4 - RGS12 differentially regulates G protein and b-arrestin signaling downstream of 
KOR 
KOR belongs to the GPCR family that includes mu- (MOR) and delta- (DOR) opioid 
receptors – also Gi/o-coupled, but with separate neuroanatomical distributions and 
functions relative to KOR (Pan, 1998; Al-Hasani and Bruchas, 2011). To determine 
whether RGS12 regulates G protein signaling downstream of opioid receptor activation, 
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we used a cAMP-based readout in HEK293T cells (Allen et al., 2011) to measure 
receptor-mediated, Gai/o-dependent inhibition of isoproterenol-induced cAMP increases 
(Fig. 3A-F). PTX pretreatment abolished KOR agonist-stimulated cAMP inhibition (Fig. 
3A inset: t(3) = 18.1, p < 0.001), validating the luciferase assay as a measure of Gi/o-
mediated signaling. Wildtype (WT) RGS12 expression reduced U50,488 potency by at 
least 20-fold (Fig. 3A: F(1,245) = 56.8, p < 0.0001; also Fig. S4A), but only affected 
agonism of MOR by ~3-fold (Fig. 3B: F(1,216) = 13.1, p = 0.0004; also Fig. S4B) and 
DOR by 2.5-fold (Fig. 3C: F(1,136) = 7.6, p = 0.007). The effect of RGS12 expression on 
KOR-mediated G protein signaling relied on both the GAP and GDI activities of RGS12, 
as loss-of-function mutations to either element within RGS12 curtailed the observed 
decrease in pIC50 from 20-fold (RGS12 WT) to less than 4-fold (Fig. 3A: RGS12E740K: F(1, 
205) = 7.1, p = 0.008; RGS12R1206F: F(1, 173) = 5.7, p = 0.018). We previously established 
that the E740K charge-reversal mutation to RGS12 eliminates RGS domain GAP activity 
(Sambi et al., 2006), whereas the R1206F mutation eliminates GoLoco motif GDI activity 
(Kimple et al., 2002; Sambi et al., 2006).  
The PDZ domain of RGS12 exhibits a high degree of similarity (Snow et al., 1998a) 
to the first PDZ domain of NHERF1 (“Na+/H+ exchanger regulatory factor-1”). NHERF1 
is known (Li et al., 2002) to employ its first PDZ domain to bind directly to a PDZ docking 
site at the KOR C-terminus (aa 376-380: -NKPV-cooh), but does not bind MOR nor DOR 
(which both lack this C-terminal sequence). As RGS12 co-immunoprecipitates with KOR, 
but not MOR, in transfected cells (Fig. 2B), we tested whether such binding specificity 
was determined by a potential PDZ domain / GPCR C-terminal tail interaction. We 
mutated the last four amino acids of the KOR C-terminus (i.e., NKPV) to four alanine 
 103 
residues and, conversely, mutated the last four amino acids of the MOR C-terminus to 
that found in the wildtype KOR sequence (i.e., NKPV) (Fig. 3D). Co-expression of 
hRGS12-WT with hKORAAAA diminished the RGS12-mediated reduction in U50,488 
potency from 20-fold down to 4-fold (Fig. 3A vs E: F(1, 272) = 5.0, p = 0.024). Conversely, 
substitution of the last four amino acids of MOR to the C-terminal PDZ docking site of 
KOR (i.e., MORNKPV) was seen to enhance the RGS12-mediated reduction of DAMGO 
potency from 3-fold to 6-fold (Fig. 3B vs F: F(1, 271) = 32.1, p < 0.0001), constituting a 2-
fold gain-of-function from the effect of RGS12 on wildtype MOR. Together, these data 
suggest that the PDZ docking site of KOR is necessary, but not sufficient in its entirety, 
to account for the selectivity RGS12 exerts on opioid agonist potency for KOR over the 
other opioid receptors.   
To determine whether RGS12 also regulates G protein-independent signaling from 
opioid receptors, we examined b-arrestin recruitment following receptor activation (Allen 
et al., 2011; Barnea et al., 2008). Expression of wildtype RGS12 augmented KOR 
agonist-dependent b-arrestin recruitment by 3-fold (Fig. 3G: F(1,410) = 211, p < 0.0001), 
but only mildly elevated MOR agonist-dependent b-arrestin recruitment (Fig. 3I: 1.2-fold; 
F(1,314) = 11.5, p = 0.0008) and DOR agonist-dependent b-arrestin recruitment (Fig. 3J: 
1.1-fold; F(1,250) = 17.6, p < 0.0001); no potency changes (EC50) were observed for any 
opioid receptor agonist used:  KOR/U50,488: F(1,410) = 0.3, p = 0.598; MOR/DAMGO: 
F(1,314) = 0.3, p = 0.561; and DOR/DADLE: F(1,250) = 1.6, p = 0.205) (Fig. 3G,I,J).  
RGS domain and GoLoco motif loss-of-function mutants did not reverse the RGS12-
dependent increase in b-arrestin recruitment downstream of KOR activation (Fig. 3G). 
RGS12E740K elicited no change in the maximal efficacy (Emax) of KOR agonist-dependent 
b-arrestin recruitment relative to wildtype RGS12 (RGS12E740K: F(1,410) = 2.1, p = 0.148), 
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whereas RGS12R1206F co-transfection resulted in a slight, but statistically significant, 
increase in KOR agonist-dependent b-arrestin recruitment relative to wildtype protein 
(RGS12R1206F: F(1,410) = 20.9, p < 0.0001). Together, these data indicate that RGS12 
requires a functional RGS domain and GoLoco motif for its full effects on KOR-mediated 
G protein signaling (Fig. 3A), but not for enhancing b-arrestin translocation to activated 
KOR (Fig. 3G), suggesting that RGS12 increases b-arrestin recruitment in a G protein-
independent manner. To confirm this idea, we evaluated KOR agonist-stimulated b-
arrestin translocation following PTX pretreatment. Overnight PTX pretreatment had no 
effect on the RGS12-mediated increase in b-arrestin recruitment to activated KOR (Fig. 
3H; p = 0.696) nor an effect on U50,488-induced b-arrestin recruitment efficacy in control 
cells expressing KOR-only (Fig. 3H; p = 0.540). Omnibus analyses revealed only an effect 
of RGS12 expression (RGS12, F(1,8) = 1160.0, p < 0.001). Data in Fig. 3H are the mean 
± SEM (N = 3 independent experiments) and were analyzed by two-way ANOVA with 
Sidak's post hoc test.  
We hypothesized that the increased KOR binding sites seen in the vSTR of RGS12-
null mice (Fig. 2E) might be due to attenuated b-arrestin-2-dependent internalization 
and/or downregulation of KOR in the absence of RGS12 expression. To test this idea, we 
performed [3H]U69,593 saturation binding assays in vSTR and dSTR membranes of b-
arrestin-2 knockout (barr2KO) (Bohn et al., 1999) and wildtype control mice. b-arrestin-2 
knockout mice exhibited increased KOR Bmax in the vSTR compared to wildtype controls 
(Fig. 3K,L: F(1,66) = 4.1, p = 0.044); in contrast, Kd values for KOR radioligand binding 
were equivalent between barr2KO and wildtype mice in both vSTR (F(1,66) = 0.1, p = 
0.701) and dSTR (F(1,68) = 0.1, p = 0.678) preparations (Fig. 3K,L). Analysis of KOR 
binding Bmax revealed that KOR levels were increased in the vSTR, but not the dSTR (Fig. 
3L: F(1,68) = 0.018, p = 0.6674). Omnibus analysis revealed effects of genotype, brain 
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region, and a trend for a genotype x brain region interaction (genotype, F(1,20) = 5.8, p 
= 0.025; treatment, F(1,20) = 14.9, p = 0.001; interaction, F(1,20) = 4.0, p = 0.057). These 
findings support the notion that increased KOR levels/binding sites in RGS12-null mice is 
related to reduced KOR-mediated b-arrestin-2 function upon RGS12 loss. All data are the 
mean ± SEM (n = 12 mice per group); data displayed in Fig. 3K-L were analyzed by two-
way ANOVA with Sidak's post hoc test. 
 
3.4.5 - RGS12 differentially regulates G protein- and b-arrestin-dependent 
behaviors mediated by KOR 
RGS12 expression selectively reduces KOR agonist-induced cAMP inhibition via its 
RGS domain and GoLoco motif (Fig. 3); these data are consistent with findings of KOR 
antagonism-mediated reversal of elevated DA uptake and DAT binding sites (Fig. 1A,B) 
and attenuated AMPH-induced hyperlocomotion (Fig. 1C), increased KOR-stimulated 
[35S]GTPgS binding (Fig. 2D), and increased sensitivity to KOR-stimulated 
hypolocomotion (Fig. 2C) upon RGS12 loss. Together, these findings suggest that 
RGS12 normally reduces G protein-dependent KOR signaling, and RGS12 loss results 
in hypersensitivity of KOR-mediated G protein signaling. To assess this hypothesis with 
an integrated, behavioral output, we interrogated supraspinal nociception using the hot 
plate assay (Sora et al., 1997); prior studies have determined that KOR-induced 
analgesia represents a G protein-dependent and b-arrestin-independent outcome of KOR 
agonism (Chavkin, 2011; White et al., 2015; Schattauer et al., 2017). Here, we tested 
whether RGS12-null mice exhibit enhanced sensitivity to the analgesic effect of U50,488 
(Fig. 4A-C). RGS12-null mice displayed significantly increased analgesia by U50,488 at 
5 mg/kg (within-subjects comparisons: RGS12-null saline vs U50,488: p = 0.033) and 
22.5 mg/kg (RGS12-null saline vs U50,488: p = 0.005), whereas wildtype littermates 
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exhibited no statistically significant analgesia to either dose (within-subjects comparisons: 
WT saline vs 5 mg/kg U50,488: p = 0.815; WT saline vs 22.5 mg/kg U50,488: p = 0.199). 
Omnibus ANOVA revealed only a significant effect of treatment at these two doses of 
U50,488 (5 mg/kg treatment, F(1,18) = 5.2, p = 0.036; 22.5 mg/kg treatment, F(1,15) = 
13.8, p = 0.002). These results suggest that RGS12-null mice have enhanced sensitivity 
to the analgesic output of KOR agonism. Following 30 mg/kg U50,488, there was no 
difference in analgesia between genotypes (Fig. 4C: RGS12-null saline vs U50,488: p < 
0.0001; WT saline vs U50,488: p = 0.0003); omnibus ANOVA revealed only a significant 
effect of treatment at this 30 mg/kg dose of U50,488 (treatment, F(1,16) = 57.6, p < 
0.0001). RGS12-null and wildtype mice pretreated with the KOR antagonist nor-BNI (10 
mg/kg, ip) 24 hours prior to U50,488 administration exhibited no analgesic responses 
(Fig. S5), indicating that the supraspinal anti-nociceptive effects of U50,488 (Fig. 4A-C) 
are mediated by KOR activation. Supporting a selective function of RGS12 on KOR 
signaling over that of other opioid receptors, RGS12-null mice were seen to exhibit normal 
analgesia to morphine (Fig. S6) – a response dependent on MOR activation (Sora et al., 
1997; Pasternak, 2010). All data from hot plate analgesia experiments are the mean ± 
SEM (n = 7-14 mice per group) and analyzed by two-way ANOVA followed by Sidak's 
post hoc test.  
While RGS12 is known to suppress G protein-dependent signaling (Snow et al., 
1998a; Kimple et al., 2002), RGS12 expression was also seen to augment b-arrestin 
recruitment independent of its heterotrimeric G protein-modulating domains (Fig. 3G). 
These data suggest that RGS12 loss may lead to decreased G protein-independent (i.e., 
b-arrestin) signaling downstream of KOR activation. Therefore, we examined conditioned 
place aversion (CPA) to U50,488, given that aversion to KOR-induced dysphoria is 
considered a b-arrestin-dependent behavior (Land et al., 2009; Chavkin et al., 2014; 
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Ehrich et al., 2015). Wildtype mice exhibited CPA following 2.5 mg/kg U50,488 (p = 
0.011); in contrast, RGS12-null mice did not express aversion at this dose (p = 0.548). 
Omnibus ANOVA analysis revealed only an effect of U50,488 treatment (F(1,25) = 7.7, p 
= 0.010) (Fig. 4D). These data suggest that RGS12 loss reduces the ability of KOR 
agonism to produce aversion/dysphoria. At 5 mg/kg U50,488, both RGS12-null and 
wildtype mice exhibited aversion (Fig. 4E) (within-subjects comparison: RGS12-null mice: 
p = 0.021; WT mice: p < 0.0001); the aversion exhibited by RGS12-null mice was 
attenuated relative to that of wildtype littermates (between-subjects comparison: RGS12-
null vs WT: p = 0.006). Omnibus ANOVA analysis revealed an effect of treatment at this 
higher U50,488 dose (treatment, F(1,22) = 44.7, p < 0.0001) and a genotype X treatment 
interaction (F(1,22) = 10.7, p = 0.004). All data from CPA experiments are the mean ± 
SEM (n = 9-15 mice per group) and analyzed by two-way ANOVA followed by a Sidak's 
post hoc test. 
A summary of the interpretation of all these findings, derived from our interrogations 
of adult RGS12-null mice, is presented in Figure 5. Constitutive loss of RGS12 may 
alternatively (or additionally) engender disruptions to KOR signaling in the vSTR via 
perturbation of neurodevelopmental processes. In response to neonatal or early life 
stress, the KOR/dynorphin system becomes hypersensitive to endogenous and 
exogenous activation, resulting in mesolimbic hypodopaminergia and behavioral 
disruption in adulthood, including altered psychostimulant responsiveness (Van't Veer 
and Carlezon, 2013; Vien et al., 2009; Karkhanis et al., 2016; Yorgason et al., 2016). 
Thus, loss of RGS12 from birth may increase pre- and/or post-natal stress susceptibility 
such that the KOR system becomes upregulated. This hypothesis is supported by 
previous work from our group and others demonstrating that (i) RGS12 is strongly 
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expressed throughout CNS regions integral to the early embryonic stages of 
neurodevelopment (Martin-McCaffrey et al., 2005), (ii) RGS12 is required for 
neurodevelopmental processes such as nerve growth factor-stimulated axonogenesis by 
sensory neurons (Willard et al., 2007), and (iii) RGS12 levels are altered during 
synaptogenesis by sensory deprivation (Butko et al., 2013) and in transgenic models of 
neurodevelopmental diseases such as schizophrenia (Sialana et al., 2018). Future 
studies will be required to elucidate whether RGS12 loss early in neurodevelopment 
contributes to the disruptions of KOR signaling and behavior observed in constitutive 
RGS12-null adult mice. 
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3.5 - Discussion 
RGS12 as an important regulator of vSTR DA homeostasis via KOR signaling 
effects on DAT 
RGS12 exhibits selective effects on KOR signaling in at least one region of the CNS 
– the ventral striatum – via a mechanism dependent on an interaction with KOR that is at 
least functional and likely direct. Single cell RNAseq data (Saunders et al., 2018) reveals 
that Rgs12 is expressed in several Oprk1 (KOR)-expressing neuronal populations within 
the corticostriatal circuit (Fig. S1C). Thus, disruptions to KOR signaling and behavior upon 
global Rgs12 deletion may, at least in part, reflect an integrated response across several 
corticostriatal brain regions and may not necessarily be restricted to abrogated functional 
interaction solely within the vSTR. For example, loss of Rgs12 in striatal dopamine 
receptor D1R+ and/or D2R+ medium spiny neurons (MSNs) seen to co-express Oprk1 
and Rgs12 in wildtype mice (e.g., Fig. S1C) could contribute to the RGS12-null mouse 
phenotypes observed, especially given the known roles these MSNs play in rewarding 
and aversive responses (e.g., to psychostimulant-drugs) (Calipari et al., 2016; Tejeda et 
al., 2017). 
KOR activation results in hypodopaminergia in the vSTR/NAc by (i) decreasing DA 
release (Di Chiara and Imperato, 1988; Donzanti et al., 1992) and (ii) increasing DAT-
mediated DA reuptake (Thompson et al., 2000; Kivell et al., 2014) in a G protein-
dependent manner. As RGS12-null mice exhibit augmented DAT-mediated DA uptake 
reversible by KOR blockade, and display increased KOR-mediated G protein signaling 
(Figs. 1, 2), we hypothesized that RGS12 loss would also reduce DA release in the 
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vSTR/NAc due to increased KOR-mediated G protein signaling. Indeed, RGS12-null mice 
exhibited attenuated DA release in the NAc core (Fig. 1); in addition, a notable trend 
towards reduced DA release was also observed in the NAc shell, but this latter result was 
not statistically different from wildtype controls. Evoked DA release is considerably lower 
in the NAc shell than the core (Melchior and Jones, 2017), which may account for our 
inability to attain statistically significant differences between genotypes when performing 
FSCV in the shell. No differences of DA release nor in nor-BNI pretreatment effects were 
detected in the dSTR (Fig. S2), further supporting that RGS12 selectively exerts DA-
modulatory effects in the vSTR, but not dSTR.  
KOR blockade via nor-BNI pretreatment did not rescue the deficient DA release seen 
in the NAc core of RGS12-null mice (Fig. 1), suggesting that this release defect is KOR-
independent or reliant on long-term neurodevelopmental maladaptation to RGS12 loss 
rather than acute KOR signaling upregulation per se. We identified a trend for nor-BNI 
pretreatment to increase DA release in RGS12-null, but not wildtype, mice within the NAc 
shell at select stimulation amplitudes (Fig. 1), although this did not reach statistical 
significance. KOR agonists have been reported to reduce DA release more potently in 
the NAc shell than the core (Melchior and Jones, 2017), and this effect may relate to the 
higher level of KOR expression in the NAc shell relative to the core seen in rodents 
(Mansour et al., 1995a; Resendez et al., 2016). Therefore, the observed trend for 
increased DA release by nor-BNI in the NAc shell, but not NAc core, of RGS12-null mice 
may have emerged given enhanced expression and function of KOR in the NAc shell over 
the core.  
Wildtype mice did not exhibit altered DA reuptake in the NAc core, NAc shell, nor 
dSTR following nor-BNI pretreatment (Fig. 1 and S2); these observations support the 
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notion that, under normal conditions, there is a lack of basal KOR tone (i.e., the presence 
of dynorphin-stimulated and/or constitutive activity of KOR) in these regions. However, 
augmented [3H]DA-uptake in the vSTR synaptosomes of RGS12-null-mice was reversed 
by systemic nor-BNI pretreatment (Fig. 1); moreover, RGS12-null mice display a trend for 
enhanced sensitivity to the effect of nor-BNI on DA reuptake in the NAc-core relative to 
wildtype controls (Fig. 1). Together, these data support the idea that KOR 
sensitivity/activity in the vSTR is enhanced in the absence of RGS12-expression. This 
effect is unlikely to be related to elevated dynorphin tone, given normal Prodyn mRNA 
expression in RGS12-null mice (Fig. S3B). RGS12-null mice may not exhibit KOR-
dependent effects on DA reuptake in the NAc shell given that this region expresses 
considerably less DAT than the NAc core (Nirenberg et al., 1997). Moreover, the minimal 
levels of extracellular DA that arise following evoked DA release in the NAc shell, 
especially in RGS12-null mice, may be insufficient to drive DAT-mediated DA reuptake at 
thresholds sufficient to engage KOR, thereby masking any modulatory effects that RGS12 
may have on KOR-dependent processes. Irrespective of the relative paucity of 
engagement within the NAc shell leading to a lack of observable signal, our data from 
brain-slice FSCV and synaptosomal [3H]DA uptake support that (i) RGS12 loss affects 
DAergic neurotransmission in vSTR, but not the dSTR, and (ii) RGS12 modulates vSTR-
KOR signaling that affects DAT function, but does not appreciably affect KOR signaling 
that specifically regulates DA release.  
vSTR synaptosomes derived from RGS12-null mice exhibit elevated Vmax of [3H]DA 
uptake (Gross et al., 2018). In contrast, DA reuptake in the NAc is similar in saline-treated 
RGS12-null mice and saline-treated wildtype controls (Fig. 1). Such differences between 
measurements of endogenous DA reuptake (e.g., via FSCV) vs exogenous DA uptake 
(e.g., via synaptosomal [3H]DA-uptake) have been demonstrated previously (Chen and 
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Reith, 2007). FSCV evaluates DA reuptake by quantifying the clearance rate (t1/2) of 
endogenous DA released into the extracellular space following stimulation of release 
(e.g., electrical) (Robinson et al., 2003; Yorgason et al., 2011). Thus, FSCV-derived 
reuptake rates are predicated, in part, on the absolute quantity of DA released from 
presynaptic DA neurons. Given that RGS12-null mice exhibit markedly reduced DA 
release in the NAc following electrical stimulation (Fig. 1), these mice may consequently 
display lower rates of DA reuptake than expected (relative to observed synaptosomal 
[3H]DA-uptake rates) simply due to the considerably lower levels of extracellular DA 
present during the experiment. Unlike in brain-slice FSCV (Phillips et al., 2002; McGinnis 
et al., 2016), in vitro synaptosomal [3H]DA-uptake experiments employ high levels of both 
[3H]-labeled and unlabeled DA to achieve DAT saturation (e.g., refs. (Bermingham and 
Blakely, 2016; Gross et al., 2018)). Consequently, this high load of exogenous DA 
produces a distinctly different measure of DA uptake capacity relative to FSCV 
(Richardson et al., 2016; Gowrishankar et al., 2018) given that it drives activation of 
endogenously expressed receptors and thereby engages negative feedback systems 
(e.g., ref. (Gowrishankar et al., 2018)). Thus, RGS12-null mice may require elevated DA 
tone in the vSTR/NAc to manifest observable differences in DAT-mediated DA uptake.   
Our finding that RGS12 modulates KOR function (this study) and DAT function (Gross 
et al., 2018) in the vSTR, but not dSTR, supports previous findings that KOR effects on 
DAT function and AMPH-induced neuronal activation are restricted to the vSTR (Gray et 
al., 1999; Thompson et al., 2000). Regio-specific RGS12 action on KOR and DAT function 
might be, at least in part, related to the greater RGS12 expression seen in vSTR relative 
to dSTR (Gross et al., 2018). An alternative (or additive) explanation might be differential 
expression of some G-protein-signaling element(s) between the vSTR and dSTR. For 
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example, DA signaling via the dopamine D2 receptor is reported as being more potent in 
the NAc (vSTR) than the dSTR (Marcott et al., 2018), given preferential coupling of D2R 
to Gao, which is more highly expressed in the NAc than dSTR relative to Gai (Lein et al., 
2007). While the RGS12 RGS domain increases the GTPase activity of both Gao and 
Gai1 proteins (Snow et al., 1998a), the GoLoco-motif binds only to Gai1/i2/i3 subunits and 
not to Gao (Kimple et al., 2002). Such differential engagement of Gai vs Gao by RGS12 
might thereby underlie a vSTR specific action of RGS12 on KOR signaling and, 
consequently, on DAT function.  
 
RGS12 as a potential target for inhibition to help direct KOR agonism toward 
beneficial analgesia and away from anti-therapeutic aversion/dysphoria? 
Neuroanatomical loci mediating supraspinal opioid-induced analgesia are located 
throughout the brain (Lipp, 1991; Jensen, 1997), with the mesolimbic dopamine-system 
playing an integral role (Altier and Stewart, 1999; Gear et al., 1999). Thus, the enhanced 
analgesic effect of U50,488 in RGS12-null mice (Fig. 4) is consistent with the augmented 
KOR agonist potency and KOR levels observed in the vSTR of these mice (Fig. 2). 
RGS12 may also regulate KOR-mediated spinal analgesia via similar mechanisms: 
RGS12 and KOR are both expressed in spinal neurons that mediate analgesia (Willard 
et al., 2007; Hylden et al., 1991; Cai et al., 2016). Dorsal root ganglion (DRG) neurons 
located adjacent to the spinal cord, as well as the dorsal horns, represent key nociceptive 
loci as they contain neurons responsible for receiving and transmitting nociceptive signals 
(Todd, 2010). Both KOR and RGS12 are highly expressed in DRGs (Tsai et al., 2010; 
Willard et al., 2007), and KOR is known to mediate analgesic responses within this 
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anatomical region (Xu et al., 2004). Thus, the effects of RGS12 loss on KOR-mediated 
analgesia may also rely, at least in part, on augmented KOR-mediated G protein signaling 
at the level of the spinal cord. RGS12-null mice exhibited normal morphine-induced 
analgesia (Fig. S6), supporting the idea that RGS12 functions selectively on KOR-
signaling relative to that of other opioid receptors, especially given the receptor-selectivity 
of morphine’s analgesic actions (i.e., the anti-nociceptive effects of morphine are 
completely lost in MOR knockout mice (Sora et al., 1997; Pasternak, 2010) yet preserved 
in mice lacking KOR (Simonin et al., 1998)). 
Prior evidence suggests that the DA-lowering effects of KOR agonists in the vSTR 
underlie their aversive/dysphoric properties (Knoll and Carlezon, 2010; Shippenberg et 
al., 1993); thus, attenuated U50,488-induced CPA in RGS12-null mice might be related 
to a constitutively elevated DA reuptake in the vSTR of these mice (Gross et al., 2018), 
resulting in reduced extracellular DA and causing a 'floor effect' whereby KOR-mediated 
reductions in vSTR DA are unable to manifest aversion in the absence of RGS12 
expression. However, this possibility is unlikely, as even DA-deficient mice display KOR-
induced CPA (Land et al., 2009). Reduced KOR-induced CPA in RGS12-null mice is also 
unlikely to reflect a learning deficit given that these mice exhibit normal conditioned-place-
preference to both amphetamine and cocaine (Gross et al., 2018). 
RGS12 over-expression was seen to reduce G protein-dependent signaling and 
increase b-arrestin recruitment downstream of KOR activation (Fig. 3). Consistent with 
these findings, Rgs12 ablation enhances KOR-stimulated G protein activation and 
sensitivity to U50,488-induced hypolocomotion (Fig. 2). KOR-induced hypolocomotion is 
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unaffected by b-arrestin-2 knockout (White et al., 2015), suggesting that reduced 
locomotion upon KOR activation is G protein-dependent. RGS12-null mice also exhibit 
increased KOR binding sites (a measure of protein expression) (Fig. 2) despite normal 
Oprk1-mRNA levels (Fig. S3), suggesting that elevated KOR levels/binding sites are not 
due to Oprk1 transcriptional upregulation. Increased KOR-protein levels and/or 
sensitivity, and not dynorphin expression levels (Fig. S3), likely underlie the increased 
vSTR DAT-mediated DA-uptake and resultant reduction in AMPH-stimulated 
hyperlocomotion seen in RGS12-null mice (Gross et al., 2018), given that these two 
effects are reversed by KOR inhibition (Fig. 1).  
In light of augmented b-arrestin-recruitment to activated KOR upon RGS12 over-
expression (Fig. 3), we speculated that RGS12 loss reduces b-arrestin-dependent 
internalization and/or downregulation of KOR -- a hypothesis strongly-supported by our 
observation of increased vSTR, but not dSTR, KOR-binding in b-arrestin-2 knockouts 
(Fig. 3). In contrast, [3H]DA-uptake is unaffected in b-arrestin-2 knockouts (Fig. S7); as 
others have demonstrated that KOR-mediated increases in [3H]DA-uptake are sensitive 
to PTX (Kivell et al., 2014), these findings collectively suggest that basal and KOR-
stimulated DA uptake are b-arrestin-independent and G protein-dependent, respectively. 
Enhanced KOR-dependent [3H]DA-uptake in the vSTR of RGS12-null-mice (Fig. 1) is 
thus likely mediated by increased G-protein-signaling downstream of KOR (Fig. 5). Under 
conditions of low accumbal DA tone, RGS12-null mice displayed an exaggerated 
response to KOR antagonist-mediated reductions in DA reuptake in the NAc core, but not 
dSTR (Figs. 1 & S2), further supporting that RGS12 loss engenders hypersensitivity to 
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the effects of KOR on DAT function selectively in the mesolimbic DA system. Augmented 
KOR-mediated G protein signaling upon RGS12-loss is further supported by increased 
sensitivity of RGS12-null mice to U50,488-induced supraspinal analgesia (Fig. 4), 
considered a G protein-dependent outcome of KOR agonism (Schattauer et al., 2017; 
White et al., 2015). Conversely, RGS12-null mice display reduced aversion to U50,488 
(Fig. 4), a behavioral outcome of KOR activation considered to be reliant on b-arrestin 
signaling (Chavkin et al., 2014; Ehrich et al., 2015), consistent with observations that 
RGS12 over-expression augments KOR-mediated b-arrestin-recruitment (Fig. 3). 
Together, our data demonstrate that (i) RGS12 and KOR functionally interact in the vSTR, 
but not dSTR, (ii) RGS12 exerts specificity for KOR over other opioid receptors, (iii) 
RGS12 differentially regulates signaling cascades downstream of KOR via independent 
mechanisms, and (iv) RGS12 is a critical determinant of KOR-mediated behavioral 
outcomes. 
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3.6 - Figures 
3.6.1 - Ventral striatal dopamine transporter (DAT) dysfunction in RGS12-null mice 
is kappa opioid receptor (KOR)-dependent. 
 
Figure 1. Ventral striatal DAT dysfunction in RGS12-null mice is KOR-dependent. (A) 
Uptake of [3H]dopamine (8 nM) and (B) the number of DAT binding sites are increased in 
vSTR synaptosomes derived from RGS12-null (Rgs12-/-) mice vs WT (Rgs12+/+) littermate 
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controls; this increase is lost upon prior administration to the mice of the KOR-selective 
antagonist nor-BNI. Mice were administered vehicle (saline) or nor-BNI (10 mg/kg, ip) 24 
hours (A) or over 14 days (B) prior to sacrifice and synaptosome or membrane 
preparation, respectively. Non-specific binding was determined in the presence of 10 µM 
GBR12935 (a selective DA reuptake inhibitor). Data are the mean ± SEM and tested by 
two-way ANOVA with Sidak’s post hoc test (n = 4-8 mice) (*, p < 0.05, **, p < 0.01, ***, p 
< 0.001). (C) Suppression of AMPH-induced hyperlocomotion by RGS12-null mice is 
reversed upon prior administration of nor-BNI. AMPH (3 mg/kg, ip)-induced changes to 
locomotion behavior are shown in RGS12-null mice (open symbols) and WT littermate 
controls (closed symbols) following 30 min acclimation to activity chambers. Mice were 
treated with either vehicle (saline; circles) or nor-BNI (10 mg/kg delivered ip; triangles) 24 
hours prior to the experiment. Data are the mean ± SEM (n = 10-13 mice per group). (C, 
inset) Total locomotion (over 80 min) by RGS12-null mice and WT littermate controls 
(derived from data in panel C) treated with saline or nor-BNI following injection of AMPH 
(3 mg/kg, ip). Data are the mean ± SEM and tested by two-way ANOVA with Sidak’s post 
hoc test (n = 10-13 mice per group) (*, p < 0.05). (D) Electrically-stimulated DA release 
(peak DA current, nA) is attenuated in the NAc core of RGS12-null mice. (E) Electrically-
stimulated DA release in the NAc shell. RGS12-null mice exhibit a trend towards altered 
nor-BNI-dependent DA release at select stimulation amplitudes (stimulation x genotype x 
antagonist treatment interaction). (F) nor-BNI treatment reduces DA reuptake (t1/2) in 
RGS12-null, but not wildtype, mice. (G) Baseline and nor-BNI-dependent DA reuptake in 
the NAc shell is not altered in RGS12-null mice relative to wildtype mice. All FSCV data 
are mean ± SEM (n = 6 - 11 mice per group) and were analyzed by general linear mixed 
model ANOVA (*, p < 0.05). 
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3.6.2 - RGS12 interacts with KOR and RGS12 loss results in elevated KOR 
sensitivity and binding sites in the vSTR. 
 
Figure 2. RGS12 interacts with KOR and RGS12 loss results in elevated KOR sensitivity 
and binding sites in the vSTR. (A) Representative immunoblots indicating that KOR and 
RGS12 co-immunoprecipitate in the vSTR of wildtype mice (N = 2 experiments). 
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Subpanel (i) indicates loss of RGS12 immunoreactivity within whole lysates of ventral 
striatum from Rgs12-null mice. Subpanel (ii) demonstrates that endogenous KOR protein 
is co-immunoprecipitated from ventral striatal lysate upon immunoprecipitation of 
endogenous RGS12 protein. Subpanels (ii) and (iii) indicate that immunoblots probed 
with a mixture of anti-KOR and an anti-KOR blocking peptide yield no KOR 
immunoreactivity, confirming antibody specificity. Immunoprecipitation of RGS12 in 
RGS12-null vSTR results in greatly reduced signal of KOR immunoreactivity (see 
densitometric quantitation below immunoblot of subpanel (ii)), supporting that KOR 
immunoreactivity in wildtype IP samples is not due to non-specific pull down. (B) 
Co-immunoprecipitation analyses of HEK293T cells transiently transfected with human 
opioid receptor (with N-terminal HA-tag) and/or full-length RGS12 vector DNA. Robust 
content of RGS12 is seen in the anti-HA antibody immunoprecipitate when RGS12 is co-
expressed with KOR, whereas co-expression of the related opioid receptor MOR yields 
only non-specific binding signal (i.e., compare first vs last lanes). Parallel immunoblots 
containing whole cell lysates resolved by SDS-PAGE demonstrate the presence or 
absence of RGS12, KOR, and/or MOR expression in appropriate conditions. (C) Total 
locomotion (over 30 min) by RGS12-null mice and wildtype littermate controls following 
administration of U50,488. RGS12-null, but not wildtype, mice exhibit a hypolocomotor 
effect to 2.5 mg/kg U50,488 relative to vehicle controls. At 5 mg/kg U50,488, RGS12-null 
and wildtype controls both display reduced locomotor activity relative to vehicle controls. 
Data are the mean ± SEM and tested by two-way ANOVA with Dunnet’s post hoc test (n 
= 7-13 mice per group) (ns, p > 0.05; *, p < 0.05, ***, p < 0.001, ****, p < 0.0001). (D) 
[35S]GTPgS incorporation into vSTR membranes from RGS12-null mice and wildtype 
littermate controls upon activation with KOR agonist U50,488. Data are normalized to 
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vehicle (saline) control (expressed as fold change). vSTR membranes from RGS12-null 
mice exhibit increased sensitivity to U50,488 relative to wildtype controls. Inset, 
[35S]GTPgS binding (at 100 µM U50,488) by dSTR membranes from RGS12-null mice 
and wildtype littermate controls. All data are the mean ± SEM and tested by two-way 
ANOVA with Sidak’s post hoc test (n = 13-19 mice per group) (*, p < 0.05, *** p < 0.001). 
(E) [3H]U69,593 saturation binding analysis of vSTR membranes from RGS12-null 
(Rgs12-/-) mice and wildtype (Rgs12+/+) littermate controls. Non-specific binding was 
determined in the presence of 10 µM nor-BNI (KOR antagonist). Inset, As derived from 
data in panel B and parallel binding data from dSTR membrane samples, Bmax was 
quantified and seen to be increased in vSTR (but not dSTR) of RGS12-null mice (RGS12-
null vSTR Bmax = 62.5 ± 3.9 fmol/mg protein vs wildtype vSTR Bmax = 42.1 ± 3.3 fmol/mg 
protein). The KD for [3H]U69,593 did not differ across genotypes (RGS12-null vSTR: 1.8 
± 0.4 nM; WT vSTR: 1.8 ± 0.4 nM). Data are the mean ± SEM and tested by two-way 
ANOVA with Sidak’s post hoc test (n = 9-12 mice per group) (***, p < 0.001).  
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2.6.3 - RGS12 differentially regulates KOR agonist-mediated G protein versus b-
arrestin signaling cascades and exerts considerable selectivity for KOR over other 
opioid receptors.  
 
Figure 3. RGS12 expression reduces potency of the KOR agonist U50,488, yet 
augments agonist-stimulated recruitment of b-arrestin to KOR via independent 
mechanisms. (A-C) RGS12 expression reduces potency of the KOR agonist U50,488 to 
a greater extent than for the MOR agonist DAMGO or the DOR agonist DADLE. 
GloSensor-22F (Promega) luciferase-based measurements of cAMP levels within 
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HEK293T cells stimulated with 100 nM isoproterenol and simultaneously treated with 
opioid receptor-selective agonists following transient co-expression of (A) KOR cDNA 
plus indicated RGS12 expression plasmids, (B) MOR cDNA with or without wildtype (WT) 
RGS12, or (C) DOR cDNA with or without WT RGS12. (A, inset) PTX (200 ng/mL) 
pretreatment abolished KOR agonist-driven cAMP inhibition, confirming that the assay is 
dependent on Gi/o-mediated signaling. Wildtype RGS12 expression reduced U50,488 
potency by 20-fold, i.e. 6- to 8-fold more than its effects on DAMGO (3-fold) and DADLE 
(2.5-fold) potency. Loss-of-function point mutants of RGS12 curtailed U50,488 potency 
reductions from 20-fold down to 3-to-4-fold. Data were normalized to vehicle control 
conditions and are expressed as the mean ± SEM from multiple experiments (N = 3). 
Concentration-response curves were fit by four-parameter non-linear regression (Prism 
7). (D-F) The PDZ domain docking site of KOR (-NKPV-c) is necessary, but not sufficient, 
to completely account for the specificity of RGS12 for KOR over MOR in assays of GPCR-
mediated G protein signaling. (D) Schematic representing creation of KOR expression 
cDNA containing mutation to the C-terminus (-NKPV-c to -AAAA-c) and MOR expression 
cDNA containing mutation of its wildtype C-terminus (MOR: -APLP-c) to KOR’s wildtype 
C-terminus (-NKPV-c). (E) Mutation to the C-terminus of KOR curtailed RGS12-mediated 
U50,488 potency reductions from 20-fold (e.g., panel A) to 4-fold. (F) RGS12 reduced 
MOR agonist potency by 6-fold following substitution of the MOR C-terminus with the 
wildtype KOR C-terminus, relative to a 3-fold potency reduction observed with wildtype 
MOR (e.g., panel B). Data are normalized to vehicle control and expressed as mean ± 
SEM from N = 3 experiments. Dose-response curves fit by four parameter non-linear 
regression (Prism). (G-J) RGS12 expression augments agonist-stimulated recruitment of 
b-arrestin to KOR, but not MOR nor DOR, in a G protein-independent manner. Tango 
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assays of b-arrestin recruitment within HTLA cells (Barnea et al., 2008; Allen et al., 2011) 
stimulated with indicated agonists following transient co-expression of (G) KOR cDNA 
plus indicated RGS12 expression plasmids, (H) KOR cDNA with or without WT RGS12 
following pretreatment with PTX or vehicle, (I) MOR cDNA with or without WT RGS12, or 
(J) DOR cDNA with or without WT RGS12. Agonist potency (pEC50 values) did not differ 
between conditions. U50,488-induced b-arrestin recruitment efficacy was ~3-fold greater 
when either WT RGS12, or loss-of-function point mutants of RGS12, was co-expressed 
with KOR, whereas WT RGS12 only increased b-arrestin recruitment to MOR by 1.2-fold 
and DOR by 1.1-fold. PTX pretreatment did not affect U50,488-induced b-arrestin 
recruitment to KOR (panel H) in the presence or absence of WT RGS12. Data were 
normalized to vehicle control conditions (fold change) and are expressed as the mean ± 
SEM from multiple experiments (N = 3). Curves were analyzed by three-parameter non-
linear regression and panel H was analyzed by two-way ANOVA with Sidak's post hoc 
test. (K) [3H]U69,593 saturation binding analysis of vSTR membranes from b-arrestin-2 
knockout (barr2KO) mice and wildtype (WT) controls. (L) As derived from data in panel K 
and parallel binding data from dSTR membrane samples, Bmax was increased in vSTR 
(but not dSTR) of b-arrestin-2 knockout (barr2KO vSTR Bmax = 150.1 ± 17.1 fmol/mg 
protein vs wildtype vSTR Bmax = 93.1 ± 14.6 fmol/mg protein; barr2KO dSTR Bmax = 74.5 
± 9.8 fmol/mg protein vs wildtype dSTR Bmax = 69.3 ± 7.7 fmol/mg protein). The KD for 
[3H]U69,593 did not differ across genotypes (barr2KO vSTR: 7.1 ± 1.8 nM; WT vSTR: 8.4 
± 2.9 nM; barr2KO dSTR: 7.8 ± 2.3 nM; WT dSTR: 6.6 ± 1.7 nM;). Data are the mean ± 
SEM and panel L was analyzed by two-way ANOVA with Sidak’s post hoc test (n = 12 
mice per group) (*, p < 0.05). 
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3.6.4 - RGS12-null mice display differential behavioral responses to KOR agonists.  
 
Figure 4. RGS12-null mice exhibit a heightened sensitivity to the analgesic effect of 
U50,488 administration but attenuated conditioned place aversion (CPA) to the aversive 
effects of U50,488. U50,488-induced analgesia at a dose of (A) 5 mg/kg, (B) 22.5 mg/kg, 
or (C) 30 mg/kg was measured in RGS12-null (Rgs12-/-) mice vs WT (Rgs12+/+) littermate 
controls using a hot plate latency test. Data are the mean ± SEM and tested by two-way 
repeated-measures (within-subjects design) ANOVA followed by Sidak’s post hoc test (n 
= 8-10 mice per group) (ns, not significantly different; *, p < 0.05; **, p < 0.01; ***, p < 
0.001; ****, p < 0.0001). (D-E) RGS12-null mice exhibit attenuated conditioned place 
aversion (CPA) to the aversive effects of U50,488. 2.5 mg/kg (D) or 5.0 mg/kg (E) of 
U50,488 was administered to RGS12-null (Rgs12-/-) mice and WT (Rgs12+/+) littermate 
controls to test for conditioned place aversion (a measure of the dysphoric property of 
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KOR agonism). Data are the mean ± SEM and tested by two-way repeated-measures 
ANOVA (for within-subjects comparisons) and between-subjects ANOVA (for between-
subjects comparisons) each followed by Sidak’s post hoc test (n = 8-15 mice per group; 
*, p < 0.05; **, p < 0.01; ****, p < 0.0001). 
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3.6.5 - Proposed model of RGS12 action in the differential outputs of KOR-activated 
signaling. 
 
 
 
Figure 5. Proposed model of RGS12 action in the differential outputs of KOR-activated 
signaling. (A) Agonist-induced activation of KOR dissociates Gi/o-coupled heterotrimers 
into free G protein subunits, evokes G protein-dependent signal transduction (thick grey 
arrow) and, ultimately, produces analgesia and regulates DAT function. RGS12 
expression is seen to reduce KOR-mediated G protein signaling via its central RGS 
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domain (by accelerating GTP hydrolysis of Gai/o·GTP) and its C-terminal GoLoco motif 
(by binding Gai·GDP). RGS12 also contains an N-terminal PDZ domain that interacts with 
MEK2 (Willard et al., 2007) and findings from this study suggest interaction with the 
C-terminal PDZ domain docking site of KOR (NKPV-c). RGS12 also contains tandem 
Ras-binding domains (RBDs) that interact with activated H-Ras and A-/B-Raf to enable 
MAPK/ERK scaffolding properties (Willard et al., 2007). Agonist-stimulated KOR 
activation is also known to drive GRK3-dependent b-arrestin-2 recruitment (Bruchas and 
Chavkin, 2010), resulting in receptor internalization, b-arrestin-dependent signal 
transduction (thick black arrow) and, ultimately, aversive behavior. RGS12 expression is 
seen to augment KOR agonist-stimulated b-arrestin recruitment independent of its GAP 
and GDI activity, suggesting that RGS12 may modulate GRK3 activity on activated KOR 
(KOR*) and/or enhance b-arrestin-2 recruitment and/or function by as yet undetermined 
molecular mechanisms (represented by question marks over dashed arrows). (B) Loss 
of RGS12 in mice results in concomitant increases in KOR-mediated G protein signaling 
and decreases in b-arrestin-2 recruitment, thus resulting in enhanced KOR agonist-
stimulated analgesia and disrupted DAT function (thicker black arrow), as well as an 
attenuation of KOR-stimulated aversion (thinner grey arrow), respectively.  
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3.8 - Supplementary Information 
3.8.1 - Supplementary Methods  
3.8.1a - b-Arrestin-2 deficient animals 
Male and female b-arrestin-2 knockout (barr2KO) (JAX Stock 023852) and wildtype 
C57BL/6 control mice (JAX Stock 000664) were purchased from The Jackson Laboratory 
(Bar Harbor, ME) and housed under identical conditions to RGS12-null and wildtype 
littermates. 
 
3.8.1b - Synaptosomal [3H]DA uptake 
Synaptosomal [3H]DA uptake was performed as described (Gross et al., 2018) with minor 
modifications. Briefly, RGS12-null mice and wildtype littermates were administered 
vehicle (0.9% NaCl) or nor-BNI (10 mg/kg, ip) 24 hours prior to dissection. Ventral striata 
were then extracted and synaptosomes prepared as described (Gross et al., 2018). 
Synaptosomal fractions were incubated with 0.8 µM DA (with [3H]DA content diluted to 8 
nM final concentration) in Krebs-Ringer buffer (Gross et al., 2018) for 10 minutes. Non-
specific uptake was determined in the presence of DAT-selective reuptake inhibitor 
GBR12935. Uptake reactions were terminated by filtration over Whatman GF/B filters with 
ice-cold Krebs-Ringer buffer, washed three times, and measured via liquid scintillation 
counting. [3H]DA uptake analyses in tissue samples from barr2KO and wildtype control 
mice were performed identically to RGS12-null and wildtype littermates, except that these 
mice did not receive vehicle or nor-BNI pretreatment before testing.  
 
3.8.1c - Locomotor activity 
AMPH-induced locomotor activity was measured as described (Gross et al., 2018) with 
the following modifications: RGS12-null mice and wildtype littermates received vehicle 
(0.9% NaCl) or nor-BNI (10 mg/kg, ip) 24 hours prior to quantification of AMPH-induced 
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hyperlocomotion. For U50,488-induced locomotion, RGS12-null mice and wildtype 
littermates were administered vehicle (0.9% saline, ip) or U50,488 (2.5 or 5 mg/kg, ip), 
immediately placed into open-field chambers (San Diego Instruments), and X,Y 
coordinate beam breaks measured in five-min bins for 30 minutes.  
 
3.8.1d - Fast-scan cyclic voltammetry (FSCV)  
RGS12-null and wildtype littermates were injected with 10 mg/kg nor-BNI or saline (i.p.). 
24 hours later, brain slices were prepared and FSCV performed as described (Schmidt 
et al., 2018). Briefly, mice under deep anesthesia were decapitated, and brain tissue was 
submerged in oxygenated ice-cold sucrose. 300 µm slices were cut with a Leica VT1000 
vibratome and placed in oxygenated artificial cerebral spinal fluid (aCSF) (Schmidt et al., 
2018) for at least 30 min prior to electrochemical testing. Striatal slices were transferred 
to an electrochemistry rig and perfused at 2 mL/min with oxygenated aCSF. Slices were 
stimulated at 100, 200, and 300 µA with a bipolar nichrome electrode (single pulse, 4 ms 
duration). DA signals were recorded with an in house fabricated 100 μm x 7 μm carbon 
fiber microelectrode placed ~ 100 um from the stimulating electrode (Kile et al., 2012); a 
custom built potentiostat (University of Washington, Seattle) and TarHeel CV written in 
LabVIEW (National Instruments) were used to apply a triangle waveform (-0.4 to 1.3 V) 
cycling at 10 Hz. Cyclic voltammograms (CVs) were analyzed with HDCV (UNC Chapel 
Hill) to create IvT (current vs time) plots that were analyzed with Clampfit 10.6 software 
(Molecular Devices, Sunnyvale, CA).  
 
3.8.1e - Radioligand binding assays  
[3H]WIN35428 binding to DAT 
Evaluation of DAT binding sites was performed as described (Gross et al., 2018), with 
minor modifications. As KOR-mediated changes to DAT levels requires prolonged drug 
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treatment (Thompson et al., 2000), mice were treated with vehicle or the long-lasting, 
irreversible KOR antagonist nor-BNI (10 mg/kg, saline, ip) for 14 days (Patkar et al., 2013) 
before DAT binding was assessed. Mice received two injections of nor-BNI, first on day 
0 and then on day 7. On day 14, mice were sacrificed, vSTR microdissected, and extracts 
frozen on dry ice. Crude membrane fractions were prepared and incubated with 
[3H]WIN35428 (52.5 nM) in the presence or absence of 10 µM GBR12935 to determine 
DAT-specific binding; as we previously found that RGS12-null mice do not exhibit 
complete DAT saturation in assays of vSTR DAT binding (Gross et al., 2018), therefore, 
the relative number of DAT binding sites was determined using a single, high 
concentration of [3H]WIN35428 (52.5 nM), as previously described (Gross et al., 2018). 
Binding reactions proceeded for 1 hour at RT and then terminated by rapid filtration over 
PEI (0.5%)-soaked Whatman GF/B filters with ice-cold Tris buffer. Protein content-
adjusted data (in fmol/mg protein) were normalized to the wildtype vehicle condition and 
expressed as fold change to control for variability in the efficacy of [3H]WIN35428 binding 
to DAT across experiments. Data are displayed as mean ± SEM across multiple 
experiments and statistical analyses performed with two-way ANOVA followed by Sidak's 
post-hoc test (n = 6 mice per group). 
 
[3H]U69,593 binding to KOR and [35S]GTPgS incorporation upon KOR activation 
KOR saturation binding and GTPgS incorporation assays were performed as described 
(Zhou et al., 2015) with modifications. Ventral and dorsal striatal brain regions were 
dissected, immediately frozen on dry ice, homogenized with a polytron homogenizer in 
10 volumes of buffer (10 mM Tris-HCl pH 7.4, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT), 
and passed through a 27-gauge needle eight times. Homogenates were centrifuged twice 
at 20,000 x g for 30 min; pellets were resuspended in KOR assay buffer:  either 50 mM 
Tris-HCl pH 7.4 for [3H]U69,593 binding, or 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 5 mM 
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MgCl2, 1 mM EDTA, 20 μM GDP, 1 mM DTT for GTPgS incorporation. For saturation 
binding, resuspensions were added to [3H]U69,593 (from 0.63 - 20 nM) and incubated for 
2 hr at room temperature. Nonspecific binding was determined in the presence of 10 µM 
nor-BNI. For GTPgS incorporation, resuspensions were added to [35S]GTPgS (0.1 nM) 
and several independent concentrations of the KOR agonist U50,488 (0.0001, 0.01, 1, 
and 100 µM; dissolved in saline). Binding was terminated by filtration over Whatman GF/B 
filters with ice-cold deionized water (washed three times) and measured via liquid 
scintillation counting after overnight drying.  
 
3.8.1f - Co-immunoprecipitations 
Co-immunoprecipitation (co-IP) analyses in brain tissue were performed with the 
Pierce co-IP Kit (Waltham, MA) according to manufacturer’s instructions with minor 
modifications. Briefly, anti-RGS12 (UNC60-26.2.1; DSHB, Iowa City, IA) was immobilized 
on the kit’s AminoLink Plus-coupled resin. Ventral striata were dissected, immediately 
frozen on dry ice, and then homogenized with a polytron homogenizer in co-IP lysis buffer 
(Pierce), followed by addition of CHAPS detergent (1% final concentration). 
Homogenates were incubated for 1 hr at 4°C (with rotation) to facilitate KOR solubilization 
(Xia et al., 2003). Solubilized lysates were precleared with quenched resin and then 
added to the anti-KOR-immobilized resin for overnight incubation (4°C with rotation). 
Immunoprecipitates were washed, eluted, and denatured with Laemmli buffer containing 
100 mM DTT (Pierce) for 30 minutes at 37°C. IP and whole lysate (input) samples were 
then subjected to SDS-PAGE, transferred to nitrocellulose, and incubated overnight at 
4°C with anti-KOR (#AOR-012; Alomone Labs, Jerusalem, Israel), a control mixture of 
anti-KOR plus blocking peptide (AOR-012 immunizing peptide/control antigen; Alomone), 
or anti-RGS12. Immunoblots were then washed, incubated with the appropriate HRP-
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conjugated secondary antibodies for 1 hr at RT, and visualized with enhanced 
chemiluminescence. 
Co-IP analyses in HEK293T cells were performed with the Pierce HA-Tag IP/Co-
IP Kit according to manufacturer’s instructions with minor modifications. Briefly, HEK293T 
cells were transiently transfected (via CaPO4 (Jordan et al., 1996)) with wildtype human 
RGS12 (hRGS12-WT) alone or co-transfected with hRGS12-WT and 3XHA-hKOR or 
3XHA-hMOR HA-tagged human opioid receptors (www.cdna.org). Forty-eight hours later, 
transfected cells were lysed with co-IP lysis buffer (Pierce), CHAPS added (1% final 
concentration), and lysates solubilized for 1 hr (4°C with rotation). Solubilized lysates 
were then added to pre-coupled anti-HA agarose spin columns and incubated overnight 
(4°C with rotation) to immunoprecipitate 3XHA-KOR or 3XHA-MOR proteins. 
Immunoprecipitates were washed, eluted, and denatured in 2X Sample Buffer with 100 
mM DTT (Pierce). IP and whole lysate (input) samples were then subjected to SDS-
PAGE, transferred to nitrocellulose, and incubated overnight at 4°C with anti-RGS12 (sc-
398545, Santa Cruz, Dallas, TX) or anti-HA (Cat. 3725, Cell Signaling Technology, 
Danvers, MA). Immunoblots were then washed, incubated with the appropriate HRP-
conjugated secondary antibodies for 1 hr at RT, and visualized with enhanced 
chemiluminescence.  
 
3.8.1g - cAMP inhibition  
HEK293T cells were transfected via CaPO4 (Jordan et al., 1996) with vectors expressing 
GloSensor-22F cAMP biosensor (Promega) and HA-tagged human opioid receptor 
(3XHA-hKOR, 3XHA-hMOR, or 3XHA-hDOR; www.cdna.org), with or without wildtype 
human RGS12, RGS domain loss-of-function RGS12 (Rgs12E740K), or GoLoco motif loss-
of-function RGS12 (Rgs12R1206F). Twenty-four hours later, transfected cells were seeded 
onto white, clear bottom, 96-well plates (8 x 106 cells/plate). Next morning, cells were 
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incubated with D-luciferin in buffer (20 mM HEPES, 140 mM NaCl, 5 mM KCl 250 µM 
NaPO4, 0.1 mM glucose, 0.5 mM KH2PO4, 1.3 mM CaCl2, 1 mM MgSO4, 5 mM NaHCO3, 
pH 7.4) for 2 hours at room temperature. Cells were then treated with various agonist 
concentrations (U50,488 for KOR, DAMGO for MOR, and DADLE for DOR) for 15 minutes 
at RT. Then, cells were treated with isoproterenol for 15 minutes to stimulate Gs signaling 
and adenylyl cyclase activation. Luminescence was measured with a FlexStation3 plate-
reader (Molecular Devices). In pertussis toxin (PTX) pre-treatment assays, to uncouple 
Gi/o-coupled GPCRs via Ga ADP-ribosylation (Katada and Ui, 1982; Moss and Vaughan, 
1988), cells were pretreated with 200 ng/mL PTX (or vehicle) for 24 hours (Pack et al., 
2018) prior to luminescence measurement.  
 
3.8.1h - b-arrestin recruitment  
Agonist-induced b-arrestin recruitment was determined using ‘Tango’ assay (Barnea et 
al., 2008; Allen et al., 2011). HTLA cells, stably expressing b-arrestin-TEV protease fusion 
and tetracycline transactivator-driven luciferase reporter (Barnea et al., 2008), were 
transiently transfected via CaPO4 (Jordan et al., 1996) with opioid receptor-Tango vectors 
(FLAG-KOR-Tango, FLAG-MOR-Tango, or FLAG-DOR-Tango; contributed to Addgene 
by Dr. Bryan Roth) with or without WT hRGS12, Rgs12E740K, or Rgs12R1206F vectors. 
Twenty-four hours later, transfected cells were seeded onto white, clear bottom, 384 well 
plates (8 x 106 cells/plate). Next morning, cells were serum starved for 6 hours, then 
stimulated with various agonist concentrations (U50,488 for KOR, DAMGO for MOR, or 
DADLE for DOR). The following morning, cells were lysed with BrightGlo (Promega) and 
luminescence measured with a FlexStation3. In Tango assays performed with PTX, cells 
were pretreated with 200 ng/mL PTX or vehicle 24 hours prior to lysis and luminescence 
measurement.  
 145 
 
3.8.1i - In silico single cell RNAseq analysis  
The DropViz single cell RNAseq database (Saunders et al., 2018) was analyzed to 
determine the mouse brain neuronal cell populations that co-express Rgs12 and Oprk1 
mRNA. Data displayed are the output (Table) derived from a query with Rgs12 and Oprk1 
(Gene) and Neuron (Limit by Class) set as query parameters. Results were sorted by the 
neuronal single cell populations expressing the highest levels of Oprk1 (Oprk1 Amount) 
and constrained to corticostriatal circuitry (frontal cortex, striatum, substantia nigra, 
globus pallidus, and thalamus) given the relevance of these regions to the behavioral 
effects of KOR agonism (Tejeda et al., 2017; Trifilieff and Martinez, 2013; Tejeda et al., 
2013).  
 
3.8.1j - In situ hybridization 
In situ hybridization on mouse brain slices was performed as previously described (Gross 
et al., 2018); dual-label detection of Rgs12 and Oprk1 expression in the claustrum was 
performed by the RNA In Situ Hybridization Core at Baylor College of Medicine, which is, 
in part, supported by a Shared Instrumentation grant from the NIH (1S10OD016167).  
 
3.8.1k - Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
Ventral striatum (vSTR) and midbrain were rapidly dissected, immediately frozen on dry 
ice, and then homogenized on ice in TRIzole reagent (InvitrogenTM). RNA was extracted 
according to manufacturer’s instructions (Direct-zol RNA MiniPrep, Zymo); genomic DNA 
was eliminated with the QuantiTech Reverse Transcription Kit (Qiagen). RNA quantity 
was assessed by QIAexpert bioanalyzer (Qiagen) and cDNA synthesized with 
QuantiTech Reverse Transcription (Qiagen). Published primers (Du et al., 2016) for 
Oprk1/KOR (F: 5'-TCCCCAACTGGGCAGAATC-3', R: 5'-
GACAGCGGTGATGATAACAGG-3') and Pdyn (F: 5'- CAGTGAGGATTCAGGATGGG-
3', R: 5'-CGTCAGGGTGAGAAAAGATGA-3') were obtained from Invitrogen. Data were 
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normalized to averaged Ct values from three housekeeping genes: b-Actin (F: 5'-
GGCTGTATTCCCCTCCATCG-3', R: 5'-CCAGTTGGTAACAATGCCATGTT-3'), 18S 
rRNA (Qiagen), and b-Tubulin (F: 5'-GGGAGGTGATAAGCGATGA-3', R: 5'-
CCCAGGTTCTAGATCCACCA). Two µL of cDNA template was used in each qRT-PCR 
reaction with SYBR Green PCR Master Mix (Qiagen). qRT-PCR was performed with a 
Qiagen Rotor Gene-Q; melt curves were analyzed after each run to ensure primer 
specificity.  
 
 
 
3.8.1l - Hot plate analgesia test 
To detect sensitivity to painful stimuli, the hot plate test of nociception was performed as 
previously described (Bohn et al., 1999) with slight modifications. Mice were placed on a 
hot plate (53 oC) and prevented from escape by a tall plastic cylinder. Latency to lick a 
hindlimb, flinch/flick, jump, or other first sign of nociception was recorded. On day 1, 
RGS12-null mice and wildtype littermates were administered saline (0.9% NaCl) 30 
minutes prior to the test and nociceptive latency recorded. On day 2, all mice were 
administered U50,488 (5, 22.5, or 30 mg/kg, ip) 30 minutes prior to the test and 
nociceptive latency was recorded.  
 
 
 
3.8.1m - Hot plate analgesia with KOR antagonist treatment  
Hot plate analgesia assays with nor-BNI-treated mice were performed identically to all 
other hot plate analgesia assays (Fig. 4A-C) except that mice were administered nor-BNI 
(10 mg/kg, ip, dissolved in 0.9% NaCl) following their baseline measurement; thus, mice 
underwent a 24 hour pretreatment of nor-BNI prior to the administration of 30 mg/kg 
U50,488 (ip) and subsequent hot plate latency testing.  
 
3.8.1n - Conditioned place aversion (CPA) 
CPA was performed as described (Schindler et al., 2012) with modifications denoted 
below. Mice were free to acclimate to a two-chambered place preference apparatus (Med 
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Associates) on day 1 for 30 min; time spent in each compartment was recorded to 
determine the most-preferred chamber (preconditioning). In the morning of days 2 and 3, 
all RGS12-null mice and wildtype littermates were administered saline (0.9% NaCl) and 
confined to their least-preferred chamber. In the afternoon of days 2 and 3, all mice 
received U50,488 (2.5 or 5.0 mg/kg, ip) and were confined to their most-preferred 
chamber for 30 min. On day 4 (postconditioning), CPA was determined by allowing mice 
to freely explore. Pre- and post (U50,488)-conditioning were computed by subtracting the 
time spent (seconds) in the most-preferred chamber (drug-paired during conditioning) 
minus the least-preferred chamber (saline-paired during conditioning). 
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3.8.2 - Supplementary Figures 
3.8.2a - Rgs12 and Oprk1 (KOR) mRNAs show similar expression patterns in 
mouse brain. 
 
 
 
Figure S1. Rgs12 and Oprk1 (KOR) mRNAs show similar expression patterns in mouse 
brain. Coronal in situ hybridization (ISH) from the Allen Brain Atlas highlighting coincident 
Oprk1 (A) and Rgs12 (B) mRNA expression in hippocampus (HPC), and the ventral 
tegmental area (VTA) and substantia nigra pars compacta (SNc), with the latter two 
regions being beds of mesolimbic and nigrostriatal dopaminergic soma, respectively. 
(C) In silico analysis of a single cell RNAseq dataset (DropViz) shows co-expression of  
Rgs12 with Oprk1 (KOR) in neuronal cell populations across several brain regions.  
Data are sorted and displayed by the neuronal cell populations expressing the highest 
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levels of Oprk1 (Oprk1 amount). Rgs12 exhibits co-expression with Oprk1 in many of 
the top Oprk1-expressing neurons, particularly within brain regions composing the 
corticostriatal circuit (e.g., frontal cortex, striatum, substantia nigra, globus pallidus, 
thalamus). The highest expressing neuronal cell type for both Rgs12 and Oprk1 are 
Nr4a2+ cells within the claustrum (a subregion of the frontal cortex), as observed in dual-
label ISH below. (D-F) Epifluorescence images of dual-label ISH of a coronal brain slice 
of a wildtype mouse with antisense RNA probes directed to Oprk1 mRNA (panel D, green) 
and Rgs12 mRNA (panel E, red); overlay of both signals is presented in yellow in panel 
F (CLA, claustrum; CTX, cortex; ec, external capsule; STR, striatum). Parallel dual-label 
ISH of a brain slice from an RGS12-null (Rgs12-/-) mouse resulted in no signal in the red 
channel (data not shown). 
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3.8.2b - Baseline and KOR-dependent DA release and DA reuptake are normal in 
the dSTR of RGS12-null mice. 
 
 
 
Figure S2. Baseline and KOR-dependent DA release and DA reuptake are normal in the 
dSTR of RGS12-null mice. (A) Electrically-stimulated DA release (peak DA current, nA) 
and (B) DA reuptake (t1/2) in the dSTR of brain slices from RGS12-null and wildtype mice 
pretreated with vehicle (saline) or nor-BNI (10 mg/kg, ip) 24 hours prior to FSCV 
measurements. Analyses reveal an effect of stimulation amplitude on DA release (p < 
0.0001); however, no genotype, treatment, or interaction effects were observed in 
measures of DA release or DA reuptake (p > 0.05). All FSCV data are mean ± SEM (n = 
6 - 11 mice per group) and were analyzed by general linear mixed model ANOVA (ns, not 
significantly different). 
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3.8.2c - Oprk1 (KOR) and prodynorphin (Pdyn) mRNA levels are unchanged in the 
vSTR and midbrain of RGS12-null mice.   
 
 
 
Figure S3. Oprk1 and prodynorphin mRNA levels are unchanged in the vSTR and 
midbrain of RGS12-null mice.  (A) Measurement of Oprk1 (KOR) mRNA levels in ventral 
striatum (vSTR) and midbrain by qRT-PCR. RGS12-null and wildtype mice exhibited 
similar Oprk1 mRNA levels in both regions (omnibus: genotype, F(1,20) = 0.2, p = 0.624; 
region, F(1,20) = 0.4, p = 0.567; interaction, F (1,20) = 0.4, p = 0.536) (multiple 
comparisons: Oprk1-vSTR: RGS12-null vs wildtype: p = 0.994, Oprk1-midbrain: RGS12-
null vs wildtype: p = 0.680). (B) Measurement of dynorphin precursor prodynorphin (Pdyn) 
mRNA levels in vSTR and midbrain by qRT-PCR. Analysis revealed that prodynorphin 
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mRNA levels in vSTR and midbrain were comparable between RGS12-null mice and 
wildtype littermates (omnibus: genotype, F(1,19) = 0.02, p = 0.885; region, F(1,19) = 1.4, 
p = 0.255; interaction, F (1,19) = 0.9, p = 0.351) (multiple comparisons: Pdyn-vSTR: 
RGS12-null vs wildtype: p = 0.809, Pdyn-midbrain: RGS12-null vs wildtype: p = 0.703). 
All data are the mean ± SEM and tested by two-way ANOVA with Sidak’s post hoc test (n 
= 6 mice per group). 
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3.8.2d - The selective effect of RGS12 on KOR-mediated G protein signaling is 
preserved in rodent RGS12 variants. 
 
 
 
Figure S4. The selective effect of RGS12 on KOR-mediated G protein signaling is 
preserved in rodent RGS12 variants. Glo-Sensor luciferase-based measurements of 
cAMP levels in HEK293T cells stimulated with 100 nM isoproterenol and simultaneously 
inhibited with indicated receptor-selective agonists following transient co-expression  
(A) 3XHA-hKOR or (B) 3XHA-hMOR cDNA plus empty vector, untagged wildtype mouse 
RGS12 (mRGS12), or myc-tagged wildtype rat RGS12 (rRGS12) expression plasmids. 
Co-expression of mRGS12 or rRGS12 each reduced KOR agonist potency by ~30-fold 
(Fig. S4A) (mRGS12: F(1, 56) = 14.1, p = 0.0004; KOR + mRGS12 pIC50 = 8.1 ± 0.2 vs 
KOR only pIC50 = 9.6 ± 0.1) (rRGS12: F(1, 56) = 12.0, p = 0.001; KOR + rRGS12 pIC50 = 
8.1 ±  0.2 vs KOR only pIC50 = 9.6 ± 0.1). In contrast, mRGS12 and rRGS12 each 
attenuated MOR agonist potency by only ~6-fold (Fig. S4B) (mRGS12: F(1, 56) = 10.7, p 
= 0.001; MOR + mRGS12 pIC50 = 7.1 ± 0.1 vs MOR only pIC50 = 7.9 ± 0.1) (rRGS12: F(1, 
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56) = 7.5, p = 0.008; MOR + rRGS12WT pIC50 = 7.1 ± 0.2 vs MOR only pIC50 = 7.9 ± 0.1). 
Data were normalized to vehicle control conditions and are expressed as the mean ± 
SEM from multiple experiments. Concentration-response curves were fit by four-
parameter non-linear regression (Prism 7). 
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3.8.2e - The analgesic effect of 30 mg/kg U50,488 is lost, in both RGS12-null mice 
and wildtype littermate controls, following pretreatment with nor-BNI. 
 
 
 
Figure S5. The analgesic effect of 30 mg/kg U50,488 is lost, in both RGS12-null mice 
and wildtype littermate controls, following pretreatment with nor-BNI. U50,488 (30 mg/kg)-
induced supraspinal analgesia is KOR-dependent. Omnibus ANOVA analysis revealed 
no effects of genotype, drug treatment (U50,488 + nor-BNI), or genotype x drug treatment 
(p > 0.05). Data are the mean ± SEM (n = 8-10 mice per group) and tested by two-way 
ANOVA.  
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3.8.2f - Responses to morphine at doses of either 5 mg/kg (A) or 10 mg/kg (B) are 
similar in RGS12-null mice and wildtype littermate controls. 
 
 
 
Figure S6. Responses to morphine at doses of either 5 mg/kg (A) or 10 mg/kg (B) are 
similar in RGS12-null mice and wildtype littermate controls. (A) Omnibus ANOVA analysis 
revealed no effects of genotype, morphine treatment, or genotype x drug treatment (p > 
0.05). (B) Omnibus ANOVA analysis revealed only an effect of morphine treatment 
(F(1,27) = 29.1, p < 0.001); multiple comparisons: RGS12-null saline vs 10 mg/kg 
morphine: p = 0.0005; wildtype saline vs 10 mg/kg morphine: p = 0.004. Data are the 
mean ± SEM (n = 7-14 mice per group) and tested by two-way ANOVA followed by Sidak’s 
post hoc test (**, p < 0.01; ***, p < 0.001). 
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3.8.2g - b-arrestin-2 is not required for [3H]DA uptake in the vSTR and dSTR. 
 
 
 
Figure S7. b-arrestin-2 is not required for [3H]DA uptake in the vSTR and dSTR. Uptake 
of [3H]DA (8 nM) in synaptosomes prepared from vSTR and dSTR brain tissue from 
barr2KO and wildtype mice. Non-specific binding was determined in the presence of 10 
µM GBR12935. Data shown are the mean ± SEM (n = 4 mice per group) from a 
representative experiment and tested by two-way ANOVA (p > 0.05). [3H]DA uptake in the 
vSTR and dSTR of barr2KO and wildtype mice was performed twice (n = 8 mice per group 
over 2 independent experiments).  
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CHAPTER FOUR 
Conclusions and Future Directions 
4.1 - General Conclusions  
 The principal findings from this work support RGS12 as an important regulator of DAergic 
and KOR-dependent signal transduction, neurotransmission, and behavior in mice. Moreover, 
these studies identify a region-specific role for RGS12, particularly within the vSTR. Specifically, 
this work highlights an integral role for RGS12 in constitutive and psychostimulant-dependent 
DAT expression and function. We demonstrate that RGS12 mediates its effects on DAT 
expression/function via a functional interaction with KOR. Further elucidation of this novel 
functional interaction between RGS12 and KOR revealed that RGS12 is a key determinant of 
proper KOR signaling (in vitro and in vivo) and behavior. Notably, our finding that RGS12 
differentially modulates G protein versus barr signaling downstream of KOR is a relatively novel 
concept for the GPCR signaling field. Namely, we reveal that interaction of a GPCR with an 
intracellular signaling protein, rather than a pharmacological agent (e.g., a biased agonist) per se, 
affects GPCR functional selectivity.  
 There are some limitations and unanswered questions remaining after this work, 
particularly with respect to the physical and functional interaction(s) between RGS12 and KOR.  
The Future Directions and Experimental Approaches section below is thus intended to provide a 
roadmap for navigating at least some of the residual questions following the conclusion of my 
dissertation work. Given that the functional interaction between RGS12 and KOR appears to 
underlie the preponderance of biochemical and behavioral effects that I have identified in RGS12-
null mice, the experimental pursuits proposed below will be focused predominantly on further 
elucidating the intricate biological relationship between these proteins.  
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4.2 - Future Directions and Experimental Approaches   
4.2.1 - Question 1: Does RGS12 affect KOR signaling and behaviors solely in KOR-
expressing neurons? 
Rationale: mRNA and protein expression data (Gross et al., 2018) suggest that Rgs12 mRNA is 
synthesized in DAergic projection neurons of the ventral tegmental area (VTA) and substantia 
nigra pars compacta (SNc), and the protein trafficked to presynaptic terminals of the striatum. 
Similar mRNA and protein distribution is observed with KOR: KOR-encoding Oprk1 mRNA is 
enriched within DAergic VTA projections, and KOR is enriched on presynaptic terminals of the 
NAc within the vSTR (Crowley and Kash, 2015; Britt and McGehee, 2008; Bruijnzeel, 2009). 
These correlations suggest that RGS12 may be co-expressed with KOR in dopaminergic striatal 
neurons, and RGS12 loss in these specific neurons engenders the observed disruptions of KOR 
expression and function, and DA homeostasis, seen in global RGS12 knockout (RGS12-null) 
mice.  
Approach: We recently established (Gross et al., 2018) that CMV::Cre-driven Rgs12 excision 
(Rgs12Δ5-6/Δ5-6) throughout the organism recapitulates the augmented DAT-mediated DA reuptake 
and reduced hyperlocomotion to psychostimulants as observed in our global Rgs12Δ5-8/Δ5-8 strain. 
Given this specific validation of our conditional RGS12 knockout (floxed) strain (Rgs12Δ5-6/Δ5-6) 
(Gross et al., 2018), we are now positioned to cross it with strains expressing Cre downstream of 
neuron subtype-specific promoters to identify those RGS12-expressing cell populations 
necessary and sufficient to engender the KOR signaling dysfunction observed in constitutive 
RGS12-null mice. We will first cross our Rgs12fl/fl mice with KOR::Cre C57BL/6 mice (which we 
have obtained from Dr. Sarah Ross; (Cai et al., 2016; Snyder et al., 2018)) and initially assess for 
Oprk1 promoter-driven Cre-mediated elimination of RGS12 expression in established KOR- and 
RGS12-expressing brain regions (e.g., vSTR, dSTR, prefrontal cortex, midbrain, hippocampus) 
by immunoblotting, as previously performed (Gross et al., 2018). We will quantify RGS12 levels 
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within microdissected brain regions from Oprk1Cre/+;Rgs12fl/fl mice (tissue-restricted knockouts) as 
compared with Oprk1Cre/+; Rgs12+/+ (wildtype control) mice.  For example, if RGS12 is expressed 
in non-KOR-expressing vSTR neurons in addition to KOR-expressing vSTR neurons, we are still 
likely to observe significant (albeit incomplete) reductions in RGS12 levels relative to wildtype 
controls, given the predominant expression of Oprk1 in this region, especially in the NAc (Mansour 
et al., 1987; Svingos et al., 2001). Rgs12 loss from Cre-expressing tissue should also be assessed 
using dual-label fluorescence in situ hybridization and validated Rgs12 riboprobes, as previously 
performed (Fig. 3.8.2a).  
Once significant reduction or loss of RGS12 is verified, we would need to perform many, if not 
all, of the biochemical assays of KOR expression and function (e.g., KOR saturation binding with 
[3H]U69,593, [35S]GTPgS binding, etc.) and DAergic neurotransmission (e.g., DAT saturation 
binding with [3H]WIN35,438; [3H]DA uptake). We would also likely require the use of the tissue-
restricted knockout strain in all behavioral assays previously performed with global RGS12-null 
mice (e.g., hot plate analgesia and CPA elicited by multiple KOR agonists [Fig. 3.6.4]). If the 
alterations to KOR signaling seen in global RGS12-null mice are due to loss of RGS12 function 
within KOR-expressing neurons, we would expect that Oprk1Cre/+;Rgs12fl/fl mice should 
recapitulate many, if not all, of the biochemical and behavioral phenotypes observed upon global 
RGS12 loss. 
 
4.2.2 - Question 2: Does RGS12 loss during neurodevelopment contribute to 
the observed biochemical and behavioral disruptions in adult RGS12-null mice? 
Rationale: If the biochemical and behavioral phenotypes observed in Oprk1Cre/+;Rgs12fl/fl mice do 
not resemble those of global RGS12-null mice (or if only some phenotypes are recapitulated), we 
would next need to probe whether alterations in KOR signaling and KOR activation-dependent 
behaviors result from neurodevelopmental disruptions caused by RGS12 loss -- disruptions that 
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may perturb the dynorphin/KOR system. This notion is supported by prior findings from the 
Siderovski group that primary DRG neurons lacking RGS12 exhibit attenuated NGF-induced 
axonogenesis (Willard et al., 2007), from the Tsien group that RGS12 levels are altered during 
synaptogenesis by sensory deprivation (Butko et al., 2013), and from the Siderovski group that 
Rgs12 is strongly expressed throughout CNS regions integral to early embryonic 
neurodevelopment (Martin-McCaffrey et al., 2005).  
Approach: To evaluate this hypothesis, we would cross Rgs12fl/fl mice with tamoxifen-inducible, 
CAGG::Cre mice to induce Rgs12 excision conditionally in the adult mouse, obviating the 
confound that pre- and/or post-natal neurodevelopmental adaptations and/or compensations may 
occur across the lifespan in the absence of RGS12 within the global RGS12-null strains. In 
another project within our laboratory, we demonstrated successful tamoxifen-induced, Cre-
mediated homologous recombination at the adult stage of a different floxed Rgs allele, namely 
that encoding RGS21, which is expressed in lingual chemosensory tissue (Schroer et al., 2018). 
Thus, we are confident that we can successfully evaluate whether RGS12 loss produces KOR 
dysfunction and altered DA homeostasis via a neurodevelopmental mechanism by crossing 
tamoxifen-inducible Cre mice with our Rgs12fl/fl mice (i.e., inducing Cre-mediated Rgs12 excision 
in adulthood). As an independent alternative approach (i.e., independent of either Oprk1Cre/+ or  
tamoxifen-inducible driver lines), we could breed our Rgs12fl/fl mice with the DAT-iCre driver strain 
(Turiault et al., 2007; Rocchetti et al., 2015), thereby restricting RGS12 loss to DAT-expressing 
dopaminergic neurons. 
Alternative IHC-based approach in parallel:  Along with cross-breeding Rgs12fl/fl mice to tissue- 
and temporally-restricted Cre drivers and phenotyping the resultant desired progeny, we could 
quantify downstream signaling events in situ, beginning with the global RGS12-null mice, to help 
establish the region-specific nature of RGS12 function(s) on KOR signaling in the brain. KOR 
activation reportedly leads to phosphorylation of select kinases in the striatum, cortex, 
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hippocampus, and amygdala (Robles et al., 2014; Bruchas et al., 2007a; Heinsbroek et al., 2018). 
KOR-mediated pERK induction is preserved in GRK3-null mice (Bruchas et al., 2007a) and thus 
likely a barr-independent, G protein-dependent output. Conversely, p38 MAPK phosphorylation 
following KOR activation is lost in GRK3-null mice (Bruchas et al., 2007a); thus, p-p38 MAPK 
induction is considered GRK3-/barr-dependent and G protein-independent (Bruchas et al., 2006). 
Thus, we will perform IHC to test whether RGS12-deficient mice exhibit altered pERK and p-p38 
induction upon KOR activation (and if this occurs in a region-specific manner). pERK and p-p38 
content can be measured in brain slices of RGS12-deficient mice and matched wildtype 
littermates treated systemically with unbiased/full KOR agonists (e.g., U50,488 in saline, ip) using 
established IHC techniques (Gross et al., 2018) and validated anti-pERK / ERK and anti-p-p38 / 
p38 MAPK antibodies (CST). pERK- and p-p38-positive cells will be counted and normalized to 
ERK- and p38-positive cells (and expressed as fold induction) across multiple regions (e.g., vSTR 
[in particular, NAc core & shell], dSTR, amygdala, hippocampus, prefrontal cortex, 
claustrum/deep cortical layers) to determine if RGS12 loss (by global or tissue-restricted 
knockout) perturbs outcomes of KOR-mediated G protein-dependent and -independent signaling. 
If no IHC differences are seen in pERK and p-p38 levels between RGS12-deficient and wildtype 
mice upon a single, high dose of KOR agonist, such a result may not preclude the possibility that 
RGS12 loss produces a potency shift in KOR sensitivity upstream of ERK and p38 
phosphorylation (i.e., any differences between genotypes may be masked by high drug dose); we 
would then perform dose-response trials (e.g., U50,488 at 5, 10, 15, 20, 30 mg/kg). Moreover, in 
vitro studies of KOR-stimulated ERK and p38 activation (Schattauer et al., 2017; Schattauer et 
al., 2012) have shown that maximal kinase phosphorylation is achieved in a temporally distinct 
fashion. Thus, we would begin by testing RGS12-deficient and wildtype mice at both 5 and 30 
minutes to capture the predicted maximal activation of pERK and p-p38, respectively (Schattauer 
et al., 2017; Schattauer et al., 2012); we will establish time-course data for phosphorylation of 
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both kinases if required. We would also likely benefit by evaluating a 2-hour timepoint in later 
analyses of KOR-stimulated pERK induction to assess whether RGS12 loss affects the late phase 
(McLennan et al., 2008) of barr-dependent ERK phosphorylation following KOR activation.  
KOR activation is reported to induce amygdala-related anxiogenesis (Crowley and Kash, 
2015; Bruchas et al., 2009; Knoll et al., 2011), frontal cortex- and hippocampal-dependent 
learning deficits (Carey et al., 2009; Paris et al., 2011), depression-like and stress-related 
behaviors involving mesolimbic structures (VTA, NAc (Bruchas et al., 2008; Chartoff et al., 2009; 
Berube et al., 2013)), and psychotomimesis and sensory gating deficits that may be related to 
KOR action in the claustrum and/or deep layers of the cerebral cortex (Ruderman et al., 2009; 
Stiefel et al., 2014; Patru and Reser, 2015). Given that RGS12 is expressed along with KOR in 
virtually all of these brain regions (Gross et al., 2018) (Allen Brain Atlas), these planned IHC 
studies for identifying particular CNS regions of RGS12 action should surely aid in selecting future 
behavioral experiments to better understand the extent to which RGS12 modulates behavioral 
outcomes of KOR signaling.  
 
4.2.3 – Question 3: Does RGS12 play a role in KOR-mediated signaling and behavior 
involving the spinal cord? 
Rationale: Our findings show that global RGS12-null mice have increased sensitivity to the 
analgesia elicited by KOR agonism in the hot plate assay (Fig. 3.6.4), a test of supraspinal 
analgesia (Hull et al., 1994; Sora et al., 1997). RGS12 may also regulate KOR-mediated spinal 
antinociception via similar mechanisms, especially with evidence that both RGS12 and KOR are 
expressed in spinal neurons that mediate nociception ((Willard et al., 2007; Cai et al., 2016; 
Hylden et al., 1991), and see also GENSAT strain Tg(Rgs12-EGFP)HW332Gsat/Mmucd). For 
example, RGS12 is highly expressed in dorsal root ganglion (DRG) neurons, and the Siderovski 
group has previously shown that RGS12 is a key regulator of NGF-stimulated axonogenesis in 
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these neurons (Willard et al., 2007; Lewin and Mendell, 1993; Lewin et al., 2014). DRGs located 
adjacent to the spinal cord, as well as the dorsal horns, represent key nociceptive loci (Todd, 
2010). Notably, KOR is also highly expressed in DRG neurons and contributes to growth factor-
stimulated neurite extension (Tsai et al., 2010) and to anti-nociceptive responses via its action 
within this anatomical region (Xu et al., 2004).  
Hypotheses: RGS12 loss in the spinal cord drives altered nociception given KOR-mediated 
G protein hypersensitivity and barr hyposensitivity; RGS12 loss increases sensitivity to the 
antinociceptive and anti-pruritic effects of KOR agonism; RGS12 loss prevents the development 
of tolerance to the antinociceptive effects of repeated KOR agonism (as elicited by either chronic 
exogenous applications of KOR agonist or the induction of neuropathic injury).  
Approaches:  
4.2.3a - (i) Antinociception: To assess if RGS12 regulates KOR activity in the spinal cord, we 
will perform the tail immersion test (McLaughlin et al., 2004) (i.e., spinal nociception to thermal 
stimulus). Like antinociceptive behaviors in the hot-plate test, increased tail withdrawal latency 
following acute KOR agonist administration is considered G protein-dependent but barr-
independent (Schattauer et al., 2017; McLaughlin et al., 2004). If RGS12 regulates spinal KOR 
signaling, we expect RGS12 deficiency to potentiate KOR agonist-induced antinociception 
relative to wildtype controls. In the tail withdrawal test, the distal 1 cm of the tail is immersed in 55 
°C water for up to 10 s, and tail withdrawal latency is monitored. Increased tail withdrawal latency 
in drug-treated mice can be used to infer the drug’s antinociceptive efficacy. Dose ranges of full 
KOR agonists (e.g., U50,488 at 1, 2.5, 7.5, 15, or 30 mg/kg, ip; (Schattauer et al., 2017)) or vehicle 
will be separately administered to RGS12-deficient (global RGS12-null and tissue-restricted 
knockout) mice and wildtype controls 30 min prior to testing. Initial data with the unbiased/full 
KOR agonist U50,488 (Fig. 4.2.3a-1 below) suggest that global RGS12-null mice do have 
augmented KOR-induced tail withdrawal latencies, albeit dose-dependently. 
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4.2.3a-1 - RGS12-null mice exhibit augmented spinal antinociception to the KOR agonist in 
a dose-dependent manner.  
 
Fig. 4.2.3a-1. RGS12-null mice exhibit augmented spinal antinociception to the KOR 
agonist U50,488 at the 2.5 mg/kg dose. Indicated single doses of U50,488 were administered 
to global RGS12-null and WT mice prior to the warm water tail immersion test. Data are the mean 
± SEM; two-way repeated-measures ANOVA (for within-subjects comparisons) and between-
subjects ANOVA (for between-subjects comparisons) each followed by Sidak’s post hoc test were 
performed (n = 5-10 mice/group; *, p < 0.05; **, p < 0.01; ****, p < 0.0001 vs baseline). 
Unpublished preliminary data. 
4.2.3b - (ii) Antinociceptive tolerance: Opioid-induced antinociception is limited by the 
development of tolerance following repeated administration -- a process facilitated by barr-
dependent downregulation of opioid receptors (Raehal and Bohn, 2014). For example, 
antinociceptive tolerance to the MOR agonist morphine is lost in barr-2 knockout mice (Bohn et 
al., 2000). Similarly, tolerance to U50,488 is attenuated in GRK3 knockout mice (McLaughlin et 
al., 2004), suggesting that KOR-mediated tolerance also relies on a GRK3-/barr-dependent 
mechanism. Given our findings that acute KOR-stimulated analgesia (G protein-dependent) is 
augmented, yet KOR-induced CPA (barr-dependent) is attenuated in RGS12-null mice (see 
 167 
Chapter 3), we hypothesize that RGS12-deficient and barr-2-deficient mouse strains will exhibit 
reduced tolerance to repeated KOR agonism.  
Approaches: To begin to assess this hypothesis, we would repeatedly administer an 
unbiased/full KOR agonist to RGS12-deficient and barr-2-deficient mice (and wildtype littermate 
controls), as previously described (McLaughlin et al., 2004). For example, mice will receive 
escalating doses of U50,488 (in saline; ip) twice daily for days 1-4 (i.e., 10 & 15, 25 & 30, 50 & 
60, and 70 & 75 mg/kg, AM/PM), then given a challenge dose of 25 mg/kg on day 5. Control 
groups for both genotypes (gene-deficient and wildtype mice) will receive saline injections, then 
acute saline or U50,488 on day 5. Tolerance will be evaluated by decreased nociceptive latency 
per the tail immersion test (as above), performed 30 min after each day’s AM injection.  
Potential Confounds and Future Pursuits for 4.2.3a and 4.2.3b:  It would be advantageous to also 
evaluate tolerance in the hot plate assay to assess barr-dependent supraspinal analgesia in light 
of our initial data that RGS12-null mice exhibit enhanced sensitivity to acute KOR-induced 
analgesia in this assay (Fig. 3.6.4). However, we anticipate that an ascending dose schedule of 
an unbiased/full KOR agonist may acutely produce profound motoric dysfunction and lack of 
coordination. In the hot plate assay, mice are placed on a 53 °C metal surface and latency to 
nociception (licking/shaking of a hindlimb or jumping) recorded. In this way, the behavior indicative 
of nociception relies upon motoric action. We have observed motor dysfunction in some mice 
receiving 30 mg/kg U50,488; others report that KOR agonists produce dysfunction in coordination 
tests, such as rotarod (White et al., 2015). Conversely, tail withdrawal is a spinal-mediated 
(reflexive) response (Janssen et al., 1963; Bohn et al., 2002) and, thus, is unaffected by repeated 
and/or high doses of KOR agonists (McLaughlin et al., 2004). It is possible that we may not see 
differences in tail withdrawal tolerance between RGS12-deficient and wildtype mice if RGS12 
regulates KOR-initiated signaling predominantly in supraspinal (e.g., vSTR), and not spinal, 
regions. If this outcome manifests, it will be even more important to use data generated by planned 
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IHC studies (see Question #2 - Alternative IHC-based approach in parallel) to better predict those 
specific CNS regions in which RGS12 modulates KOR signaling, and then correlate those findings 
to observed behaviors following KOR agonism relevant to the regions identified.  
 
4.2.3c - Anti-pruritus:  
Rationale: KOR activation produces anti-pruritic effects via action within DRG neurons of the 
spinal cord (Ross et al., 2010; Kardon et al., 2014). Intractable itch can occur secondary to 
disease (e.g., chronic renal failure (Simonsen et al., 2017)) or after neuraxial opioid administration 
(Ko, 2015) and often requires clinical intervention. KOR agonists mitigate itch in humans and 
rodents (Kumagai et al., 2012; Morgenweck et al., 2015). Conversely, KOR antagonists induce 
itch (Kamei and Nagase, 2001; Inan et al., 2009), but this effect is only partially attenuated in 
KOR-knockout mice, suggesting that KOR-independent mechanisms also contribute 
(Morgenweck et al., 2015). The KOR-selective G protein-biased (Schattauer et al., 2017) agonist 
nalfurafine is approved in Japan to treat pruritus in hemodialysis patients (Kumagai et al., 2012); 
the newer G protein-biased KOR agonist, triazole 1.1, also retains the anti-pruritic efficacy of 
unbiased KOR agonists (Brust et al., 2016), underscoring the concept that KOR-induced anti-
pruritus may be G protein-dependent and barr-independent.  
Hypothesis: RGS12-deficient mouse strains will exhibit increased anti-pruritic responses to a 
conventional (unbiased) KOR agonist relative to controls, given our findings that RGS12 loss 
engenders KOR-mediated G protein signaling hypersensitivity and barr signaling hyposensitivity 
(see Chapter 3)  
Approach: We would evaluate KOR-induced anti-pruritus as previously described (Brust et al., 
2016; Schlosburg et al., 2009; Schlosburg et al., 2011). Briefly, RGS12-deficient and wildtype 
control mice will be injected with an unbiased KOR agonist (see dose considerations below), and 
injected 10 min later with either vehicle or the pruritus-inducing agent chloroquine phosphate (CP, 
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40 mg/kg, sc midscapular (Kuraishi et al., 1995) or nape of neck (Morgenweck et al., 2015)). 
Hindlimb scratching bout frequency and duration will be quantified in 5-min bins over 1 hr by a 
genotype-blinded investigator. Given the potentially subjective nature of these scoring 
procedures, a subset of videos will need to be re-scored by an independent investigator to ensure 
intra- and inter-observer reliability.  
Potential Confounds and Methods Considerations for Anti-Pruritus Testing:  Studies of KOR 
agonist-induced anti-pruritus often precipitate scratching with the KOR antagonists nor-BNI or 
5'GNTI (Brust et al., 2016; Schattauer et al., 2017; Morgenweck et al., 2015). KOR antagonist-
induced itch is preserved (albeit reduced) in KOR-deficient mice, and is attenuated in barr-2-
deficient mice (Morgenweck et al., 2015), suggesting that itch produced by KOR antagonists is, 
at least in part, KOR-independent and barr-2-dependent. Conversely, CP-induced itch (KOR-
independent) is robustly inhibited by G protein-biased KOR agonists, and this effect of KOR 
agonism is unaltered in barr-2-deficient mice (Brust et al., 2016), supporting the notion that the 
anti-pruritic effect of KOR agonism on CP-stimulated itching is G protein-dependent. Thus, we will 
evaluate (at least initially) KOR agonist-induced anti-pruritus to CP (i.e., not to KOR antagonism) 
to assess whether RGS12-deficient mouse strains exhibit KOR-mediated G protein 
hypersensitivity in this spinal-dependent behavior. We will also consider the polycationic mast cell 
degranulator compound 40/80 to precipitate scratching behavior (via localized histamine release 
(Schlosburg et al., 2009; Schlosburg et al., 2011), as an additional alternative to avoid using KOR 
antagonists.  
U50,488 administration prior to CP injection robustly suppresses CP-induced itch (Brust et al., 
2016) at doses as low as 1 mg/kg U50,488. Thus, 1 mg/kg will be the highest dose in initial 
U50,488 dose-response trials, systematically decreased until we identify the lowest U50,488 dose 
that does not affect wildtype littermate controls. We will then test whether matched RGS12-
deficient mice display reduced scratching at this lowest U50,488 dose, which would suggest that 
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RGS12 loss increases KOR-mediated G protein signaling sensitivity, as first seen in previous 
experiments (Fig. 3.6.2 & Fig. 3.6.4). Future studies should seek to replicate the effect using 
nalfurafine instead of U50,488, because nalfurafine is approved in Japan for treatment of pruritus 
and is a G protein-biased KOR agonist (Schattauer et al., 2017; Kumagai et al., 2012). 
 
4.2.3d - Neuropathic pain  
Rationale: Peripheral nerve damage causes neuropathic pain (Zimmermann, 2001) by producing 
hyperalgesia (increased pain response to noxious stimuli), allodynia (pain response to innocuous 
stimuli), and spontaneous pain. Such neuropathic pain increases acute and prolonged dynorphin 
release and increases KOR activation within the dorsal horn (Xu et al., 2004; Wagner et al., 1993; 
Wang et al., 2001). Antagonism or genetic deletion of KOR enhances hyperalgesia (Xu et al., 
2004; Obara et al., 2003) and allodynia (Xu et al., 2004) following chronic constriction injury (CCI) 
of the sciatic nerve, an established rodent model of neuropathic pain (Jaggi et al., 2011). These 
data suggest that neuropathic injury-induced KOR activation in the spinal cord by endogenous 
dynorphins helps mitigate increased nociception following damage.  
Approach: To test whether RGS12 functions in the spinal cord to modulate dynorphin/KOR-
related reductions of neuropathic pain, we will perform CCI surgeries (in collaboration with the 
Kinsey lab) on RGS12-deficient mouse strains (both global and tissue-restricted knockouts), and 
compare resultant hyperalgesia (e.g., Hargreaves’ plantar stimulator test), and mechanical (e.g., 
von Frey filament) and cold (acetone-induced) allodynia vs wildtype littermate controls using 
established techniques in measuring rodent neuropathic pain (Crowe et al., 2017; Crowe et al., 
2015; Kinsey et al., 2010; Kinsey et al., 2013; Wilkerson et al., 2016). Unpublished pilot data (from 
the Kinsey lab) suggest that global RGS12 deficiency indeed leads to reduced allodynia post-
CCI; this finding supports the notion that RGS12 loss may reduce sciatic nerve injury-induced 
allodynia by augmenting KOR-mediated antinociception.  
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Fig. 4.2.3d-1. RGS12-null mice exhibit attenuated allodynia after CCI. 
 
 
Fig. 4.2.3d-1. RGS12-null mice exhibit attenuated allodynia after CCI. Wildtype mice (Rgs12+/+; 
n = 16) and RGS12-null mice (Rgs12-/-; n = 20) each received a chronic constriction injury of the 
right sciatic nerve. After the indicated elapsed time, resultant mechanical allodynia (paw 
withdrawal threshold [PWT]) was assessed at the right hind paw using a series of von Frey 
filaments as previously described (Kinsey et al., 2010; Kinsey et al., 2013; Crowe et al., 2015; 
Crowe et al., 2017; Wilkerson et al., 2016); mean contralateral (left paw control) withdrawal 
thresholds are graphically represented as the horizontal dotted line. *, p < 0.05, from unpaired t-
test comparing right hind paw PWT between genotypes. Unpublished preliminary data produced 
by Floyd Steele, PhD candidate in the Kinsey lab, using mice provided by the Siderovski and 
Setola labs. 
To first test KOR mediation of post-CCI nociception differences in RGS12-deficient mice, we 
will pretreat mice with KOR antagonist (e.g., the long-lasting, irreversible KOR antagonist nor-
BNI) prior to testing hyperalgesia (Hargreaves’ plantar stimulator test) and allodynia (e.g., as 
performed in Fig. 4.2.3d-1 above) at 7, 11, and 14 days post CCI injury. Systemic nor-BNI is seen 
to reverse KOR-mediated antinociception for up to 14-21 days post-injection (Bruchas et al., 
2007b; Patkar et al., 2013); thus, a single administration of nor-BNI (10 mg/kg, ip, dissolved in 
saline) 24 hours prior (i.e., day 1) to CCI surgery (day 0) should suffice to ascertain whether any 
effects engendered by RGS12 deficiency are dynorphin/KOR-mediated. As an alternative to the 
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use of nor-BNI, we could also consider JDTic (Bruchas et al., 2007b; Munro et al., 2012); however, 
we would avoid employing 5’-GNTI owing to its off-target PAM effect at the a1A-adrenergic 
receptor (Munro et al., 2013). 
CCI is reported (Xu et al., 2004) to reduce the ability of exogenous KOR agonists to attenuate 
the hyperalgesia and allodynia that result after nerve injury; this phenomenon of reduced KOR 
agonism affecting post-CCI is considered consistent with the development of tolerance to KOR 
agonism-induced antinociception observed in the tail immersion test (McLaughlin et al., 2004). 
Moreover, this reduced KOR agonism effect post-CCI is lost in GRK3-deficient mice and thus 
considered barr-dependent (Xu et al., 2004). Therefore, our initial observation of reduced CCI-
induced allodynia in global RGS12-null mice may be due, at least in part, to attenuated KOR-
mediated barr signaling in the absence of RGS12 and, therefore, reduced development of 
KOR tolerance that normally occurs in response to prolonged dynorphin release elicited by CCI 
(Xu et al., 2004; Kajander et al., 1990; Malan et al., 2000; Gardell et al., 2004). This notion is 
consistent with our observation that RGS12 deficiency attenuates KOR agonist-induced CPA 
(considered a barr-dependent behavior; Fig. 3.6.4) and, conversely, RGS12 over-expression 
greatly enhances barr recruitment to activated KOR in vitro (Fig. 3.6.3).  
Thus, to evaluate whether global or tissue-restricted RGS12-deficient mice exhibit diminished 
barr-dependent KOR tolerance related to neuropathic pain, we will perform CCI (and sham) 
surgeries on RGS12-deficient and wildtype littermate mice, and then assess at 7, 11, and 14 days 
post-CCI hyperalgesia and mechanical/cold allodynia following acute administration of KOR 
agonists (e.g., U50,488 in escalating doses). We would suspect that RGS12 deficiency will 
attenuate (or abolish) the potency reduction (rightward EC50 shift) normally seen in KOR agonist-
induced antinociception post-CCI (i.e., as seen in GRK3-null mice (Xu et al., 2004)); such 
observations would support a role for RGS12 in facilitating barr-dependent KOR tolerance.  
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Potential Confounds and Future Directions for Neuropathic Pain Assessment: Peripheral nerve 
injury can also lead to supraspinal KOR activation (Abraham et al., 2000; Narita et al., 2006; Cahill 
et al., 2014), which may modulate spinally mediated nociceptive behaviors. For example, some 
evidence (Cahill et al., 2014) suggests that chronic pain is regulated by KOR-dependent 
modulation of mesolimbic DA, proposed to govern the negative affect experienced during pain 
and thus contribute to nociceptive responsiveness following neuropathic injury. Because we have 
evidence that the disrupted mesolimbic DAergic neurotransmission observed in RGS12-null mice 
is KOR-mediated (Fig. 3.6.1), it is plausible that any behavioral effects observed in neuropathic 
pain assays may be due, at least in part, to central effects of KOR (e.g., in the mesolimbic DA 
system), rather than direct spinal cord effects. Thus, if systemically administered KOR antagonist 
blocks the attenuation of CCI-induced nociceptive responses in RGS12-deficient mice (e.g., Fig. 
4.2.3d-1 above), we will then test whether this reversal is due specifically, or in part, to changes 
in KOR signaling in the ventral striatum caused by RGS12 loss. To test this, we would locally 
deliver KOR antagonist (e.g., 100 nM nor-BNI) or saline into the vSTR by reverse dialysis, as 
previously described (Gray et al., 1999; Yang et al., 2015; Virk et al., 2016). Briefly, we would 
perform stereotaxic surgery on RGS12-deficient mice and wildtype littermates to implant dialysis 
probes into the vSTR. Following surgical recovery, we would administer KOR antagonist or 
vehicle via reverse dialysis 24 hours prior to CCI surgery. Following 7, 11, and 14 days post-CCI, 
we would perform nociceptive testing of hyperalgesia (as above for experiments using 
systemically administered KOR antagonist) and allodynia (e.g., as in Fig. 4.2.3d-1 above). Like 
systemic administration, nor-BNI delivered directly into the CNS remains detectable (Patkar et al., 
2013) in mouse brain for up to 21 days. Thus, a single administration of nor-BNI by reverse 
dialysis should be sufficient to antagonize KOR for the duration of the experiment.  
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4.2.4 - Question 4: Do RGS12 and KOR associate via a PDZ-mediated interaction? 
Rationale: An early paper on RGS12 from the Siderovski lab (Snow et al., 1998) described the 
binding specificity of its PDZ domain and noted a high degree of sequence similarity between the 
RGS12 PDZ domain and the first PDZ domain of NHERF1. Subsequent work (Li et al., 2002) has 
shown that NHERF1 directly binds a PDZ-recognition site at the KOR C-terminus (amino acids 
376-380: -NKPV), but does not bind MOR (which lacks this C-terminal sequence; e.g., Fig. 10); 
furthermore, NHERF1 over-expression is reported (Li et al., 2002) to impact both KOR agonist-
induced signaling and KOR trafficking/recycling. Thus, the first plausible candidate for 
investigating the molecular determinant(s) of selectivity of RGS12 action on KOR is a PDZ 
domain/C-terminal interaction, similar to that of the NHERF1/KOR interaction (Li et al., 2002). Our 
initial evidence using a KOR mutant with the last four amino acids of the wildtype KOR C-terminus 
mutated to alanines (NKPV à AAAA), as well as a gain-of-function MOR mutant containing KOR's 
wildtype C-terminus in substitution of its native C-terminal sequence (MORAPLP>NKPV), supports 
that the effects of RGS12 on KOR-mediated G protein signaling are PDZ-dependent (Fig. 3.6.3).  
Approach: Bioluminescence resonance energy transfer (BRET): To help visualize potential 
interactions between RGS12 and KOR in a real-time, cellular context, we would initiate BRET 
analyses using Promega’s NanoBRET system (Machleidt et al., 2015), similar to prior studies 
from the Siderovski lab (Giguere et al., 2012; Giguere et al., 2014) interrogating GPSM3 
interactions with NLRP3, 14-3-3, and G protein subunits. The Siderovski group has previously 
established (Willard et al., 2007) that RGS12 can be modified at either the N- or C-terminus with 
a fusion protein (e.g., YFP or CFP) while retaining normal subcellular localization and cellular 
function. To leave the KOR C-terminus unperturbed*, we would likely engineer the NanoLuc or 
HaloTag fusion in the receptor’s third intracellular loop (Wu et al., 2012). We should also test 
placing the NanoLuc or HaloTag fusion in the first or second intracellular loops, or within the C-
terminus (prior to the final -NKPV sequence). To test interaction specificity, MOR, DOR, and D2R 
would need to be tagged in the same fashion as the optimized KOR construct. Initial experiments 
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will test whether RGS12 is located in close proximity to KOR under basal and/or KOR agonist-
stimulated conditions. Mutagenesis studies (subaim (i) above) will inform further BRET construct 
development to elucidate those key determinants underlying any observed intracellular BRET 
between RGS12 and KOR.  
Potential Confounds and Future Pursuits: *Caveat: To facilitate the Tango assay (Barnea et al., 
2008) GPCR ORFs like that of KOR are cloned with C-terminal fusions: i.e., the vasopressin V2R 
tail, a TEV protease cleavage site, and a tTa transcription factor; this C-terminal extension 
prevents the KOR NKPV PDZ sequence from being displayed at the extreme C-terminus of the 
resultant GPCR fusion protein. However, there is ample evidence (Gee et al., 1998; Penkert et 
al., 2004; Wong et al., 2003; London et al., 2004) that PDZ domains also recognize internal 
peptide sequences (e.g., PDZ domains of syntrophin, Par-6, and Dishevelled). 
One possible outcome is that a PDZ-mediated interaction between RGS12 and KOR is 
established that critically depends on the free -NKPV C-terminus of KOR and, thereby, only 
affects G protein-dependent signaling and not barr interaction. RGS12 might augment barr 
interaction with KOR through a PDZ domain-independent protein segment, or alternatively, 
through regulating a specific signaling process (independent of the RGS domain and GoLoco 
motif; Fig. 10A) that is unique to KOR relative to other receptors.  
barr recruitment can engage myriad kinases, including tyrosine kinases (e.g., c-Src (Fan et al., 
2001; Ribas et al., 2007)) and Ras-dependent MAPKs (Eishingdrelo and Kongsamut, 2013; 
Claing, 2013). Thus, RGS12 may augment barr recruitment by enhancing tyrosine 
phosphorylation- and/or Ras-dependent signaling events via its PTB domain and/or tandem 
RBDs, respectively. Dissecting these particular molecular determinants would proceed in a similar 
fashion to what is articulated above for the “PDZ domain hypothesis.” For example, the Siderovski 
group previously characterized (Uhlik et al., 2005) the RGS12 PTB domain as belonging to a new 
subclass with unique electrostatics, and also established (Willard et al., 2007) a loss-of-function 
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mutation (H995L) to the first RBD of RGS12 that reduces binding to H-Ras without abrogating 
Raf association. If required, unbiased determinations of previously unidentified RGS12-interacting 
partners would be performed to generate additional hypotheses as to the nature of the selective 
RGS12 / KOR interaction, similar to the proteomics and yeast two-hybrid screens that the 
Siderovski group has successfully performed for RGS12 and GPSM3 interactants (Willard et al., 
2007; Giguere et al., 2012; Giguere et al., 2014). 
If the effect of RGS12 on KOR-mediated signaling is dependent on a PDZ-mediated 
interaction, we could consider using CRISPR / Cas9-based genome editing to induce a 
quadruple-alanine mutation to the KOR C-terminus (KOR NKPV>AAAA) within the mouse Oprk1 gene 
and thereby assess whether abrogating PDZ-dependent interactions with the KOR C-terminus 
will reproduce the KOR signaling and DA homeostasis imbalance phenotypes observed upon 
global loss of RGS12 (e.g., Figs. 7-9, 12, and other phenotypes as described (Gross et al., 2018)). 
This pursuit would not be able to directly implicate RGS12 alone in any KOR- and/or DA-related 
phenotypes we observe in KOR NKPV>AAAA mice, given that NHERF1 and GEC1 are also assumed 
to bind KOR using this motif (Huang et al., 2004; Chen et al., 2006). However, if we were to 
demonstrate that KOR NKPV>AAAA mice phenocopy some of the deficiencies/perturbations of one or 
more RGS12-deficient mouse strains, it will nonetheless provide strong correlative evidence that 
PDZ domain-dependent interactions between KOR and RGS12 account for at least some of the 
behavioral and biochemical disruptions observed upon RGS12 loss.  
 
4.2.5 - Question 5: Which specific brain regions and protein domains are responsible for 
the disruptions to DA and KOR function observed with global RGS12-null mice? 
Rationale: To make the case for RGS12 as a valid target for future drug discovery towards small 
molecule-mediated modulation of KOR agonist functional selectivity, a demonstration of reversal 
of mouse biochemical and behavioral deficits elicited by RGS12 deficiency is a required 
milestone. To date, no validated chemical probe for RGS12 modulation has yet been established. 
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Thus, a genetic rescue strategy is required for a proof-of-principle demonstration of the region 
specificity of RGS12 in select biochemical and/or behavioral outcomes:  i.e., viral transduction of 
RGS12 into select CNS regions of RGS12-deficient mouse strains.  
Hypothesis: (1) Targeted re-expression of wildtype RGS12 will reverse or attenuate one or more 
of the behavioral deficits elicited by Rgs12 ablation; (2) re-expression of RGS12 loss-of-function 
mutants will ascertain the importance of select protein-protein interactions to such function by 
RGS12 in vivo.  
Approach: Given the <5 kb packaging restriction of adeno-associated viruses (Shevtsova et al., 
2005) vs the >4 kb size of the Rgs12 open-reading frame (NCBI NM_173402), lentiviruses 
expressing epitope-tagged, wildtype RGS12 will need to be constructed, purified, and titered.  
The Siderovski group has previously found that fluorescent protein-tagging RGS12 at either N- or 
C-termini has no effect on RGS12 expression or function (Willard et al., 2007); GFP only-
expressing lentivirus will be used as a negative control. To evaluate RGS12 function in select 
neuronal populations, lentivirus transducing Rgs12 from cell type-specific promoters (e.g., DAT 
promoter for striatal DA neurons) will be constructed pending success in reversing behavioral 
deficits with RGS12 expressed from a more global PGK or synapsin1A promoter. 
Expectations and Future Pursuits - For one or more of the observed, CNS-centered, behavioral 
deficits seen upon global RGS12 loss (see Chapter 2 & Chapter 3), we expect viral-mediated 
restoration of vSTR RGS12 expression to normalize these behaviors. While we cannot overlook 
the possibility that constitutive RGS12 loss causes aberrant mouse behavior owing to a pleiotropy 
of dysfunctions (e.g., across multiple CNS regions and circuits; across a lengthy 
neurodevelopmental time-span), our expectation above arises from the unique effects that 
RGS12 loss (and barr-2 loss) is seen to engender for KOR specifically within the vSTR (Fig. 3.6.1-
3.6.3). If reversal by viral-mediated RGS12 re-expression in the vSTR is seen for deficits 
attributable to RGS12 deficiency, the mesolimbic circuitry and DAT-dependent functions of virally 
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infected mice will then be assessed biochemically to test whether behavior reversal by RGS12 
re-expression is correlated with normalization of mesolimbic DA neurotransmission (i.e., 
particularly DAT function and expression). Furthermore, evidence of reversal by wildtype RGS12 
re-expression would allow subsequent delivery of loss-of-function point mutants of RGS12 in 
head-to-head comparison with wildtype RGS12 to identify particular protein functions critical to 
RGS12 action in this context. These loss-of-function mutants will come from results of the 
experimental pursuits from Question 4 above, as well as prior studies of the Siderovski lab that 
have validated several loss-of-function point mutations, including a charge reversal (E740K) that 
eliminates RGS domain GAP activity (Sambi et al., 2006), an Arg-to-Phe change (R1206F) to the 
GoLoco motif which eliminates Ga binding and endosomal targeting of RGS12 (Sambi et al., 
2006), and a His-to-Leu change (H995L) to the first Ras-binding domain that reduces RGS12 
binding to activated H-Ras without abrogating Raf kinase association (Willard et al., 2007). 
 
4.2.6 - Question 6: How does RGS12 regulate psychostimulant-evoked DA levels in vivo? 
Rationale: Reduced hyperlocomotion in RGS12-null mice to psychostimulants (Fig. 2.6.2) 
suggests that RGS12 is involved in drug-induced increases in extracellular DA levels in the live 
organism. These behavioral outcomes are correlated with disruptions in DAT radioligand binding, 
[3H]DA uptake, and [3H]DA efflux (Chapter 2) -- all measures of ex vivo transporter 
function/activity. Although drug-induced [3H]DA release in synaptosomes provides valuable 
information for ascertaining biochemical processes disrupted upon RGS12 loss, it cannot reflect 
neurotransmission in the animal with intact neurocircuitry. Thus, future studies should employ in 
vivo microdialysis -- continuous sampling of extracellular contents (e.g., monoaminergic 
neurotransmitters such as DA, 5-HT, norepinephrine [NE]) in live, awake RGS12-null and wildtype 
animals, rather than post-mortem preparations.  
Approach: - Psychostimulant (e.g., AMPH, METH)-induced DA release should be assessed by in 
vivo microdialysis as previously performed by members of our lab (Doly et al., 2008). Specifically, 
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mice would undergo stereotaxic surgery to implant microdialysis probes in dSTR and vSTR with 
coordinates from the Paxinos atlas. Upon recovery from surgery, mice would be injected with 
releasing agents (e.g., AMPH, METH) and dialysate collected every 10 minutes over 190 minutes. 
DA concentrations in dialysates would then be determined by HPLC with electrochemical 
detection. Additional studies with other psychostimulants that produce deficient hyperlocomotor 
responses in RGS12-null mice (e.g., cocaine) should also be examined.   
Expectations and Future Plans: AMPH- and METH-induced DA release is likely significantly 
attenuated in RGS12-null mice, given reduced hyperlocomotion to these drugs (Fig. 2.6.2 & 
unpublished observations for METH). However, AMPH and METH-also exhibit appreciable affinity 
for the 5-HT (SERT) and NE transporter (NET), and induce transport reversal through these 
transporters (Steinkellner et al., 2011). To rule out any contribution of altered 5-HT or NE release 
to reduced hyperlocomotion of RGS12-null mice, we would need to also employ the microdialysis 
outlined here to evaluate SERT and NET function in RGS12-null mice (i.e., drug-induced changes 
in 5-HT and NE levels in relevant brain regions) and thereby assess the possible contribution of 
this molecular target to reduced AMPH-/METH--induced hyperlocomotion.  
Potential Limitations and Control Experiment(s): Microdialysis is limited by poor temporal 
resolution (10 min collection intervals are most often employed) vs other techniques like 
voltammetry (Chefer et al., 2009). Thus, microdialysis may not fully reflect real-time monoamine 
neurotransmitter dynamics. However, we have found RGS12-null mice have reduced 
hyperlocomotion to AMPH-like drugs over an 80 min period (e.g., post-drug; Fig. 2.6.2). 
Therefore, dialysate collection in 10-min intervals should still inform whether perturbations in 
monoamine neurotransmitter dynamics are related to the reduced hyperlocomotion to AMPH-like 
drugs of RGS12-null mice. Also, stereotaxic implantation of a probe is invasive and can damage 
tissue, which could result in disrupted behavioral responses independent of drug-treatment. To 
verify that behaviorally-salient damage has not occurred, spontaneous locomotor activity ought 
 180 
to be measured in probe implanted, saline-treated RGS12-null and wildtype mice and compared 
to saline-treated mice that have not undergone stereotaxic surgery.  
 
4.2.7 - Question 7: Does RGS12 modulate SERT expression/function and serotonergic 
behaviors via KOR-dependent mechanism(s)? 
Rationale: We have shown that increased DAT expression and DA uptake, as well as reduced 
AMPH-induced hyperlocomotion, are reversed following antagonism of KOR (Fig. 3.6.1). 
Similarly, RGS12-null mice exhibit increased SERT expression and 5-HT uptake in a region-
dependent manner, and these effects correlate with disrupted MDMA-induced hyperlocomotion 
(unpublished observations) and several other 5-HT-dependent behaviors (stress-
coping/depression-like behavior, anxiety, and social interaction -- unpublished observations). 
Chronic stress (with concomitantly increased endogenous dynorphin release and KOR activation) 
and KOR agonists have been shown to increase plasmalemmal SERT expression and SERT-
mediated 5-HT uptake in a region-dependent manner and these changes are proposed to underlie 
a 'depression-like' phenotype (Schindler et al., 2012). Thus, it is reasonable to suspect that 
augmented SERT function and expression in RGS12-null mice is related to increased KOR 
expression/sensitivity and that these alterations to the serotonergic system underlies the 
observed disruptions to 5-HT-dependent behaviors (i.e., MDMA-induced locomotor activity, 
forced swim stress, tail suspension stress, elevated zero/plus maze, and social interaction).  
Hypothesis: KOR blockade is sufficient to reverse or rescue SERT dysfunction and perturbation 
of 5-HT-dependent behaviors in RGS12-null mice.  
Approach: Experiments will be designed exactly as described for studies evaluating DAT 
expression, [3H]DA uptake, and AMPH-induced hyperlocomotion (Fig. 3.6.1), except that KOR 
antagonist (nor-BNI, 10 mg/kg, 24-hour pretreatment, ip)-treated RGS12-null and wildtype mice 
will be evaluated for (1) [3H]citalopram saturation binding to SERT, (2) SERT-mediated [3H]5-HT 
uptake, (3) MDMA-induced [3H]5-HT efflux, (4) MDMA (10 and 30 mg/kg)-induced locomotor 
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activity, (5) forced swim stress, (6) tail suspension stress, (7) elevated zero and/or plus maze, 
and (8) social interaction as per methods employed previously (Doly et al., 2008; Jin et al., 2017; 
Bey et al., 2018). Additionally, future studies of serotonergic neurotransmission and behavior 
should employ the use of the KOR::Cre-Rgs12 floxed mouse strain described above (in section 
4.2.1), as this strategy could help determine whether RGS12 impacts serotonergic function via 
action specifically within KOR-expressing neurons.  
Expectations and Future Pursuits: Given our observations with the effect of RGS12 on DAT (Fig. 
3.6.1) and prior work by others demonstrating that KOR induces similar effects on SERT 
(Schindler et al., 2012), we would suspect that KOR antagonism would reverse the SERT 
dysfunction (i.e., SERT radioligand binding, 5-HT uptake, 5-HT efflux, and MDMA-induced 
locomotor activity) observed in RGS12-null mice (unpublished observations). Given that the 
disruptions to 5-HT-dependent behavioral outcomes (i.e., forced swim stress, tail suspension 
stress, elevated zero and/or plus maze, and social interaction) in RGS12-null mice (unpublished 
observations) is drug-independent (i.e., these are basal phenotypes of the mouse strain absence 
any drug application), it is reasonable to suspect that these phenotypes may manifest via one or 
more different neurobiological perturbations, even if these behaviors all are strongly associated 
with serotonergic neurotransmission. Thus, if KOR antagonism is not sufficient to reverse or 
rescue any of these behavioral perturbations, future studies will require additional 
pharmacological intervention, including (but not limited to) direct manipulation of the serotonergic 
system (i.e., KOR-independent 5-HT neurotransmission) with selective serotonin reuptake 
inhibitors (SSRIs) and/or specific 5-HT receptor agonists/antagonists. With respect to the latter, 
initial studies should employ the use of agonists/antagonists selective for Gai/o-coupled 5-HT 
receptors (e.g., 5-HT receptor 1A [HTR1A]), given the specificity of RGS12 for this Ga subunit 
subtype.  
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APPENDIX A 
 
RGS12 and Prepulse Inhibition  
 
Appendix A.1 - Deletion of schizophrenia-associated gene RGS12 in mice results in 
baseline prepulse inhibition deficiencies that are not reversed by antipsychotics  
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Figure Appx. A.1. Deletion of the schizophrenia-associated gene RGS12 (Xu et al., 2011; 
Guipponi et al., 2014) in mice produces baseline deficiencies in prepulse inhibition that are not 
reversed by several different antipsychotics. (A) Baseline prepulse inhibition of acoustic startle 
(% PPI) in RGS12-null (Rgs12-/- - open bars) and wildtype littermate control (Rgs12+/+ - closed 
bars) mice to four different prepulse intensities: 4 (PP4), 8 (PP8), 12 (PP12), and 16 (PP16) 
decibels (dB) above background noise (65 dB). Data were analyzed by two-way ANOVA (n = 14-
19 mice per group). (B) Average baseline startle amplitude (millivolts, mV) (a measure of startle 
reactivity) across three blocks of a complete PPI session in RGS12-null and wildtype littermate 
controls. Block 1 consisted of 6 sequential startle pulse-only (120 dB) white noise bursts at the 
beginning of the session, Block 2 consisted of 12 startle pulse-only exposures interspersed 
pseudorandomly throughout the PPI session, and Block 3 consisted of 6 sequential startle pulse-
only exposures at the end of the PPI session. Data were analyzed by two-way ANOVA (n = 18 
mice per group) (C) PPI following vehicle, acute (0.1 mg/kg, 30-min pretreatment, ip), or repeated 
(0.5 mg/kg, 14 consecutive days, once/day, ip) administration of the prototypical 1st generation 
antipsychotic haloperidol (a dopamine D2 receptor antagonist) in wildtype (left panel) and RGS12-
null (right panel) littermate controls. Data were analyzed by two-way ANOVA (n = 8-10 mice per 
group) (D) PPI following vehicle or acute administration of the prototypical 2nd generation 
antipsychotic clozapine (a serotonin 5-HT2A and dopamine D2 receptor antagonist)  at various 
doses (0.5, 1.0, or 2.0 mg/kg, 30-min pretreatment, ip) in wildtype (left panel) and RGS12-null 
(right panel) littermate controls. Data were analyzed by two-way ANOVA (n = 4-18 mice per group) 
(E) PPI following vehicle or acute administration of the prototypical 3rd generation antipsychotic 
aripiprazole (a serotonin 5-HT2A and dopamine D2 receptor partial agonist) at various doses (1.0 
or 3.0 mg/kg, 30-min pretreatment, ip) in wildtype (left panel) and RGS12-null (right panel) 
littermate controls. Data were analyzed by two-way ANOVA (n = 6-7 mice per group) All data are 
the mean +/- SEM. * p < 0.05, ** p < 0.01, p < 0.0001. 
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Appendix A.2 - Deletion of schizophrenia-associated gene RGS6 in mice does not alter 
baseline prepulse inhibition or startle reactivity  
 
 
 
Figure Appx. A.2. Deletion of schizophrenia-associated gene RGS6 (Schizophrenia Working 
Group of the Psychiatric Genomics, 2014) in mice does not alter prepulse inhibition or startle 
reactivity. (A) Baseline prepulse inhibition of acoustic startle (% PPI) in constitutive RGS6-null 
(Rgs12-/- - open bars) and wildtype littermate control (Rgs6+/+ - closed bars) mice to four different 
prepulse intensities: 4 (PP4), 8 (PP8), 12 (PP12), and 16 (PP16) decibels (dB) above background 
noise (65 dB). Analysis by two-way ANOVA revealed no significant differences between 
genotypes (n = 10-12 mice per group; p > 0.05). (B) Average baseline startle amplitude (millivolts, 
mV) (a measure of startle reactivity) across three blocks of a complete PPI session in RGS12-
null and wildtype littermate controls. Analysis by two-way ANOVA revealed no significant 
differences between genotypes (n = 10-12 mice per group; p > 0.05).  
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